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Abstract 
Background: Pathogenesis of systemic lupus erythematosus (SLE) is 
thought to be closely related to B-cell dysfunction, and accordingly this is the 
usual target for therapies. However, non-B-cell mechanisms such as tumour 
necrosis factor (TNF) and interferons may also be important in the onset as 
well as established disease.  
Objectives: (i) To assess biomarkers of progression from At-Risk (ANA-
positive but limited symptoms) to connective tissue disease (AI-CTD); (ii) to 
identify predictors of non-response and serious infections with rituximab; and 
(iii) to assess new therapies to overcome rituximab deficiency with respect to 
anti-rituximab antibodies and B-cell-independent inflammation in discoid lupus 
erythematosus (DLE). 
Methods: Prospective observational studies were conducted in (i) At-Risk of 
AI-CTD and (ii) SLE patients treated with rituximab. Patients with anti-
rituximab antibodies were treated with alternative humanised anti-CD20 
agents. (iii) A single arm, phase II open label trial of intra-dermal injection of 
etanercept for remission induction in DLE (TARGET-DLE) was undertaken.  
Results: (i) Higher IFN-Score-B and a family history of autoimmune rheumatic 
diseases at baseline were predictive of progression from At-Risk to AI-CTD. 
(ii) B-cell depletion at 6 weeks post-rituximab was predictive of major response 
to rituximab and was not associated with increased serious infection post-
therapy in SLE. During repeat rituximab cycles, 12% of SLE patients lost 
depletion, which was attributed to anti-rituximab antibodies. These patients 
were switched to humanised agents, and all depleted and responded. (iii) For 
TARGET-DLE, the primary and most of the key secondary endpoints were 
met. Therapy was tolerable without inducing systemic autoimmunity.   
Conclusion: In this thesis, a personalised approach to treatment based on 
immunopathogenesis in At-Risk and established SLE led to better outcomes 
for patients. The predictive values of the biomarkers presented may allow 
stratification of patients for disease progression. While results from the use of  
novel therapies presented support further development in multi-centre trials. 
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Chapter 1. Introduction 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
that causes significant morbidity and mortality (1). The management of SLE 
demands a personalised approach due to heterogeneity in clinical 
presentation, severity and response to therapy. If left untreated, patients with 
SLE have a 67% higher mortality rate than age- and gender-matched healthy 
individuals (2) and the annual direct medical cost is increased two-fold to over 
£4500 per patient in the UK for treatment  of a severe flare (3).  
Current treatment is mainly unlicensed and many therapies (especially 
corticosteroids) have significant long-term toxicity (4, 5). Therefore, the focus 
of management should ideally be directed towards intervention at the ‘pre-
clinical’ stage; defined as a period of detectable autoimmunity and/or 
inflammation predating the onset of clinically apparent tissue inflammation and 
injury (6). In established disease, the challenge is to use the right therapy at 
the right time to prevent accumulation of damage and drug toxicity.  
There is a significant unmet need for therapies that improve efficacy, for end-
organ manifestations whilst improving quality of life. Nevertheless, many 
theoretically well-established agents did not meet their respective primary 
endpoints in clinical trials as a result of inefficacy, a problem with trial design 
and/or safety issues (7, 8). Belimumab, a human monoclonal antibody (mAb) 
that inhibits B-cell Activating Factor of the tumour necrosis factor ligand 
Family, (BAFF, also known as B-lymphocyte stimulator (BlyS)), is the only 
biologic approved by the United States Food and Drug Administration (US 
FDA) and the European Medicines Agency (EMA) since 2011 for use in 
moderate to severe autoantibody positive SLE (9). However, belimumab is 
expensive and the phase III trials excluded patients with severe lupus nephritis 
and neuropsychiatric manifestations (10, 11). Thus, it took 5 years from 
licensing as well as a substantial discounted price from the manufacturer 
before this drug was approved by the National Institute for Health Care and 
Excellence (NICE) in the UK in 2016 (12).  
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Rituximab, a chimeric anti-CD20 mAb is the mostly widely used biologic for 
SLE and is commissioned by NHS England for refractory SLE based on 
efficacy on a wide spectrum of SLE manifestations from strong open label 
evidence (13-15). However, the clinical response to therapy and the degree 
of B-cell depletion are highly variable; both of which can contribute to the poor 
response in some patients (16). Evidence from the use of rituximab in its 
licensed indications such as rheumatoid arthritis (RA) and B-cell malignancies 
have indicated several potential mechanisms that confer resistance of B-cells 
to rituximab along with modification of therapy that may improve clinical 
response. Data in SLE are more limited, thus will be a focus of my 
investigation in this thesis. 
Certain manifestations of SLE appear to be B-cell-independent. Cutaneous 
lupus is particularly variable and we have previously shown that none of the 
patients with discoid lupus erythematosus (DLE) responded to rituximab. 
Additionally, new chronic cutaneous lupus erythematosus (CCLE) lesions 
were observed despite B-cell depletion (17). Therefore, alternative 
inflammation pathways should be targeted in DLE. Tumour necrosis factor 
(TNF) may be pathogenic in DLE and this may respond to TNF-blockade (18). 
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1.1 Thesis hypothesis 
The unifying hypothesis of this thesis is: 
  
1.2 Overview of planned investigations 
Planned investigations to test the unifying and hypotheses for each chapter 





Figure 1-1 Planned investigations of this thesis 
 
A personalised approach to treatment based on immunopathogenesis in At-
Risk and established SLE will lead to a better outcome for patients 
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1.3 Thesis outline 
The outline of this thesis is summarised below. 
Chapter 2: Review of the literature 
A review of literature was performed focusing on recent understanding of 
immunopathogenesis of SLE,  the natural course of progression from benign 
autoreactivity to autoimmunity, outcome measures in assessing disease 
activity and management of moderate to severe SLE manifestations using B-
cell and non B-cell targeted therapies including critical reviews of trial designs 
in lupus trials. This review concluded with the unmet needs in SLE, which  
were addressed in my thesis. 
 Chapter 3: PRediction to allow Early interVENTion in At-Risk of 
autoimmune connective tissue disease (PREVENT-CTD) 
This chapter aimed to assess plausible predictors of progression from 
autoreactivity to autoimmune connective tissue disease (AI-CTD) including 
clinical, imaging, blood and skin interferon biomarkers with a view to formulate 
a strategy for disease prevention. 
Chapter 4: Predicting and managing primary and secondary non-
response to rituximab in systemic lupus erythematosus 
This chapter sought to evaluate the long-term efficacy and safety of rituximab 
in SLE, identify predictors of primary and secondary non-response to 
rituximab including validation B-cell biomarkers for response prediction and 
management of secondary non-depletion and non-response by switching to 
alternative humanised anti-CD20 mAb agents. 
Chapter 5: B-cell biomarkers in systemic lupus erythematosus and 
other B-cell mediated autoimmune rheumatic diseases 
This chapter discussed the use of B-cell biomarkers, as measured using 
Highly Sensitive Flow Cytometry (HSFC) in predicting response and imminent 
relapse to rituximab in SLE including validation studies and factors 
contributing to incomplete B-cell depletion after rituximab. The use of these 
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biomarkers were compared to other B-cell mediated diseases including RA 
and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). 
Chapter 6: Candidate predictors for safety and rationale for 
immunoglobulin monitoring during rituximab treatment in systemic 
lupus erythematosus and other autoimmune rheumatic diseases 
This chapter aimed to assess predictors of serious infection within the first 12 
months from starting rituximab and with repeat courses of therapy. In 
particular, the effect of B-cell depletion on the risk of serious infection as well 
as rationale for immunoglobulin monitoring were dissected, with a view to 
establish an algorithm for safe use of rituximab in SLE and other autoimmune 
rheumatic disease (ARDs). 
Chapter 7: TARGeted therapy using intradermal injection of Etanercept 
for remission induction in Discoid Lupus Erythematosus (TARGET-
DLE) 
This chapter described the first results from a phase II open label trial of  a 
novel route of administration using the existing drug, etanercept for remission 
induction in DLE. 
Chapter 8: Discussion 
This last chapter brought together the findings from all chapters of this thesis. 
Their contribution to the published literature, impact and future research 
direction were discussed. 
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Chapter 2. Review of the Literature 
This review describes background of SLE including its classification criteria. 
This is important for early recognition of disease and treatment. Recent 
advance in the understanding of aetiology and immunopathogenesis of SLE 
will be discussed as well as the natural course of progression from benign 
autoreactivity to autoimmunity. Various outcome measures in assessing 
disease activity for lupus in general, organ-specific and objective outcome 
measures will also be reported. The use of B-cell and non B-cell targeted 
therapies in the management of moderate to severe SLE will be discussed, 
with a particular focus on critical review of trial designs in lupus trials. Finally, 
based on the current data, this review concludes by addressing the unmet 
needs in SLE.  
2.1. Systemic lupus erythematosus 
SLE is a complex inflammatory disorder, characterised by the presence of 
antinuclear antibodies (ANAs) and can affect virtually any organ or tissue. Its 
presentation is heterogeneous and encompasses a wide range of clinical and 
serological manifestations. SLE is a chronic autoimmune disease typically 
running a relapsing and remitting course. The severity of lupus symptoms can 
range from mild to severe and may vary tremendously between patients.  
2.1.1. Epidemiology 
In Europe, the prevalence of SLE ranges between 20 to 50 per 100 000 
people, although much higher rates have been reported for Afro-Caribbean 
descent (19, 20). In the UK, the prevalence had increased from 65 per 100 
000 in 1999 to 97 per 100 000 in 2012 (21). While in the US, prevalence 
ranges between 20 to 150 per 100 000 people (22, 23). African American and 
Hispanics are affected more than Caucasians, and have higher disease 
morbidity (24-26).    
SLE has a female preponderance (10:1) with a peak incidence in the 
reproductive years between the age of 20 to 40 years old (20, 27). The 
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incidence of lupus has nearly tripled between 1950 to 1992, mainly due to 
improved recognition and diagnosis of mild disease (28). Incidence rates of 
SLE in North America, South America and Europe are estimated between 1 
to 23 per 100 000 per year (23). In the UK, the age-standardised incidence is 
8.3 per 100 000 per year for females and 1.4 per 100 000 per year for males, 
of which the highest incidence rates are seen in those of African-Caribbean 
descent,  31.4 per 100 000 per year compared with 6.7 per 100 000 per year 
for those of white European descent (21).  
2.1.2. Classification criteria 
Classification criteria for SLE were initially developed by the American College 
of Rheumatology (ACR) in 1971 (29), and subsequently revised in 1982 (30) 
and 1997 (31). However, there were notable deficiencies including i) the 
criteria were developed and validated in patients with longstanding disease 
and might exclude those with early or limited disease; ii) some systems were 
over-represented such as the mucocutaneous manifestations; iii) inability to 
classify patients with organ-threatening manifestation such as renal disease 
as SLE since they often presented with immunological abnormalities only and 
iv) classification of individuals with negative ANA as SLE should four criteria 
were met in other domains. 
The Systemic Lupus International Collaborating Clinics (SLICC) group 
overcame these deficiencies and revised the classification criteria using real-
case datasets and several validation steps. The advantages of the 2012 
SLICC classification criteria over the ACR criteria include i) greater sensitivity 
but similar specificity for classifying SLE; ii) a reduction in items that are similar 
e.g. malar rash and photosensitivity are largely overlapping; iii) lupus nephritis 
in the presence of at least one of the immunologic variables as a “stand alone” 
criterion and iv) the requirement for at least ONE clinical and ONE 
immunologic criterion for SLE classification (32). A comparison between the 
two criteria is presented in Table 2-1. 
At the time of this review, the 2018 revised ACR/European League Against 
Rheumatism (EULAR) Classification criteria for SLE is undergoing validation 
process and drafting. This proposed new criteria add weighting to the 
immunological and clinical items that are attributed to SLE. Within each 
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domain, only the highest weighted criterion is counted towards the total score. 
Patients with a score of at least 10 can be classified as SLE based on this 
revised criteria (33).  
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Table 2-1 The revised 1997 ACR and the 2012 SLICC classification criteria for SLE   
Criteria 1997 Revised ACR (31) 2012 SLICC (32) 
Mucocutaneous 1. Malar rash. Fixed erythema, flat or raised, over the 
malar eminences, tending to spare the nasolabial folds 
2. Discoid rash. Erythematous raised patches with 
adherent keratotic scaling and follicular plugging; atrophic 
scarring occur in older lesions 
3. Photosensitivity. Skin rash as a result of unusual 
reaction to sunlight either by patient history or physician 
observation 
4. Oral or nasopharyngeal ulceration 
1. Acute cutaneous lupus (ACLE) [lupus malar rash, bullous lupus, 
toxic epidermal necrolysis variant of SLE, maculopapular lupus rash 
and photosensitive lupus rash] OR subacute cutaneous lupus (SCLE) 
[non-indurated psoriasiform and/or annular polycyclic lesions that 
resolve without scarring] 
2. Chronic cutaneous lupus (CCLE) [classic discoid rash: localised or 
generalised, hypertrophic verrucous lupus, lupus panniculitis 
(profundus), mucosal lupus, lupus erythematosus tumidus, chilblains 
lupus, discoid lupus/lichen planus overlap] 
3. Non-scarring alopecia 
4. Oral or nasal ulcers 
Arthritis 5. Non-erosive arthritis involving ≥2 peripheral joints, 
characterised by tenderness, swelling or effusion 
5. Inflammatory synovitis in ≥2 joints: 
a. Characterised by swelling or effusion, or 
b. Tenderness and ≥30 minutes of morning stiffness 
Serositis 6. Any of: 
a. Pleuritis: convincing history of pleuritic pain or rub heard 
by a physician or evidence of pleural effusion 
6. Any of 
a. Typical pleurisy lasting >1 day, or pleural effusions or pleural rub 
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Criteria 1997 Revised ACR (31) 2012 SLICC (32) 
b. Pericarditis: documented by ECG or rub or evidence of 
pericardial effusion 
b. Typical pericardial pain (pain with recumbency, improved by sitting 
forward) for >1 day, or pericardial effusion, or pericardial rub or 
pericarditis by electrocardiography 
Renal 7. Any of: 
a. Persistent proteinuria >0.5 g/day or >3+ on urine 
dipstick if measurement is not performed 
b. Cellular casts: red cell, haemoglobin or granular tubular  
7. Any of: 
a. Urine protein/creatinine (or 24 h urine protein) representing ≥500 
mg of protein/24 hour, or 
b. Red blood cell casts 
Neurological 8. Any of:     
Seizures: in the absence of offending drugs or known 
metabolic derangements 
b. Psychosis: in the absence of offending drugs or known 
metabolic derangements 
8. Any of: 
a. Seizures 
b. Psychosis 
c. Mononeuritis multiplex 
d. Myelitis 
e. Peripheral or cranial neuropathy 
f. Cerebritis (acute confusional state) 
Haematological 9. Any of: 
a. Haemolytic anaemia with reticulocytosis 
b. Lymphopaenia: <1500/mm3 
9. Haemolytic anaemia 




Criteria 1997 Revised ACR (31) 2012 SLICC (32) 
c. Thrombocytopaenia: <100 000/mm3 11. Thrombocytopaenia (<100 000/mm3) of at least once 
Immunological 10. Any of: 
a. Anti-DNA: antibody to native DNA in abnormal titre 
b. Anti-Sm: presence of antibody to Sm nuclear antigen 
c. Positive finding of anti-phospholipid antibodies based 
on: (i) an abnormal serum concentration of IgG or IgM anti-
cardiolipin antibodies, (ii) a positive test result for SLE anti-
coagulant or (iii) a false-positive serological test for syphilis 
known to be positive for ≥6 months and confirmed by 
Treponema pallidum immobilisation or fluorescent 
Treponemal antibody absorption test 
12. Anti-dsDNA above laboratory reference range (except enzyme-
linked immunosorbent assay (ELISA): twice above reference range) 
13. Anti-Sm 
14. Anti-phospholipid antibody, SLE anti-coagulant, false-positive test 
for syphilis 
15. Anti-cardiolipin (at least twice normal or medium–high titre), or 
anti-β2 glycoprotein 1 
16. Low complement: low C3, or low C4, or low CH50 
17. Direct Coombs test in the absence of haemolytic anaemia 
Anti-nuclear 
antibody (ANA) 
11. Abnormal titre of ANA by immunofluorescence or an 
equivalent assay at any time and in the absence of drugs 
known to be associated with ‘drug-induced SLE’ syndrome 
18. ANA above laboratory reference range 
Rules for 
Classification 
At least 4 out of 11 criteria Either biopsy-proven lupus nephritis in the presence of ANA OR anti-
dsDNA as a ‘stand-alone’ criterion, OR 




2.2. Aetiology  
The exact aetio-pathology of SLE remains elusive. Multifactorial interaction 
among various genetic, epigenetic, hormonal and environmental factors is 
probably involved (18). Recent understanding suggest that defective immune 
regulatory mechanisms such as the clearance of apoptotic cells and immune 
complexes are important contributors to the development of SLE (34, 35). 
Abnormalities of these factors may lead to an irreversible breakdown of 
immunological tolerance manifested by aberrant immune responses against 
endogenous nuclear and other self-antigens (36).  
2.2.1. Genetic 
The importance of genetics in the pathogenesis of SLE is supported by 
several observations including i) a high concordance rate of up to 57% of SLE 
in monozygotic twins (37, 38); ii) siblings of patients with SLE are 29 times 
more likely to develop SLE than those without an affected sibling (as reported 
in a large population-based study of over 23 million participants) (39) and iii) 
first-degree relatives of patients with SLE have a 17-fold increased risk to 
develop the disease compared with the general population (40).  
The most common genetic predisposition is found at the major 
histocompatibility (MHC) locus which contains genes for antigen-presenting 
molecules i.e. class I human leukocyte antigens such as HLA-A, -B and –C 
and class II HLA molecules including HLA-DR, -DQ and DP. Predisposing loci 
which consists of HLA-DR2 and HLA-DR3 are associated with increased 
hazard ratio (HR) of approximately 2 (41, 42). Within the HLA-DRB1 loci, HLA-
DRB1*0301 and HLA-DRB1*1501 predispose to SLE whereas 
HLADRB1*1401 reduces the risk of development (43). 
Genetic factors that confer the highest HRs (between 5 to 25) for SLE are 
deficiencies in the complement components C1q (required to clear apoptotic 
cells), C2, C4A and B (44, 45) or the presence of a mutated TREX1 gene (46). 
The last encodes the 3-prime repair exonuclease1 enzyme that degrades 
deoxyribonucleic acid (DNA). 
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Genome-wide association studies (GWAS) have identified over 50 gene loci 
with polymorphisms (mutations or copy numbers) that predispose to SLE (47-
49). These SLE susceptibility genes and their common variants have been 
associated with impaired apoptosis, autophagy and clearance defects 
resulting in increased exposure of nuclear autoantigens, pro-inflammation, 
nuclear factor-kappa B (NFκB) pathway and immune cell signalling or 
migration (50). They also highlight the importance of excessive activation of 
type I interferon (IFN-I) signalling via toll-like receptors (TLRs) or nucleic acid 
sensors pathways (51, 52). Additionally, several single-nucleotide 
polymorphisms (SNPs) have been associated with sub-phenotypes such as 
lupus nephritis (53). Nevertheless, this genetic information accounts for only 
about 20% of susceptibility to SLE (54), suggesting a large component of 
environmental or epigenetic influences.  
2.2.2. Epigenetic effects 
Epigenetic effects such as DNA methylation, post-translational histone 
modifications and micro ribonucleic acids (miRNAs), either genetically 
determined or environmentally induced may influence the risk of SLE (55). 
The role of epigenetics is supported (at least in part) by the discordance seen 
in identical twins who are discordant for SLE (56). The most well-understood 
type of epigenetic factor is DNA methylation, which affects specific genes and 
variation in acetylation of histones, thus influences transcription into protein. 
DNA methylation plays a role in a variety of human processes. Abnormal 
methylation has been associated with development of SLE (57).  
miRNAs are essential in both adaptive and innate immunity by controlling the 
differentiation of various immune cell subsets such as B-cells, T-cells and their 
immunological functions (58, 59). Aberrantly expressed miRNAs have been 
observed in different cell types, tissues and play an important role in the 




2.2.3. Hormonal effects 
The pathogenic role of hormones including oestrogen, testosterone, 
progesterone, prolactin and thyroid in SLE may be related to their effects on 
immune responsiveness.  
Oestrogen stimulates thymocytes, CD8+ and CD4+ T-cells, B-cells, 
macrophages and the release of certain cytokines such as interleukin 1 (IL-1) 
(61). Oestrogen also reduces apoptotic activity in self-reactive B-cells, thus 
promoting selective maturation of autoreactive B-cells with high affinity for 
anti-double stranded DNA (dsDNA) (62). As a result, women are more 
predisposed than men to make autoantibodies that eventually lead to clinically 
apparent SLE. Indeed, data from the Nurse's Health study showed that 
women with early menarche or treated with oestrogen-containing regimens 
such as oral contraceptives or postmenopausal hormone replacement 
therapies had a significantly increased risk for SLE (HR of 1.5 to 2.1) (63, 64). 
In contrast, testosterone level is lower in male patients with SLE compared to 
those without the disease (65). 
Progesterone contributes to the development of SLE by downregulating T-cell 
proliferation and increases the number of CD8+ cells (66). Both high 
progesterone and oestrogen levels promote a T-helper 2 (Th2) response, 
which favours autoantibody production (67). While hyperprolactinaemia has 
been associated with lupus flare (68). Lastly, there is an increased incidence 
of thyroid disease in patients with SLE compared to healthy controls (HCs) as 
well as elevation of both anti-thyroid antibodies and serum thyroid-stimulating 
hormone (TSH) levels (69). 
2.2.4. Environmental factors 
Candidate triggers of SLE include ultraviolet light, infectious, endogenous 
viruses or viral-like elements and certain drugs.  
Exposure to ultraviolet causes aberrant apoptosis of keratinocytes and 
contributes to the accumulation of apoptotic cells in the skin of patients with 
SLE (70). Apoptotic cells that fail to be cleared by phagocytes undergo 
secondary necrosis and subsequently releasing inflammatory mediators 
including IL-1, IL-3, IL-6, granulocyte macrophage colony-stimulating factor 
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(GM-CSF), IFNs and TNF, thereby stimulating B-cells to make more 
antibodies (71). In addition to the local effects in skin, ultraviolet light may also 
increase systemic autoimmunity by interfering with antigen processing and 
activation of macrophage by decreasing T-cell DNA methylation, which in turn 
lead to overexpression of lymphocyte function-associated antigen (LFA)-1 
(72). These T-cells may then become autoreactive, thus resulting in 
autoantibody formation. 
A number of exogenous viruses particularly Epstein-Barr virus (EBV) have 
been linked to the pathogenesis of SLE. Patients with SLE have high antibody 
titres to EBV, increased circulating EBV viral loads and make antibodies to 
retroviruses including to protein regions that are homologous to nuclear 
antigens (73). Consequently, production of antibodies to these mimicry 
molecules and endogenous retroviruses may contribute to the development 
of autoimmunity. Moreover, human endogenous retroviruses (HERV) 
including HRES-1, ERV-3, HERV-E 4-1, HERV-K10 and HERV-K18 have also 
been implicated in SLE (74). HERVs can be inherited since they are 
incorporated into human DNA. Viral infection can also induce defective 
apoptosis, resulting in loss of immune tolerance. 
More than 100 drugs have been reported to cause drug-induced lupus (DIL). 
For agents that are metabolised by acetylation such as procainamide and 
hydralazine, a genetic predisposition may play a role too since DIL cases are 
frequently reported in the slow acetylator phenotype (75). 
2.3. Pathogenesis of SLE 
As SLE is characterised by the generation of large amounts of autoantibodies 
directed against a variety of self-antigens, the loss of B-cell tolerance is 
believed to play a key role in pathogenesis of the disease (76). Evidence that 
the breakdown of B-cell tolerance occurs very early in SLE and may precede 
or trigger other immune abnormalities, is demonstrated by observation that 
SLE patients express ANAs several years before the onset of clinical disease 
(77, 78). Thus, in order to understand how tolerance is subverted in SLE, it is 
essential to review the normal B-cell development first.  
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In this section, B-cell biology and tolerance will be discussed. This comprises 
a carefully regulated process that involves the sequential differentiation of 
bone marrow precursors into immature and transitional B-cells, with further 
differentiation and maturation to mature naïve and memory subsets occurring 
in peripheral lymphoid organs (79).  
Recent advances on pathogenesis of disease, particularly highlighting the role 
of innate immune mechanisms leading to the aberrant adaptive immune 
responses in SLE, will also be reviewed.  
2.3.1. Overview of B-cell biology: Development, maturation and 
activation 
B-cell development in bone marrow and B-cell receptor 
B-cells arise from the bone marrow. They are continuously generated from 
pluripotent hematopoietic stem cells (pHSCs), multipotent myeloid progenitors 
(MPPs) and common lymphoid progenitors (CLPs) under the control of 
several key cytokines, chemokines and transcription factors including Fms-
like tyrosine kinase 3 ligand (FLT3LG), Interleukin-6 (IL6), C-X-C motif 
chemokine 10 (CXCL10), CXCL12, transcription factor 3 (TF3) and paired box 
gene 5 (PAX5) (80, 81).  
A critical step in B-cell development is the generation of B-cell receptors 
(BCRs). (82). BCRs for naïve mature B-cells are membrane-bound 
monomeric forms of IgD and IgM (83, 84). They have two identical heavy 
chains and two identical light chains, connected by disulfide bonds into a “Y” 
shape. Genetic rearrangement of hundreds of immunoglobulin (Ig) gene 
segments occur from the early stage of B-cell development; pre-pro B-cell to 
the late stage; pre B-cell, in order to provide the necessary diversity of BCR 
specificities (85, 86). The light and heavy chain loci comprise a series of V 
(variable) gene elements, followed by several D (diversity) segments (for the 
heavy chain gene only), some J (joining) segments, and C (constant region) 
exons. Genetic rearrangement of all possible combinations of V-D-J (heavy 
chain) and V-J (light chain) provides millions of unique antigen-binding sites 




In bone marrow, the first step of B-cells maturation is an assessment of the 
functionality of their antigen-binding receptors. This is carried out through 
positive selection for B-cells with normal functional receptors (89). Next, a 
negative selection is used to eliminate autoreactive B-cells in order to 
minimise the risk of autoimmunity. This negative selection process includes 
elimination of autoreactive B-cells by clonal deletion (induction of apoptosis 
following IgM cross-linking), light chain editing (upregulation of recombination 
activation gene 1 (RAG-1) and RAG-2 following binding of IgM by self-antigen 
resulting in further light chain gene rearrangement), or induction of anergy in 
the B-cell (90-92). Subsequently, immature B-cells that pass these two 
selection processes in the bone marrow then travel to the spleen for their final 
stages of maturation. They then become naïve mature B-cells. 
B-cell activation 
Following maturation in the bone marrow and spleen, naïve B-cells remain in 
peripheral tissues until they encounter an antigen. Upon encounter with an 
antigen, naïve B-cells become activated and differentiate into antibody-
producing plasma cells and memory B-cells. Some plasma cells migrate to 
the bone marrow, where they persist for several years. Moreover, they 
continue to produce antibodies even in the absence of antigen (93).  
B-cell activation can occur through T-cell independent and T-cell dependent 
mechanisms. In T-cell independent activation of B-cells, BCRs interact with T-
independent antigens (e.g., polysaccharide capsules, lipopolysaccharide). 
These T-independent antigens have repetitive epitope units within their 
structures, which allow for the cross-linkage of multiple BCRs, thus providing 
the first signal for activation (94, 95). Since T-cells are not involved in this 
activation of B-cells, the second signal has to come from other sources such 
as interactions of toll-like receptors (TLRs) with pathogen-associated 
molecular patterns (PAMPs) or interactions with factors from the complement 
system (96-98). However, this T-cell independent response is short-lived and 
does not result in the production of memory B-cells. Therefore, it will not result 
in a secondary response to subsequent exposures to T-independent antigens. 
In contrast, T-cell dependent activation of B-cells is more complex than T-cell 
independent activation. Once a BCR binds a T-cell dependent antigen, the B-
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cell internalises the antigen bound receptor through receptor-mediated 
endocytosis (99, 100). Following this internalisation, the peptide fragments of 
the antigen are presented to the cell surface of T-cells via MHC Class II 
molecules to cognate CD4+ T-cells. T-helper (Th) cells, typically follicular T-
helper cells (TFH), that were activated with the same antigen, subsequently 
recognise and bind these MHC-II-peptide complexes through their T-cell 
receptor (TCR) (101). Following the binding of TCR-MHC-II-peptide, T-cells 
then express the surface protein CD40L as well as cytokines such as IL-4 and 
IL-21 (102, 103). CD40L is an important co-stimulatory factor for B-cell 
activation by binding the B-cell surface receptor CD40, which in turn promotes 
B-cell proliferation, immunoglobulin class switching, somatic hypermutation, 
sustains T-cell growth and differentiation (104, 105). B-cells are activated 
once these signals have been received.    
Upon activation, B-cells participate in a two-step differentiation process that 
produces both short-lived plasmablasts for immediate protection, long-lived 
plasma cells and memory B-cells for persistent protection. The first step 
occurs outside lymphoid follicles but still in the secondary lymphoid organs. In 
this process, activated B-cells proliferate, may undergo immunoglobulin class 
switching and differentiate into plasmablasts that produce mostly IgM 
antibodies (106, 107). While in the second step, activated B-cells enter a 
lymphoid follicle and form a germinal center (GC), which is a specialised 
microenvironment where the B-cells can undergo extensive proliferation, 
immunoglobulin class switching and affinity maturation, directed by somatic 
hypermutation. As a result, both high-affinity memory B-cells and long-lived 




Checkpoints that control B-cell development 
Tolerance to autoreactive B-cells can occur through various mechanisms and 
at different B-cell differentiation stages. Although several stringent 
checkpoints are available, these autoreactive B-cells may evade them, 
leading to production of autoantibodies. These checkpoints are illustrated in 
Figure 2-1 and summarised below: 
i. Central tolerance – Two checkpoints are available in the bone marrow. 
In human, a majority (55-75%) of immature B-cells and only a minority 
(6-20%) of mature B-cells are autoreactive (110), suggesting that a 
significant proportion of immature autoreactive B-cells are removed 
during maturation. During different phases of BCR expression, B-cells 
with high-affinity reactivity for self-antigens are eliminated by a process 
called clonal deletion (Checkpoint-1) (111) and/or receptor editing 
(Checkpoint-2). The latter can be a double-edge sword as it can 
potentially lead to immature B-cells that express both non-autoreactive 
i.e. receptor-edited and autoreactive i.e. primary autoreactive BCRs. 
These dual specificity B-cell expressing BCRs could contribute to 
autoantibody production (112, 113) since they may rearrange their 
receptors, express non-autoreactive BCRs and evade this negative 
selection (114, 115). Other mechanisms for central tolerance to be 
breached include ‘ignorance’ and ‘anergy,’ for which autoreactive B-
cells evade removal by apoptotic cell death and emigrate from the bone 
marrow into peripheral circulation (110, 116).  
ii. Peripheral tolerance – Checkpoint-3 of tolerance occurs during B-cell 
maturation and/or differentiation in the periphery. Despite the 
mechanisms of central tolerance above, about 10% of the autoreactive 
B-cells bypass these checkpoints (117, 118). Here, the transitional B-
cells in the periphery undergo peripheral tolerance based on their BCR 
specificity and signal strength, for which the signal strength must both 
be above the range of for positive selection and below the threshold 
signaling for negative selection (119, 120). This “transitional B-cell 
tolerance” is the first B-cell tolerance check point in the periphery, 
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which eliminates about two-thirds of the transitional B-cells (121, 122). 
Unlike the central tolerance mechanisms, transitional B-cell tolerance 
is not as stringent and depends on the interplay between BCR-
mediated signals and B-cell Activating Factor of the TNF of the ligand 
Family (BAFF) signaling. Elevated BAFF levels lead to defect in 







Figure 2-1 Checkpoints that control B-cell development 
Development of B-cell begins in the bone marrow and completes in peripheral 
lymphoid tissues such as the spleen. In the bone marrow, development 
progresses sequentially through pro-B, pre-B, and immature B cell stages.  B-
cell receptors in the developing B-cells are generated by random V(D)J gene 
recombination, resulting in abundant B-cells that are autoreactive. Immature B-
cells with strong reactivity to self-antigen undergo clonal deletion (Checkpoint 
1) and/or rearrange their immunoglobulin gene segments; a process called 
receptor editing (Checkpoint 2), which eliminates self-reactivity and thus, allows 
entry to the transitional B-cell pool. Transitional B-cells depend on BAFF for 
survival and to differentiate into mature-B cells in the spleen (Checkpoint 3). 
The transitional 1 and 2 (T1/T2) B-cells with strong self-reactivity undergo clonal 
deletion or remain outside splenic follicles as hyporesponsive anergic B-cells 
that can be rescued upon receiving T-cell help to enter the mature B-cell pool. 
Overexpression of BAFF can lead to a breach in peripheral tolerance. BAFF: 





2.3.2. The roles of innate immunity mechanisms in SLE pathogenesis 
Pathogenesis of SLE is thought to be closely related to B-cell dysfunction, and 
accordingly this is the usual target for therapies. However, an intricate 
interplay between both innate and adaptive immune elements has been 
observed in protective anti-infective immunity (125) as well as in detrimental 
autoimmunity (126). Advances in the understanding of SLE pathogenesis also 
have shed light on innate immunity pathways in not only perpetuating 
inflammation cascades, leading to disease flares, but also continues to fuel 
adaptive immune responses throughout the course of the disease. Thus, this 
provides a rationale for targeting the innate immune system for the treatment 
of SLE. 
Inducers and sensors of innate immunity 
In contrast to adaptive immunity, which uses specific immune receptors for 
each antigen, the innate immune is equipped with receptors called pattern 
recognition receptors (PRRs) that are specialised in their recognition (127). 
They are expressed by antigen presenting cells such as dendritic cells (DCs) 
and macrophages as well as other immune and non-immune cells (128). At 
least three PRRs have been described including a) the toll-like receptors 
(TLRs), which recognise nucleic acids on the cell membranes or on 
endolysosomal compartments but not in the cytosol (129); b) the nucleotide 
binding and oligomerisation domain (NOD) receptors (NLRs), which monitor 
the cytosolic compartment closely and interacting with TLR signaling 
pathways (130); and c) the retinoid acid inducible gene (RIG)-I-like receptors 
that recognise RNA or DNA in the cytoplasm (RLRs) (131). Upon activation, 
they induce various cellular responses including the transcription of several 
genes that ultimately result in the elimination of the antigen. Moreover, some 
of these receptors (e.g. NLR) are also involved in sensing “danger” signals 
resulting from perturbations of normal cellular processes (132, 133). 
Dendritic cells and innate immunity activation 
DCs are a heterogenous population of professional antigen presenting cells, 
which link the innate and adaptive immunity. There are at least two distinct 
subsets of human DCs, arising from hematopoietic stem cell.  Myeloid DCs 
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(mDCs) are thought to derive from a common myeloid progenitor and reside 
in tissues and lymphoid organs. They circulate as monocytic precursors (134). 
The other major subset of DCs, plasmacytoid (pDCs), are thought to derive 
from a common lymphoid precursor and circulate in blood (135). pDCs are 
considered the primary source of IFN-α (136, 137), which, makes them 
relevant to the immunopathology of SLE. 
In the absence of exogenous triggers, DCs contribute to the clearance of dying 
or apoptotic cells and the maintenance of tolerance. Uptake of pathogenic 
antigens in the presence of a variety of accessory danger signals such as 
microbial-derived pathogen-associated molecular patterns (PAMPs), necrotic 
cells, heat-shock proteins and oxidation products induces DC maturation 
(138, 139), manifested by downregulation of phagocytic receptors, 
upregulation of antigen presentation machinery and costimulatory molecules 
(140, 141). Moreover, activated DCs play various roles including to secrete 
chemokines that attract innate and adaptive responders to the site of injury 
(142), stimulate naïve T-cells in order to generate immunological memory 
(143), as well as present antigen to antigen-specific T-cells (144), which 
subsequently can trigger both Th1 and Th2 responses (145). However, in the 
context of autoimmunity, a number of mechanisms by which aberrant DC 
function and regulation could have immunologic consequences have been 
described including imbalances in DC number, altered uptake and response 
to benign and harmful antigenic stimuli and aberrant interactions with other 
immune effector cells, triggering inappropriate downstream responses (146, 
147). 
Type I Interferon 
Type I interferon (IFN-I) comprises a large family of cytokines, including 
multiple subtypes of IFN-α and the single IFN-β, which are rapidly produced 
in response to viral infections, and act as critical mediators of host antiviral 
responses. Although many cell types can produce IFN-I, the major producers 
are pDCs (136, 137). Many different immune complexes (ICs) can activate 
pDCs, but RNA containing ICs triggering endosomal TLR seems to be the 
best IFN-α inducer (148, 149). However, IFN-I production can occur without 
TLR activation (150).  
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IFN-I presents many immunological functions such as promoting B-cell 
differentiation, immunoglobulin switch, autoantibody production and survival 
of the activated B- and T-lymphocytes (151). Detection of circulating IFN is 
often challenging but many studies have shown a correlation between SLE 
activity and the expression of IFN-inducible genes; known as “IFN gene 
signature” in peripheral blood mononuclear cells (152, 153). IFN gene 
signature also has been reported in cutaneous lesions (154), glomerular (155) 
and synovial tissue (156), suggesting a key role of IFN-I in tissue damage. 
Further studies will be required for a better comprehension of the roles of IFN-
I and DCs in SLE pathogenesis but at present, they appear to play a key role 
at the interface between innate and adaptive immunity.  
2.3.3. Summary of the interplay between innate and adaptive immune 
systems in the pathogenesis of SLE 
Key events in the immunopathogenesis of SLE are summarised into 5 steps 
below and are illustrated in Figure 2.2. 
Step 1: Loss of self-tolerance 
Deficiency in clearance of apoptotic cells leads to an abundance of nucleic 
acid remnants. These activate the TLR7 and TLR9 (157, 158), expressed by 
the pDCs, which then stimulate excessive production of various inflammatory 
cytokines including IFN-α. IFN-α activates variety components of the immune 
system including mDCs. Once activated, mDCs present self-antigens and 
other proteins (including BAFF and APRIL) to T- and B-cells leading to cell 
proliferation, maturation, differentiation and survival, and excess autoantibody 
and cytokine production (159, 160). 
Step 2: Production of autoantibody 
T-cell receptor interacts with MHC on antigen presenting cells and triggers the 
T-cell response. However, T-cell needs a second co-stimulatory signal. Co-
stimulatory molecules such as CD28:B7 and CD40:CD40 ligands help 
activate B-cells (161). Thus, autoreactive T-cells provide help to B-cells which 
subsequently produce large quantities of autoantibodies. These 
autoantibodies form immune complexes (ICs). 
Step 3: Deposition of immune complexes 
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Circulating ICs that are not adequately cleared will then be deposited in 
tissues or organs such as kidneys and skin. 
Step 4: Immune complex-associated inflammation 
In healthy individuals, immune complexes are cleared by Fc and complement 
receptors (162). However in SLE, genetic variations in FcR genes and the 
C3bi receptor gene (ITGAM) (47, 163) may impair the clearing of immune 
complexes, which then deposit and cause tissue injury at sites such as the 
skin and kidney. Immune complex-associated inflammation can also occur 
activation of macrophages and neutrophils via surface Fc-receptors which 
bind IgG (164). 
Step 5: Tissue fibrosis and damage 
Production of pro-inflammatory and pro-fibrotic cytokines including IL-4 and 
tissue growth factor-beta (TGF-β) lead to irreversible tissue damage or 
scarring (165, 166). Finally, when these immune elements remain 
dysregulated in SLE, these lead to further tissue damage and cell death, 























Figure 2-2 Immunopathogenesis of SLE 
The interplay between innate and adaptive immune system in SLE pathogenesis. 1) Deficiency in clearance of apoptotic debris leads to abundance of nucleic acid 
remnants. These activate Toll-like receptors (TLR7 and 9) expressed by pDCs, which then stimulate excessive production of IFN-α. 2) IFN-α is a pluripotent 
cytokine that activates a variety components of the immune system including mDCs, T-cells and B-cells, leading to cell proliferation, maturation, differentiation and 
survival, as well as excess autoantibodies and cytokines production. 3) These autoantibodies then form ICs, which subsequently deposit in tissues or organs such 
as the kidneys and skin. 4) IC-associated inflammation can occur via complement activation classical pathway, activation of macrophages and neutrophils via 
surface Fc-receptors that bind IgG. 5) Finally, production of pro-inflammatory and pro-fibrotic cytokines including IL-4 and tissue growth factor-beta (TGF-β) can 
lead to irreversible tissue damage or scarring. APRIL: A PRoliferation-Inducing Ligand; Ab: antibody; BAFF: B-cell Activating Factor of the tumour ncrosis factor of 
the ligand Family; DNA: deoxyribonucleic acid; FcR: Fc receptor; IC: immune complex; mDC: myeloid dendritic cell; pDC: plasmacytoid dendritic cell; PMN: 
polymorphonuclear cell family; TGF-β:  Tissue growth factor beta; TLR: Toll-like receptor 
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2.3.4. Autoreactivity and autoimmunity 
The presence of ANAs with a range of specificities in apparently healthy 
individuals is common, with studies from geographically diverse locations 
reporting about one-quarter of individuals express at least low levels of 
autoantibodies, corresponding to immunofluorescence assay titres of at least 
1:40 dilution (167, 168). The high prevalence of autoreactivity in the population 
suggests that autoantibodies may be expressed as part of a healthy immune 
response as well as exhibit important immune regulatory functions (169).  
Nevertheless, in a small number of these individuals, presumably with 
additional pre-existing genetic and/or epigenetic susceptibility factors, these 
autoantibodies may promote activation of immune responses that result in 
progression from benign autoreactivity to autoimmunity. Therefore, individuals 
with ANA constitute an “At-Risk” population of whom a minority will progress 
to overt, clinically apparent disease. It remains unclear how this controlled 
state of autoimmunity develops into clinical disease. If this transition from pre-
lupus to SLE could be predicted, early and potentially more effective 
intervention could be employed. 
Over time, the risk of progression to systemic autoimmune disease may 
increase as autoimmune responses escalate and damage accumulates. 
Thus, non-specific intermittent symptoms that characterise the At-Risk 
individuals may develop into clinical SLE with subsequent progression of the 
disease, ultimately resulting in severe organ manifestations in a subset of 
patients. This natural course from benign autoreactivity to autoimmunity is 





Figure 2-3 The natural course of progression from autoreactivity to 
clinical autoimmunity 
After a variable period of time from autoantibody production i.e. immune 
onset, circulating immune complexes can be formed and may be 
deposited in tissues and organs, where they can potentially initiate an 
inflammatory process. This process can be regarded as the pathology 
onset of SLE. Subsequently, immune complex-associated inflammation 
in the target tissues or organs may lead to formation of immune 
histopathological changes, albeit individuals are asymptomatic clinically. 
This is termed as sub-clinical SLE. Finally, all clinical and immunological 
abnormalities occurring between clinical onset and diagnosis or 





2.4. Outcome measures 
Given the heterogeneity of disease presentation and clinical course among 
patients with SLE, the British Society of Rheumatology (BSR) 2017 Guidance 
recommends that all patients should be monitored on a regular basis for 
disease manifestations, clinical activity, drug toxicity and co-morbidities (170). 
Assessment and monitoring can be achieved by using several validated 
indices for clinical and clinical trial purposes. Only the widely used indices that 
are relevant to this thesis are described in details below. These indices or 
tools can be used to assess lupus in general or may be organ-specific. Several 
objective outcome measures that are relevant to this thesis are also described 
in this section. It is important to note that during these assessment, features 
attributable to active SLE must be distinguished from chronic damage, drug 
toxicities and other causes such as infection or malignancy. 
2.4.1. British Isles Lupus Assessment Group (BILAG)-2004 Index 
The classic British Isles Lupus Assessment Group (BILAG) was originally 
developed to match the physician’s intention to change therapy (171). The 
revised BILAG Index (version 2004) measures disease activity (scored from 
grade A to E) in 9 body or organ systems affected by SLE based on clinical 
assessments and laboratory results (172). The BILAG-2004 index covers 97 
items as opposed to 86 items in the classic BILAG and records disease activity 
occurring over the past 4 weeks. Each domain or system is then given an 
overall grade of: 0 = not present, 1 = improving, 2 = same, 3 = worse, or 4 = 
new. The grading is detailed Table 2-2. The numerical global BILAG-2004 
score has also been introduced to facilitate comparison with other disease 
activity indices (173). Each grade is weighted as follows: grade A = 12 points, 
grade B = 8 points, grade C = 1 point and grades D/E = 0. The global BILAG-
2004 score is then calculated by adding the total points from the nine BILAG 
grades.  
The BILAG-2004 Index is recognised as a valid and comprehensive tool in 
measuring disease activity due to SLE (174). The strengths of this tool include 
highlighting the importance of assessing patients' individual bodily systems 
rather than a global or overall score, it incorporates the important element of 
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change in disease state with time, is sensitive to small changes (175) and 
distinguishes between disease activity and disease severity. Its 
disadvantages include high administrative burden and requirement of formal 
training as may be difficult to perform by inexperienced raters.  
Table 2-2 Grade and definition of BILAG-2004 index  
Category Definition 
A Severely active disease (sufficient to require disease-
modifying treatment ie: >20mg/day prednisolone, 
immunosuppressant and  cytotoxics) 
B Moderately active disease (requires only symptomatic therapy, 
for example, prednisolone ≤20mg/day prednisolone, or anti-
malarials 
C Mild stable disease (no indication for changes in treatment) 
D Inactive now but previously active 
E Never affected 
 
2.4.2. SLE Disease Activity index (SLEDAI) and its versions 
The SLE disease activity index (SLEDAI) was first developed and introduced 
in 1985. The SLEDAI-2K (version 2000) is a modified validated instrument that 
measures disease activity within the last 10 days. It is a global index and 
includes 24 clinical and laboratory variables that are weighted by the type of 
manifestation but not by severity (176). The total score falls between 0 and 
105, with higher scores representing increased disease activity. The SLEDAI-
2K has been shown to be a valid and reliable disease activity measure in 
multiple patient groups (177, 178).  
Another modified version of SLEDAI was developed for use in the Safety of 
Estrogens in Lupus National Assessment (SELENA) study; SELENA-SLEDAI. 
A glossary was added and the modification allowed for documentation of 
persistent active disease in some descriptors such as rash, mucosal ulcers, 
and alopecia, which were previously not scored unless they were new or 
recurrent. Additionally, the SELENA-SLEDAI also accepts the presence of 
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either the objective or subjective findings for the descriptor to be scored as 
present (64). 
The advantages of SLEDAI and its versions include low administrative burden, 
practicality and are the most commonly used global disease activity measures 
in longitudinal observational studies and clinical trials. The disadvantages 
include inability to capture improving or worsening of symptoms, do not 
account the severity within an organ system and some items that are clinically 
important and potentially life-threatening such as haemolytic anaemia and 
ascites, are not included as descriptors.  
2.4.3. SLE Responder Index (SRI) 
The SLE Responder Index (SRI) is a composite outcome that incorporates a 
modification of SELENA-SLEDAI, BILAG and a 3-cm visual analogue scale 
(VAS) of physician’s global assessment (PGA) to determine patient 
improvement. The SRI was derived following post-hoc analysis of a phase II 
belimumab study in SLE in order identify subjects with a meaningful clinical 
improvement in disease activity and response to treatment (179). A responder 
was defined if fulfilling all of the following: (i) ≥ 4-point reduction in SELENA-
SLEDAI score; (ii) no new BILAG A (severe disease activity) or two new 
BILAG B scores (moderate disease activity) and (iii) no deterioration from 
baseline in the PGA by at least 0.3 points (or 10 % of 3-point VAS). 
The advantages of SRI include it ameliorates the limitations of each of the 
individual index that constitute this composite measure and SRI has been 
associated with global benefit for patients with SLE in clinical trials (180, 181). 
However, the SRI has some significant differences in outcome from the scores 
from which it was derived.  For example, the BILAG component is only defined 
by no new worsening. Thus, a patient can qualify as a responder when a 
feature of SLEDAI resolves, while other features (if present at baseline) stayed 
the same or worsened slightly (one x BILAG B). The relevance of this index 
for clinical practice is therefore currently less clear. 




The BILAG-Based Composite Lupus Assessment (BICLA) is a composite 
index that was derived by expert consensus of disease activity indices. The 
BICLA response was first used as the primary endpoint in the phase II 
randomised controlled trial (RCT) of Epratuzumab in autoantibody positive 
SLE (182). Requirement for the BICLA response were: (i) BILAG-2004 
improvement (all A scores improved to B/C/D and all B scores improved to C 
or D); (ii) no worsening in disease activity (no new BILAG A or more than one 
new BILAG B score); (iii) no worsening of total SLEDAI-2K score from 
baseline; (iv) no significant deterioration (<10% worsening relative to baseline) 
in physician’s global assessment and (v) no treatment failure (initiation of non-
protocol treatment).  
The strength of BICLA index is that it requires a stringent response in all body 
systems that are involved at baseline and require that there are no new flares 
in the remaining body system. Moreover, BICLA also incorporates treatment 
failure which is clinically meaningful particularly in terms disease burden and 
comorbidity perspectives, whether this may be cessation of therapy, 
increment in daily oral prednisolone dose or addition of alternative 
immunosuppressant. The disadvantage includes administrative burden as 
formal training is essential for commercial or academic optimal performance 
and further validation is needed for BICLA to be used widely in clinical practice 




2.4.5. Cutaneous Lupus Erythematosus Disease Area and Severity 
Index (CLASI) and the revised version (RCLASI) 
Several organ-specific disease activity indices have been developed in lupus. 
Since mucocutaneous and musculoskeletal complaints are two most common 
manifestations of SLE, indices and outcome measures related to these are 
described below.  
Current methods for assessing cutaneous lupus erythematosus (CLE) include 
using the validated clinical indices such as the CLE Disease Area and Severity 
Index (CLASI) (183) and the revised CLASI (RCLASI) (184). CLASI is a 
comprehensive tool that comprises assessment for disease activity and 
damage in CLE. The activity components attempt to quantify the level of active 
inflammation in the skin, scalp, and oral mucosa. For example, lesions with 
greater visual intensity (dark purple is worse than faint erythema) and scaling 
are considered to be more active and would be scored appropriately higher 
than those without. While the components for damage are dyspigmentation, 
scarring or atrophy and scarring alopecia. CLASI  has been shown to be valid, 
reliable and is sensitive to changes (185, 186). A four-point or 20% decrease 
in CLASI activity score has been shown to be the most specific criterion in 
classifying patients as responders or non-responders and represents the 
minimal clinically important change (187). Nonetheless, CLASI scoring is 
heavily influenced by the number of areas involved rather than the coverage 
of skin within each area, higher weighting of visible areas tends to cause 
greater patient impairment as well as subjective elements in assessing 
mucocutaneous ulcers and alopecia.  
A study from Germany reported that the descriptors in CLASI did not reflect 
an accurate assessment for all CLE subtypes particularly the chronic CLE 
(CCLE) and lupus erythematous tumidus (188). Therefore, the RCLASI was 
derived by adding oedema or infiltration and subcutaneous nodules or 
plaques as descriptors for disease activity. RCLASI has been used in clinical 
trials however the limitations include high administrative burden and lack of 
use in clinical practice.   




Discoid lupus erythematosus (DLE) is a disfiguring inflammatory skin disease 
and is a form of CCLE. Since DLE has distinct morphologies compared to 
other CLE subtypes, the Score of Activity and Damage in Discoid Lupus 
Erythematosus (SADDLE) was derived to account for items that were 
attributed to DLE (189). The items for activity include erythema, scaling and 
induration while for damage are scarring or atrophy and dyspigmentation. 
Each item is graded between 0 to 3 in 13 parts of the body with a total score 
ranges between 0 and 195. SADDLE index has been shown to be valid, 
correlates well with other global assessment scores and has been used in 
clinical studies (190, 191). Further studies are required to investigate its 
responsiveness to change with therapy.  
2.4.7. Musculoskeletal Ultrasound 
The most widely used disease activity indices for the assessment of 
musculoskeletal symptoms in SLE are the musculoskeletal items of the 
SLEDAI and BILAG-2004 indices. However, these tools were designed to 
assess multi-organ system disease and therefore might capture less details 
on an individual organ system compared to established composite index such 
as Disease Activity Score in 28 joints (DAS28) for RA. 
The low frequency of clinical synovitis makes measurement of 
musculoskeletal disease activity difficult in SLE. Musculoskeletal ultrasound 
(MSK-US) can provide objective assessment of inflammation, detect 
subclinical synovitis and has been widely used in other rheumatologic 
conditions like RA for trial and clinical practice (192, 193). However, there are 
limited data in SLE. In a systematic review for which I am the co-author, we 
found that the rates of abnormality in terms of synovitis, tenosynovitis and 
erosions were highly variable among the studies included. Besides that, there 
were poor to moderate association between ultrasound abnormalities and 
disease activity indices and immunological findings. Notably, there was 
moderate to high risk of bias and there were concerns about applicability in 
most studies (194). Thus although MSK-US has potential value in the 
assessment of musculoskeletal symptoms in SLE, studies that address these 
methodological variation and promote consensus on ultrasound abnormalities 
are required before it can be used as a valid outcome measure in lupus.  
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2.4.8. Laser Doppler Imaging 
Disease activity indices for CLE such as CLASI, RCLASI and SADDLE were 
developed to document activity in the whole parts of the body rather than 
localised lesions and were subjective to physicians and patient’s report. Thus 
novel quantitative outcome measures that are valid and assess individual 
lesion accurately is needed.  
One attractive approach is to measure the skin microcirculation. 
Microcirculatory abnormalities contribute to the pathophysiology of many 
autoimmune rheumatic diseases (ARDs) including CLE (195). Furthermore, 
various novel targeted therapies are currently under development or 
investigation in CLE with pharmacologic effect on skin microcirculation. Laser 
Doppler imaging (LDI) is a non-invasive imaging modality that monitors the 
total local microcirculatory blood perfusion including the perfusion in 
capillaries, arterioles, venules and shunting vessels and has been used to 
assess responsiveness after pharmacological stimuli (196). Alteration in 
peripheral blood flow (as measured by LDI) has been shown to correlate with 
the degree of inflammation in skin psoriasis (197). Our group for which I am 
the first author, is the first to report the use of LDI in CLE. We demonstrate 
that LDI is valid, reliable, has a better correlation with histology from skin 
biopsy compared to currently used clinical tools and is responsive to change 




2.5. Overview of targeted therapies  
A wide range of immunological abnormalities have been described in relation 
to pathogenesis of SLE. Figure 2-4 illustrates the range of target molecules 
and the corresponding therapeutic agents currently available or under 
investigations. 
B-cells have traditionally been seen as central to this. The loss of B-cell 
tolerance is the key to the production of autoantibodies. In addition to 
functioning as sources of autoantibodies, B-cells are also efficient antigen-
presenting cells (199) and secrete a wide range of cytokines which exhibit 
both autocrine and paracrine effects (200). For instance, once an appropriate 
stimulus is detected by both B-cell receptor (BCR) and CD40, B-cells secrete 
pro-inflammatory cytokines such as lymphotoxin-alpha, TNF and IL-6, which 
may act as growth and differentiation factors and assist in formation of 
germinal centre structures in inflamed tissues.   
T-cells play a role in the pathogenesis via T-cell–antigen-presenting cell 
interaction and B-cell help (201), defects in various intracellular signal 
transductions in T-cell pathways (202) and inadequate suppression of 
autoreactive cells by regulatory T-cells (Tregs) (203).   
Recent advances in SLE pathogenesis have focussed on abnormalities in 
clearance of apoptotic and secondary necrotic cells as well as increased 
innate sensing of nuclear antigen as demonstrated by overactive IFN-I and 
IFN-III production and TLR signalling in patients with SLE (151).  
Despite heterogeneity in pathogenesis, translating targeted therapy from 
bench to bedside has been more problematic in SLE than in other ARDs, with 
many theoretically well-founded agents appearing to have failed in clinical 
trials as a result of inefficacy, problem with trial design and/or safety issues 
(7). Table 2-3 summarises biologics currently available and in late 













Figure 2-4 Range of target molecules based on immunopathogenesis of SLE and their corresponding therapeutic agents 
Only therapeutic agents that are currently available and in late development in SLE are shown. IFN-α activates a variety of components of the immune 
system including mDCs, T-cells, B-cells and JAK-STAT signalling, leading to cell proliferation, maturation, differentiation, survival, and excess autoantibody 
and cytokine production. IFN and IFN receptor can be targeted using sifalimumab and anifrolumab respectively. While JAK-STAT can be targeted using 
baricitinib. T-cells need a second co-stimulatory signal such as CD28:B7 and CD40:CD40 ligands to activate B-cells. The latter co-stimulatory molecule can 
be targeted using abatacept. Activated B-cells can be targeted using anti-CD20 depleting agent such as rituximab and by inhibiting their B-cell activating 
factors either using belimumab or atacicept. Activated B-cells secrete a wide range of cytokines including interleukin-6 and interleukin-12. Both cytokines 
can be targeted using sirukumab and ustekinumab respectively. Ag, antigen; APC, antigen presenting cells; APRIL, a proliferation-inducing ligand; BAFF, B 
cell-activating factor of the tumour necrosis factor family receptor; BAFF-R, BAFF-receptor; BCMA, B cell maturation antigen; IFN-α,  interferon-alpha; IL-
6R, interleukin-6 receptor; JAK-STAT, janus kinase signal transducer and activator of transcription; mDC, myeloid dendritic cells; pDC, plasmacytoid dendritic 
cell; TACI, tumour necrosis factor receptor superfamily member 13
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Table 2-3 Summary of biologics currently available and in late development for the treatment of SLE  
Drug Molecular Target Phase Comments Ref 
Belimumab BAFF blockade III Both Phase III trials met their primary endpoints; 
improvement in the SRI-4 at week 52. The first biologic 
approved by the US FDA for use in SLE. 
(10, 11) 
Rituximab CD20 depletion III Both non-renal and renal Phase III trials failed to meet their 
primary  endpoints; achieving and maintaining BILAG 
overall clinical response and overall renal response 
respectively at week 52. Post-hoc analysis in non-renal trial 




Abatacept Selective T-cell 
co-stimulation modulator 
II/III Phase II study in non-renal failed to achieve its primary 
endpoint; the proportion of patients with at least a new 
BILAG grade B flare at week 52 after the start of the steroid 
taper. Might be beneficial in arthritis manifestation.  
Phase III trial in renal lupus failed to meet its primary 





Drug Molecular Target Phase Comments Ref 
Atacicept BAFF and APRIL 
blockade 
II/III Phase II/III trial in renal SLE was suspended due to severe 
infection. Phase II/III trial in non-renal SLE is ongoing. 
(208) 
Sifalimumab Type I IFN-α blockade II Primary endpoint; SRI-4 at week 52 was met with 
improvement in skin and joint manifestations, although the 
treatment effects were modest. 
(209) 
Anifrolumab Type I IFN-α receptor 
blockade  
II Primary endpoint; a composite of SRI-4 and sustained 
reduction of corticosteroid <10mg/day at week 24 was met 
in non-renal SLE indication with clinically important 
improvement in skin and joint manifestations. 
(210) 
Baricitinib Selective janus kinase I  
(JAK1) and JAK2 blockade 
II Primary endpoint; the proportion of patients achieving 
resolution of SLEDAI-2K arthritis or rash at week 24 was 
met in non-renal SLE indication, with significantly greater 
resolution of arthritis or rash in baricitinib compared to 
placebo. 
(211) 
Ustekinumab Interleukin 12/23 blockade II  Primary endpoint, SRI-4 at week 26 was met including the 
largest SRI-4 response rate against placebo (29%) reported 




Drug Molecular Target Phase Comments Ref 
Sirukumab Interleukin-6 receptor 
blockade 
II Primary endpoint; change in proteinuria from baseline to 
week 24 was not met. About 15-20% of the sirukumab-
treated group achieved meaningful reduction in proteinuria 
versus placebo, 0%. 
(213) 
 
APRIL, a proliferation-inducing ligand; BAFF, B cell-activating factor of the tumour necrosis factor family receptor; BILAG, British Isles Lupus 
Asessment Group; IFN-α, interferon-alpha; JAK, janus kinase; SRI-4, systemic lupus erythematosus responder index using a 4-point reduction in 





2.6. B-cell Targeted Therapy
As B-cells have multiple pathogenic roles in SLE, various strategies for B-cell 
blockade have been investigated including B-cell depletion, inhibition of the 
survival factors, inhibition of B-cell receptor signalling, development of B-cell 
tolerogens and targeting plasma cells with varying degree of success in 
clinical trials (214). In this literature review, only currently available biologics; 
belimumab, rituximab and abatacept are discussed in details, in line with the 
aim of my thesis. 
2.6.1. Belimumab  
Belimumab is a fully humanised mAb that specifically binds to and neutralises 
the soluble cytokine, BAFF, preventing it from binding to its receptors on the 
surface of B-cells. B-cell survival, maturation and differentiation are mediated 
by the two cytokines; BAFF and its homologue, A PRoliferation-Inducing 
Ligand (APRIL) (215, 216). They bind to three receptors that are expressed 
on B-cells at different developmental stages, thus activate their own signalling 
pathways: i) BAFF receptor (BAFF-R) binds BAFF strongly; ii)  B-cell 
maturation antigen (BCMA) binds APRIL and iii) TNF receptor superfamily 
member 13b (TACI) binds both BAFF and APRIL (217).  
Belimumab was the first therapy in over 50 years, which had gained approval 
from the US FDA and EMA for the treatment of active, autoantibody positive 
SLE. This approval was supported by the success of two RCTs; the Study of 
Belimumab in Subjects with SLE for 52 weeks (BLISS-52) (10) and the other 
was a parallel study that allowed the treatment to continue through 76 weeks 
(BLISS-76) (11). In these RCTs, both trials used a new composite index as 
the primary endpoint; improvement in the SRI-4 at week 52.  
2.6.2. Critical review of trial design in belimumab studies 
In BLISS-52 trial, higher SRI rates were achieved with belimumab 1 mg/kg 
(51%, p=0.0129) and 10 mg/kg (58%, p=0.0006) than placebo (44%) at week 
52 (11). While significantly greater SRI response at week 52 was only 
achieved in the belimumab 10mg/kg dose compared with placebo (43.2% 
versus 33.5%; p=0.017) in BLISS-76 trial (10). Thus the higher dose was 
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approved due to consistency in efficacy in both trials. Over time, data from 
long-term extension studies (LTEs) of the phase II trials showed that SRI 
response and safety profile were maintained in autoantibody positive SLE 
patients taking belimumab plus standard therapy for up to 7 years (218). 
The success of these trials is a prime example in modifying a clinical trial 
based on lessons learned from earlier trials. The results of a phase II trial of 
belimumab was negative. Co-primary endpoints; the change in the SELENA-
SLEDAI score at week 24 and the time to first SLE flare were not met in the 
belimumab-treated group. This could be  attributed to recruitment of around 
30% patients without ANA (181). The post-hoc analysis showed that ANA 
positive patients maintained responses better in the extension studies (181). 
Thus, ANA positivity was set as the inclusion criteria for both BLISS trials. 
Moreover, the phase II investigators also reviewed the various components of 
clinical response criteria used in the phase II study and derived a new 
composite response index, the SRI as the primary endpoint. The SRI 
combined elements of the SLEDAI and BILAG to ensure that both clinical 
improvement and no simultaneous clinical worsening were documented. 
Lastly, large numbers of patients (over 800 patients in each trial) were 
recruited to increase the power of the study.  
Despite meeting its primary endpoint; SRI-4 at week 52, the effect size of 
belimumab in autoantibody positive and active SLE appears small, prompting 
a search for subgroups with higher levels of response. Indeed, the magnitude 
of difference between rituximab and control groups in the phase III trial of 
Lupus Nephritis Assessment with Rituximab (LUNAR) was comparable with 
the differences observed in BLISS trials numerically but with ten times the 
numbers of patients in the latter (219).  
In clinical practice, rheumatologists use biological agents in severe cases with 
end-organ involvement and refractory to conventional immunosuppressant 
whereas both BLISS trials recruited patients mainly with mucocutaneous and 
musculoskeletal manifestations (about 2/3 of cases). Patients with severe 
lupus nephritis and neuropsychiatric manifestation were excluded although 
15% of the former had improvement in proteinuria in post-hoc analysis (32). 
These factors have contributed to the cost-effectiveness estimation being 
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problematic. In the UK, NICE estimated the cost of belimumab at £61,200 per 
quality adjusted life year (QALY), which was more than the normally 
acceptable cost of £20,000 to £30,000 per QALY. After several appeals as 
well as a substantial discounted price from the manufacturer, NICE finally 
recommended its use as an option or add-on treatment for active 
autoantibody-positive adults with SLE in 2016 (12).    
Although a pooled analysis demonstrated that greater therapeutic benefit with 
belimumab group over standard of care, might be achieved in patients with 
higher disease activity as well as greater serologic activity (i.e. anti-dsDNA 
positivity and hypocomplementaemia) (220), a more accurate means to 
identify patients likely to respond well to belimumab is needed. Several studies 
are already in the pipeline to address this including a phase III trial in lupus 
nephritis. 
2.6.3. Abatacept 
Abatacept is a fusion protein of the extracellular domain of cytotoxic T-
lymphocyte antigen 4 (CTLA4) and the constant region of IgG, that has been 
developed to block the co-stimulatory interactions between B- and T-cells. 
CTLA4-Ig acts as a competitive inhibitor for CD28 on the T-cell surface by 
binding with either CD80 (ligand B7-1) or CD86 (ligand B7-2), thus preventing 
T-cell activation (221). Consequently, this inhibits both T-cell dependent 
inflammatory pathways and T-cell dependent-B-cell responses. 
Despite promising results in animal models, RCTs in extra-renal lupus and 
renal lupus failed to meet their primary endpoints; the proportion of patients 
with at least a new BILAG grade B flare after the start of the steroid taper and 
complete renal response respectively, at week 52. However in the trial of non-
renal lupus, abatacept was associated with fewer major BILAG A flares 
compared to placebo and a subset of patients with polyarthritis showed 
significant response in secondary analyses (206).  
2.6.4. Critical review of trial design in abatacept studies 
In the trial of lupus nephritis, the problem with choosing an appropriate primary 
endpoint resurfaced. In a phase II/III trial of abatacept in lupus nephritis, 
complete response was defined if fulfilling all the following criteria: i) 
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Modification of Diet in Renal Disease (MDRD) estimated glomerular filtration 
rate (eGFR) ≥90% of screening level if normal at screening visit or eGFR 
≥90% of 6-month pre-flare value if abnormal at screening); ii) urinary protein-
to-creatinine ratio (UPCR) <0.26 gm/gm (30 mg/mmol); and iii) inactive urinary 
sediment. All complete response criteria had to be met once again, 4 weeks 
after they were initially achieved. These stringent endpoints used in defining 
renal response might have led to negative results, with only 8-11% achieving 
the complete renal response in both the treatment and placebo arms at 52 
weeks (207). A comparative analysis was performed by applying the definition 
of renal response used in the LUNAR trial of rituximab (205), showed higher 
achievement of complete renal response rates in the abatacept versus 
placebo groups; 22% and 6% respectively (219). For this reason along with 
other findings from post-hoc analyses (i.e. significant reduction in proteinuria 
in patients with nephrotic-range proteinuria and improvement in anti-dsDNA 
levels), abatacept may still have role in SLE.  
2.7. Rituximab 
2.7.1. Therapeutic indications for rituximab 
Rituximab was the first licensed, chimeric anti-CD20 mAb, initially approved 
in 1997 for the treatment of relapsed or refractory low grade or follicular 
CD20+ B-cell non-Hodgkin’s lymphoma (NHL) (222). It has since been 
licensed for diffuse large B-cell lymphomas, chronic lymphocytic leukaemia 
(CLL), patients with severe RA who have had an inadequate response or 
intolerance to other conventional synthetic disease-modifying anti-rheumatic 
drugs (csDMARDs) including one or more TNF-inhibitors and remission 
induction of AAV (223).  
In SLE,  a high degree of efficacy in a wide spectrum of SLE manifestations 
including a systematic review of off-label use in 188 cases (13) and a pooled 
efficacy analysis of lupus nephritis (14) were reported in the initial open label 
case series of rituximab, generally in highly resistant SLE. Despite the 
success of these reports, two RCTs in non-renal lupus, The Exploratory Phase 
II/III SLE Evaluation of Rituximab (EXPLORER) and renal lupus, LUNAR 
failed to meet their primary endpoints; achieving and maintaining BILAG 
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overall response and overall renal response respectively at week 52. The key 




Table 2-4 Results of phase III RCTs of rituximab and belimumab in SLE   
Characteristic EXPLORER (204) LUNAR (205) BLISS-52 (11) BLISS-76 (10) 
Number of patient 267 144 867 819 
Follow-up (weeks) 52 52 52 52 
Inclusion Criteria ANA +ve, Active disease (>1 
BILAG A or ≥2 BILAG B) and 
1 stable DMARDs 
ANA +ve history, 
≥ Class 3 LN on biopsy and 
Proteinuria (UPCR ratio >1) 
ANA/Anti-dsDNA +ve, Active 
disease (SELENA/SLEDAI ≥6) & 
stable DMARDs 
ANA/Anti-dsDNA +ve, 
(SELENA/SLEDAI ≥6) & HCQ 
could be added up to week 16 
Exclusion Criteria Severe CNS or LN and ≤12 
weeks recent use of CyC or 
CAL 
> 50% glomerular sclerosis 
and eGFR <25 ml/minute/1.73 
m2 
Severe LN or CNS,  prior RTX & 
<6 months use of CyC  
Severe LN or CNS, prior RTX  
& <1 year use of other 
biologics 
Dosing Schedule Pb + Pred + DMARDs vs 
RTX + Pred + DMARDs 
Pb + Pred + MMF vs RTX + 
Pred + MMF 
Pb + Pred  vs BLB 1mg/kg + 
Pred vs BLB 10mg/kg + Pred 
Pb + Pred  vs BLB 1mg/kg + 
Pred vs BLB 10mg/kg + Pred 
Primary Endpoint Major or Partial or No 
response based on BILAG 
Complete or Partial or No 
Renal Response Rate 
SRI SRI 
Achieved? (Yes/No) No No Yes Yes 
Comments Secondary endpoints were 
not achieved. 
Primary endpoint was met in 
Hispanic & African-American. 
Anti-dsDNA ↓, Complement ↑ 
Secondary endpoints were not 
achieved. African-Americans 
showed more partial response 
than Caucasian although was 
not statistically significant 
BLB 10 mg/kg was efficacious 
against the placebo in all three 
SRI components & reduction of 
>50% Pred dose from baseline 
Only BLB 10 mg/kg statistically 
met primary endpoint and was 
still efficacious despite index 
threshold increased 
 
ANA, anti-nuclear antibody; BILAG, British Isles Lupus Asessment Group; BLB, belimumab; CAL, calcineurin inhibitor; CNS, central nervous system; CYC, cyclophosphamide; DMARDs, disease modifying anti-rheumatic drugs; 
dsDNA, double-stranded deoxyribonucleic acid; HCQ, hydroxychloroquine; LN, lupus nephritis; MMF; mycophenolate mofetil; Pb, placebo; Pred, prednisolone; RTX, rituximab;  SRI, systemic lupus erythematosus responder index; 
UPCR, urine protein creatinine ratio
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2.7.2. Posology and pharmacokinetic of rituximab 
Rituximab is formulated for intravenous administration and administered over 
several hours (based on the standard infusion schedule). For the treatment of 
RA and SLE, the licensed dose of a course of rituximab consists of two 
consecutive 1000 mg intravenous infusions, given on Days 1 and 15 (223).  
Owing to the risk of infusion-related reactions, rituximab should be 
administered in clinical environments where full resuscitation facilities are 
available, although severe infusion reactions are uncommon in the treatment 
of ARDs. Prophylaxis with paracetamol (1 gram) and diphenhydramine 
hydrochloride (25 to 50mg, or equivalent dose of similar agent) should be 
given 30 to 60 minutes before infusion of rituximab (224). 
Clinical pharmacokinetic data are available for two consecutive doses of the 
licensed dose; 1000mg (RTX1000) and half-dose regimen; 500mg (RTX500). 
Mean terminal elimination half-life ranged from 18 to 21 days (after the second 
infusion) for RTX1000 and 16 to 16.5 days (after the second infusion) for 
RTX500. With repeat courses of therapy, there was no difference in 
pharmacokinetics between first and second courses (223).  
2.7.3. Pharmacology of rituximab 
Rituximab is an anti-chimeric mAb. The chimeric structure of rituximab 
consists of human IgG 1 and kappa-chain constant regions and heavy- and 
light-chain variable regions, from a murine antibody to CD20. The murine 
variable regions selectively bind to the CD20 antigen, expressed on the 
surface of both normal B-lymphocytes and most autoreactive B-cells. While 
the Fc domain allows rituximab to bind to Fc receptors on human effector cells, 
to recruit antibodies and complements to mediate cell lysis (225).  
The development of B-cell depletion targeted at the CD20 molecule as a 
therapeutic modality such as rituximab, represents a major advance in 
autoimmune rheumatic disease (ARD). CD20 is considered as a general B-
cell marker but it is neither expressed on stem cells nor on plasma cells that 
have returned to the bone marrow (226). This selective expression on mature 
B-cells but not on precursors such as stem cells or antibody secreting plasma 
cells makes it an attractive therapeutic target, particularly from a safety point 
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of view. Depletion via CD20 permits B-cell regeneration and moderates 
reduction of immunoglobulin levels, at least with initial therapy (223, 227).  
2.7.4. Mechanism of B-cell killing by rituximab 
B-cells killing by rituximab can be achieved through a combination of (i) 
antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of 
effector cells; (ii) activation of complement resulting in complement-dependent 
cytotoxicity (CDC) and (iii) cross-linking of multiple CD20 molecules, resulting 
in cell death via induction of non-classical apoptosis (228). These 
mechanisms are illustrated in Figure 2-5. 
ADCC is regarded to be the most important mechanism for cell killing (229). 
Evidence from use of rituximab in haematology patients has shown that 
targeted epitope expression may decline after infusion of mAbs. It has been 
demonstrated in vitro that rituximab/CD20 complexes may be removed from 
B-cells by acceptor cells via Fc gamma receptor (FcγR), preventing their killing 

















Figure 2-5 Mechanisms of B-cell killing by rituximab 
There are three possible mechanisms of B-cell killing or lysis by rituximab; 1) antibody-dependent cell-mediated cytotoxicity (ADCC), 2) complement-
dependent cytotoxicity (CDC) and 3) induction of apoptosis. ADCC is generally believed to be the predominant mechanism. In ADCC, cell killing depends 
on Fc-gamma receptor bearing natural killer (NK) cells or monocytes following the binding of rituximab to CD20. FcγR, Fc gamma receptor; MAC, the 
membrane attack complex 
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2.7.5. Critical review of trial design in rituximab studies 
The EXPLORER trial was a placebo-controlled, double-blind, multicentre 
study which recruited 257 SLE patients with moderate to severe non-renal 
and non-central nervous system lupus from North America population (204). 
Patients received either a cycle of rituximab, 2 x 1000mg infusion given 2-
week apart or a placebo with continuation of the background 
immunosuppressant. All patients also received 0.5–1.0 mg/kg of steroids 
which were tapered to 10mg daily by week 10. The primary endpoint was to 
achieve and maintain clinical response (major, partial or no clinical response) 
at week 52, assessed using BILAG criteria. No difference in both major clinical 
responses and partial clinical responses was observed between the placebo 
and rituximab groups with overall response rates of 28.4% and 29.6% 
respectively; p=0.973. Post-hoc analysis showed superiority of rituximab 
versus placebo in the African-American and Hispanic subgroups. The rates of 
BILAG A flares were also lower in the rituximab group (204).   
To assess the efficacy and safety of rituximab in lupus nephritis, the LUNAR, 
a double-blind, placebo-controlled phase III trial, randomised 144 patients in 
a 1:1 ratio to receive either rituximab or placebo, both in combination with a 
background mycophenolate mofetil (MMF) and prednisolone (205). The 
primary endpoint at 52 weeks was not achieved. There was no statistically 
significant difference in the overall renal response (complete and partial) 
between the rituximab and placebo groups; 57% versus 46% respectively 
(p=0.180).  
Despite the failure of both trials in meeting their primary endpoints, there were 
several lessons to be learned particularly the issues regarding to the trial 
design (214, 231). Firstly, both studies permitted aggressive background 
immunosuppressant and mandated concurrent high dose of oral 
prednisolone. Consequently, more than 50% of the patients in both rituximab 
and control groups had become steroid-dependent, while in the LUNAR study, 
patients were also co-prescribed a high dose of MMF up to 3g/day. Thus, the 
intensity of these “standard of care” therapy might have masked the 
therapeutic benefit of rituximab against placebo.  
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Secondly, the primary endpoint used in EXPLORER required patients to first 
meet a low disease activity landmark (BILAG C or better in all domains) at 6 
months, and then to not flare in the second 6 months. However, the initial 
landmark was difficult to achieve since only 27% of patients achieved score C 
or better in all domains, resulting in lower power to detect a difference in flare 
rate subsequently. This difficulty might have been contributed by (i) most 
patients had considerably higher baseline scores than the 1 x BILAG A or 2 x 
BILAG B scores required in inclusion criteria, so even a substantial 
improvement in disease activity was not sufficient and (ii) because BILAG B 
scores were sometimes poor at differentiating partial responses. For instance, 
a mild transient malar rash scored the same as deep scarring discoid while 
the number of joints with synovitis (scored as B) were highly variable. 
Nonetheless, even in patients who did meet the 6-month endpoint, there was 
no evidence of a significant rise in BILAG total score again in the placebo arm 
since a high dose steroid regime might have been sufficient to restore stable 
disease when given with background immunosuppressant. To sum up, this 
endpoint relied on passing an initial endpoint in a first phase and then not 
flaring in a second. However, the first of these was rarely achieved and the 
second was probably unnecessary. 
Lastly, the BILAG might have been scored inappropriately in EXPLORER, 
both as an inclusion and a response criterion. The BILAG index originally was 
developed to match the physician’s intention to change therapy. Although only 
just over one third of patients achieved major clinical response (MCR) or 
partial clinical response (PCR), and post treatment mean global BILAG was 
approximately 8 (on the scale A=9, B=3, C=1), withdrawals due to rituximab 
inefficacy were relatively low. About 70% of patients continued the trial for one 
year as per trial protocol. This observation suggested that either residual 
disease activity was actually felt by treating physicians not to be as severe as 
the BILAG scores awarded, or that the disease activity present at baseline 
was not as severe as the BILAG scores suggested, or both. 
It is worth noting that failure of RCTs of rituximab has been largely attributed 
to poor trial design including inappropriate endpoints, the use of an active 
comparator, inadequate inclusion criteria for a heterogeneous disease and 
underpowered sample size (214). For this reason as well as evidence of 
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efficacy from off-label use including the BILAG Biologics Registry (BILAG-BR) 
in the UK (232), rituximab is commissioned by the National Health Service 
(NHS) England for use in patients with refractory SLE (233). Nevertheless, 
further evidence pertaining to its efficacy is demanded. Better-designed trials 
of rituximab in renal and non-renal lupus are currently being planned.  
2.7.6. B-cell depletion and association with clinical efficacy 
Treatment with rituximab is followed by peripheral B-cell depletion, evident as 
early as two weeks after administration of the first infusion. Early studies 
indicated inconsistent relationship between peripheral B-cell numbers and 
clinical response to rituximab when they were measured using conventional 
flow cytometry. For example, in the EXPLORER trial, about 10% of the 
patients in the rituximab group did not achieve complete depletion after the 
second infusion. Removing patients with incomplete B-cell depletion did not 
change the primary outcome (204). While in the LUNAR trial, among 
rituximab-treated patients with high baseline anti-dsDNA titres (>123 IU/ml), 
those who were renal responders at week 52 had a greater depletion of 
CD19+ cells compared with renal non-responders (205).  
A better means for enumerating peripheral B-cells is by using highly sensitive 
flow cytometry (HSFC), a protocol that is optimised for the detection of 
plasmablasts (234). Plasmablasts have a different morphology than mature 
naïve and memory B-cells. Naïve and memory B-cells are mostly resided 
within the lymphocyte regions while plasmablasts mostly outside lymphocyte 
region. Moreover, plasmablasts have lower and heterogenous CD19 
expression. For this reason their numbers are underestimated should the 
gating only focus on the CD19 positive lymphocyte region as in conventional 
cytometry. Thus, enumeration of B-cells using HSFC results in a more 
stringent definition of depletion; peripheral CD19+ <1 cell/µl compared to the 
conventional cytometry; CD19+ between 50–100 cells/µl.  
Our group previously reported that complete B-cell depletion (after the second 
infusion of rituximab) was associated with clinical response (MCR or PCR) 
compared to those with incomplete depletion; 100% versus 68%; p=0.012 
respectively. This B-cell biomarker will require validation prior to its use in 
clinical practice.  
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In other ARD such as RA, persistence of plasmablasts after the first infusion 
of rituximab was associated with inferior clinical response at 6 months (234). 
Moreover, patients with lower numbers of plasmablasts pre-rituximab were 
associated with plasmablast depletion and good clinical response using half 
dose regimen (500mg x 2) (235) while doses of rituximab even higher than 
licensed might be employed in those with persistence of plasmablasts after 
therapy (236).  
2.7.7. Factors associated with incomplete depletion during rituximab 
Experience in B-cell malignancies has identified five different potential 
mechanisms that may explain the reasons for incomplete B-cell depletion with 
rituximab. However to date, there are no data on which of these mechanisms 
predominates in SLE. This knowledge will be fundamental in order modify the 
use of rituximab for a more efficient depletion and outcome.  
Insufficient rituximab dose 
There are two dosing regimens to administer rituximab in ARDs: (i) 1g given 
2-week apart (standard RA dose) and (ii) 375 mg/m2 of body-surface area, 
once weekly for 4 weeks (full lymphoma dose). However, there is no head-to-
head study that compares these regimens. Our group previously showed that 
adding an extra 1g infusion of rituximab at 4 weeks in RA patients with 
incomplete B-cell depletion, resulted in better depletion and clinical response 
than the standard RA dose (236).  
In SLE, a group in London reported that patients with SLE had markedly lower 
serum rituximab levels than patients with RA at both 1 and 3 months, 
regardless of the level of depletion (237). This could be explained by 
internalisation and destruction of rituximab by target B-cells regulated by 
FcλRIIb (238). Other plausible reason could be due to trogocytosis (CD20 
shaving) as reported in CLL (239). Nevertheless, the absence of an inverse 
correlation between serum rituximab levels and B-cell counts at 1 month might 
suggest other intrinsic resistance of B-cells to rituximab-induced depletion. 
In our previously reported SLE cohort, the time-to-relapse was highly variable. 
The median time to re-treatment with rituximab was 18 months, by which time 
substantial B-cell repopulation and clinical relapse had occurred (16). Data in 
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RA indicated that giving a second cycle of rituximab at 6 months, if there was 
active disease, enhanced depletion and clinical response (240).   
Ineffective complement function 
Complement is a group of over 30 proteins that act in concert in the recognition 
and elimination of pathogens via direct killing and/or stimulation of 
phagocytosis (241). Type 1 mAbs, such as rituximab localises CD20 into lipid 
rafts, thus enhances C1q recruitment and activation of CDC. Induction of CDC 
is critically dependent on the distance between the mAb binding site and the 
plasma membrane, with closer binding associated with more efficient coating 
of active complement components onto the target cell (229). 
To maximise the clinical effect of rituximab, it is important to consider whether 
patients with SLE will be able to elicit CDC and ADCC responses to the drug. 
Some patients harbour deficiencies in classical complement components, 
C1q, C2 and C4, resulting in defective immune complex clearance. Studies in 
CLL showed that over a third of patients were deficient in one or more 
complement components, correlating with reduced CDC responses (242). 
However, there is limited data in SLE. Deficiencies in classical complement 
components have also been linked to patients being more susceptible to 
infections with organisms such as Streptococcus pneumonia and Nisseria 
meningitides (243). These findings raise an important questions: first, do 
complement deficiencies correlate with ineffective complement function; and 
second, how do these affect the efficiency of mAb treatments? 
Fc-gamma receptor (FCGR) genetics variants 
ADCC is an important effector mechanism in the eradication of the 
autoreactive cells particularly in vivo. Most biological agents including 
rituximab have IgG1 Fc regions, which bind to the FCGR on immune effector 
cells. SNPs in the coding regions of the FCGR2A and FCGR3A genes appear 
to have clinical significance as they have been reported to correlate with 
responses to therapeutic mAbs in B-cell malignancies (244). Data in SLE are 
limited. A small study (n=12) suggested that low-affinity (FF) alleles of the 
FCGR3A gene required about a 10-fold increase in rituximab levels to achieve 
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the same degree of B-cell depletion in patients with high-affinity genotypes 
(VV or VF) (245). 
Development of human anti-chimeric antibody (HACA) 
In the EXPLORER and LUNAR trials, 26.0% and 15% of patients respectively 
in the rituximab group were tested positive for human anti-chimeric antibody 
(HACA) at any time during the 52-week follow-up. The results of HACA 
analyses did not affect the primary and secondary efficacy outcomes (204, 
205).  
Interestingly, HACAs were also detected in less than 10% of patients who 
were in the placebo arm and did not receive treatment with rituximab. Their 
titres were lower than those who were treated with rituximab. These 
observations highlighted the need to interpret a positive test for HACA with 
caution during rituximab treatment and raised a question on their applicability 
in clinical practice. Nevertheless, in LUNAR trial, the rituximab-treated patient 
with the highest HACA titre experienced a severe infusion reaction while 
infusion-related adverse events (AEs) were less frequent in HACA-negative 
patients (205).  
Another means in assessing the impact of immunogenicity (clinically) to 
rituximab is by combining clinical characteristics such as severe infusion 
reaction after the first infusion of rituximab, measuring one’s ability to deplete 
the CD20+ B-cells and the degree of clinical response (246). Risk factors for 
developing HACA with rituximab have not been reported. In patients with high 
HACA titres and with incomplete B-cell depletion, treatment with rituximab 
should be withdrawn as these patients will be at risk of severe infusion 




B-cell killing inhibited by BAFF and APRIL 
BAFF and its homologue, APRIL, mediate B-cell survival, maturation and 
differentiation (247). A recent study showed following an initial treatment with 
rituximab in SLE, BAFF levels were elevated and these were associated with 
rising anti-dsDNA antibody levels and subsequent disease flare (248). Thus, 
several studies are in progress to investigate the efficacy of sequential therapy 
of a BAFF-inhibitor, belimumab as maintenance following remission induction 
with rituximab in terms of flare reduction.  
2.7.8. Rituximab biosmilars 
Roche’s patent on the reference rituximab, MabThera for its licenced 
indication had expired in the European in November 2013 and the US in 
September 2016 (223). As a result, several manufacturers have developed 
biosimilars. A biosimilar is defined as a biological product that is highly similar 
to the reference product notwithstanding minor differences in clinically inactive 
components, with no clinically meaningful differences between the biological 
product and the reference product in terms of the safety, purity, and potency 
of the product. Because of the potential differences in efficacy and 
immunogenicity from a new manufacturing process, in vitro analytical studies 
and in vivo clinical trials are required to confirm clinical equivalence of the 
biosimilar with the reference rituximab prior to approvals (249). At the time of 
writing this chapter, two rituximab biosimilars; Truxima and Rixathon have 
gained marketing approvals in Europe and the US following RCTs that 
showed bio- and clinical equivalences to MabThera in RA (250, 251). The 
licensing of these biosimilars will further enhance rituximab cost-effectiveness 
profile since they are often cheaper than the originator agent. 
2.7.9. Other type 1 and 2 anti-CD20 molecules 
Anti-CD20 mAbs can be classified into type 1 or type 2 based on their ability 
to induce the reorganisation of CD20 molecules into lipid rafts upon binding 
(228). Type I mAbs induce a translocation of CD20 into lipid rafts and 
efficiently activate the classical pathway of the complement system. Examples 
of type 1 mAbs include rituximab, ofatumumab and ocrelizumab. In contrast, 
type 2 mAb such as obinutuzumab poorly activates complement but directly 
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induces cell death upon binding to CD20 without cross-linking by secondary 
antibodies. Both types of mAbs are capable of inducing ADCC in the presence 
of effector cells.  
Ocrelizumab (OCR) is a humanised anti-CD20 mAb binding to an overlapping 
CD20 epitope to rituximab with increased ADCC and reduced CDC. It met its 
endpoints; American College of Rheumatology 20% improvement criteria 
(ACR20) in clinical trials in RA (252) and was investigated in SLE (253). 
Development in these indications was halted due to major safety concerns 
(254). In post-hoc analysis of the RA trial, OCR500 + methotrexate group 
demonstrated improvement in clinical response included radiographic 
outcome but this dose was associated with an increased incidence of serious 
infection events (SIEs). In contrast, OCR200 + methotrexate group did not 
show superior efficacy compared with existing therapies, but there were no 
major safety signals  and therapy was well-tolerated (254). In the RCT of OCR 
in renal lupus, two doses of OCR were used; 400mg and 1000mg. Despite 
enhanced B-cell depletion being achieved in the OCR groups, the trial was 
halted due to increased SIE and opportunistic infections; some of which were 
fatal in the OCR + standard of care groups (253). The drug is still being 
developed in multiple sclerosis.  
Ofatumumab is a fully human anti-CD20 mAb binding to a different epitope 
than rituximab. It is licensed for resistant CLL and with evidence for efficacy 
in RA (255). No study has been done in SLE. Obinutuzumab is a humanised 
anti-CD20, also binding a different epitope to rituximab as well as an Fc region 
of the molecule that is glycoengineered to enhance ADCC. It has been 
licensed in combination with chlorambucil as a first-line treatment for CLL and 
is currently investigated in an RCT of lupus nephritis in SLE. 
2.8. Safety of rituximab in SLE and other B-cell mediated 
diseases 
The immunomodulatory properties of biological therapies including rituximab 
have naturally raised safety concerns prompting careful evaluation in clinical 
trials and intensive post-marketing surveillance. Observations from these data 
also provide insight into pathogenic basis of infectious diseases (8).   
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There are no new safety signals including the risk of infection and 
malignancies from the long-term data (RCTs + LTE studies up to 11 years) on 
use of rituximab in RA (256). With regards to SLE, although the rates of any 
infection event were similar between placebo and rituximab groups, 
interestingly, higher SIEs were observed in the placebo groups; 17% and 
9.5% respectively in the EXPLORER trial (204) and 21% versus 16% 
respectively in the LUNAR trial (205). Data regarding SIEs from RCTs and 
LTE in RA, SLE and AAV are summarised in Table 2-5. 
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Table 2-5 Summary of safety data from RCTs and LTE studies on the use of rituximab in autoimmune rheumatic diseases   













Event (SIE)  
Opportunistic Infections Risk Factors for 
Infection 
Pooled data  (RCT + LTE) 




11 962 PY RTX (Either 













years in RTX 
Group versus 
3.79/100 PY 
in Placebo + 
MTX group) 
Lung TB reactivation (n=2) 
 
Rate of other OIs: 0.06/100 PY 
(Atypical pneumonia; n=2, 
Candida; n=1, pharyngeal 
abscess; n=1, Scedosporium 
lung infection; n=1, 
Pneumocystis jirovecii 
pneumonia; n=1 and JC Virus; 
n=1) 
 
Rate of herpes zoster in RTX 
group (9/100 PY) versus  
(11.7/100 PY in Placebo + MTX 
Group 
SIE rates were similar 
before and during/after low 
IgG, but both rates were 
significantly higher than in 
patients who never 
developed low IgG 
 
Baseline risk factors for 
development of low IgG: 
older, longer disease 
duration, lower mean 
CD19+count, lower mean 
IgG levels and had 























Event (SIE)  
Opportunistic Infections Risk Factors for 
Infection 
RCT 





for 4 weeks) 
for remission 
induction 
Rate of SIE 
was similar:   
7% and 12% 





7% and 11% 
in CyC + AZA 
maintenance 
Group 
None in RTX group but 3 x fatal 
infections in CyC + AZA 
maintenance Group (i) 
Enterococcus/Escherichia coli 
sepsis (ii) Pseudomonas 
aeruginosa sepsis and (iii) 
Pneumocystis jirovecii 
pneumonia with secondary 
Staphylococcus aureus/ 
Escherichia coli sepsis in a 
patient who was not compliant 
with prophylaxis 
 
No risk factors were 
identified 





for 4 weeks) 
for remission 
induction 






CyC + AZA 
maintenance 
Group 
2 cytomegalovirus infections 
reported in RTX Group and 
none in the CyC + AZA 
maintenance Group 
RTX-treated patients had 
higher VDI at baseline 
(median, IQR: 2 (0-3)) 
compared to CyC + AZA 
maintenance (1 (0-2)) 
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Event (SIE)  
Opportunistic Infections Risk Factors for 
Infection 
EXPLORER (204) SLE 
(n=169) 
 
78 weeks Single course 
RTX (2 x 
1000mg) 
Higher rate of 









More herpes zoster infection in 
16 RTX + Group (9.5%) versus   
3 in Placebo + csDMARDs 
Group (3.4%)  
None reported 
LUNAR (205) SLE (n=72) 78 weeks Single course 










3 OIs in RTX + csDMARDs 
Group: colitis, histoplasmosis, 
and cryptococcal pneumonia 
plus fungal sepsis, respectively 
versus  









2.8.1. Risk factors for serious infection 
Incomplete and transient depletion of B-cells as well as sparing of plasma cells 
may be one reason for the relative safety of rituximab. However, excessive 
repeat cycles of rituximab may lead to progressive reduction of 
immunoglobulin  levels and increase the risk of infection (260, 261). There is 
a notable absence of data pertaining to the effect of B-cell depletion and B-
cell numbers with infection. Other risk factors associated with serious infection 
during rituximab are described below.  
Low immunoglobulin levels prior to and after therapy 
Data from a French registry in RA showed that low IgG level (<6 g/L) before a 
cycle of rituximab was associated with SIE, particularly in the 3 months 
following rituximab infusion; 16.2% versus 3.9% without low IgG (262). In 
RCTs and LTE studies in RA, low IgM and IgG levels were exclusion criteria 
for trial entry. In these studies, a similar increase in SIE rate was seen 
following rituximab both before and after the development of low IgG 
compared with those who never developed low IgG (257). This might attribute 
the SIE to other pre-existing demographic or clinical risk factors rather than 
the low IgG itself. Careful interpretation is needed, as the number of patients 
with low IgG level post-therapy was low, 3.5%. More data are needed to 
assess the effect of secondary low IgG with the risk of SIE after repeat cycles 
of rituximab. 
IgM level tends to decline following therapy. In particular, IgM levels were 
lower in patients receiving 2x1000 mg rituximab versus those receiving 2x500 
mg doses (263). In the RCTs + LTE studies in RA, 22.4% of patients 
developed low IgM (257). Low IgM level prior to and post-rituximab was not 
associated with SIE (257, 262) although this analysis might have been limited 
by the low incidence of SIE. The development of low IgA level post-rituximab 
was uncommon (1.1%) and thus, did not appear to be associated with SIE 
(257). 
In AAV, remission induction with cyclophosphamide was associated with a 
decline in all immunoglobulin classes at 6 months post-therapy and remained 
below the baseline levels up to 36 months. Following a clinical relapse, a 
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single cycle of rituximab further aggravated the decline in IgM and IgG levels 
(264). 
Concomitant glucocorticoid and csDMARDs 
Glucocorticoids impair phagocyte function and suppress cell-mediated 
immunity, thus may increase the risk of infection. Data from registries in 
France and Spain showed an increased risk of SIE with concomitant 
glucocorticoids (262, 265).  
Interestingly, the co-prescription of csDMARD appears to be safe. The initial 
phase II RCT in RA showed no increase in SIE rates using combination 
methotrexate or cyclophosphamide with rituximab (266). Data from a registry 
in Spain showed no significant difference in infection rate when rituximab was 
used either in combination with leflunomide, methotrexate or as monotherapy; 
rates were 6.2%, 6.6% and 7.4% respectively (267).  
Age and Comorbidity  
An increasing number of elderly patients with multiple comorbidities are 
diagnosed with ARDs in current practice. These patients are at increased risk 
of SIE post-rituximab (262, 265). Comorbidities investigated including chronic 
obstructive pulmonary disease, interstitial lung disease (ILD), renal failure, 
hypertension and cardiac insufficiency (262). 
Rituximab-associated neutropaenia 
Neutropaenia is recognised as a complication of rituximab when used in B-
cell malignancies with an incidence of 3-27% (268). Data in ARDs are more 
limited and the optimal management of these patients has not been defined. 
Data from large cohort studies suggested an incidence of 2.5-3.0% in RA and 
increased to 20% in AAV (269-271). In most cases, neutropaenia recovered 
promptly but counts <0.5 x109/L were associated with severe infection 
requiring treatment with intravenous antibiotics and granulocyte-colony 
stimulating factor (GCSF). Current data therefore suggests retreatment with 
monitoring is appropriate, with additional caution needed only in severely 
neutropaenic patients (270). The mechanism of rituximab-associated 
neutropaenia remains elusive. 
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2.9. B-cell independent SLE manifestations 
It is important to acknowledge that SLE is not exclusively a B-cell-dependent 
disease as evidenced by various molecules or immune pathways that are 
responsible for the pathogenesis and variability in the success of various B-
cell targeted therapies in SLE as described above.  
In a paper of which I am the co-author, we previously showed that the clinical 
response to rituximab in cutaneous manifestations of SLE relied on the 
subtype. Of 8 patients with CCLE, none of them responded. Additionally, new 
CCLE lesions were observed during B-cell depletion, suggesting that the 
initiation and activity of these lesions were not B-cell dependent (17).  
2.9.1. Discoid lupus erythematosus and the unmet needs 
DLE is a form of CCLE. It usually occurs on sun-exposed skin such as the 
face, ears and scalp. The prevalence has been reported ranging from 12.5 
per 100 000 in England to 50.8 per 100 000 in certain groups in the US (272). 
DLE can occur as an independent entity or form a part of SLE.  
Without effective treatment, DLE leads to permanent destructive scarring on 
the face and scalp and irreversible, severe hair loss. DLE can severely impair 
quality of life through impact on body image, leading to physical and 
psychological disability (273). Thus, there is a significant unmet need for 
effective therapy to improve the quality of life of patients with DLE. 
2.9.2. Challenges and opportunities in the management of DLE 
A significant proportion of patients with DLE are resistant to conventional 
therapies. There is no guideline pertaining to management of cases that are 
refractory to steroid as well as after the first line agent, anti-malarials. The 
latter are only effective in 50% of the patients at 6 months (190). For patients 
who have exhausted conventional therapies, most clinicians would use high 
dose systemic corticosteroids, experimental therapies or enrolment in clinical 
trials as available.  
One attractive opportunity is to develop a targeted approach based on the 
immunopathogenesis of DLE. Skin disease is particularly heterogeneous. 
Although immune complex deposition is a common feature, non B-cell 
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mechanisms are also responsible through activation and apoptosis of 
keratinocytes and production of inflammatory cytokines and chemokines such 
as TNF (70, 274).  
2.10. Non B-cell targeted therapies 
Given the role of pro-inflammatory cytokines in both the innate and adaptive 
immunopathogenesis of lupus, a number of anti-cytokine therapies have been 
the focus of research to more selectively and efficaciously manage patients 
with SLE. 
2.10.1. Interferon-blocking therapy 
IFN-I is a key mediator that links the sensing of classic lupus-associated 
nuclear antigens with an adaptive immune response. Its importance is 
indicated by numerous genetic associations as well as the high spontaneous 
expression of type I IFN-induced genes in circulating mononuclear cells 
(MNCs) and peripheral tissues in patients with SLE. High expression levels of 
these genes are associated with high disease activity in SLE (275).  
IFN-I is therefore a logical therapeutic target that may have certain 
advantages over B- and T-cell targets. Rontalizumab is an anti-IFN-α mAb.  
Although it did not demonstrate efficacy in a phase II RCT (276), there was 
evidence that baseline IFN activity might help to identify patients who would 
likely to respond. In this study, patients were screened at baseline to 
characterise IFN signature-positive vs -negative patients using gene 
expression in a 3:1 ratio. Patients with a positive signature had higher 
biological indices of disease activity compared with signature-negative 
patients, although clinical indices of disease activity were similar in both 
groups. Surprisingly, higher SRI response rates as well as reduced number of 
flares were observed in the rontalizumab group in the IFN signature-negative 
patients (versus placebo). None of these differences were observed in 
patients with a positive IFN signature at baseline. This intriguing evidence 
might suggest that either the dose of rontalizumab was too low to neutralise 
the IFN in patients with high IFN scores or a problem with variability in 
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detection of type 1 IFN-inducible genes with the simple 3 gene whole blood 
signature that was used. 
Results for Sifalimumab, another anti-IFN-α mAb was positive according to 
the phase II RCT of moderately to severe SLE (excluding severe lupus 
nephritis and neuropsychiatric). The primary endpoint, the SRI-4 at week 52 
was met with clinically important improvement in skin and joint manifestations, 
although the treatment effects were modest. The Cochran-Armitage trend test 
of all treatment groups showed that the number of patients achieving the 
primary endpoint was greater for sifalimumab versus placebo (p=0.053). 
Pairwise comparisons demonstrated that these effects were consistent for 
each sifalimumab dosage (200 mg monthly: 58.3%, p=0.057; 600 mg monthly: 
56.5%, p=0.094; 1200 mg monthly: 59.8%, p=0.031) compared with placebo 
(45.4%) with improvement reaching a peak at week 24, after which there was 
a plateau in the effect. Although the 1200 mg dosage provided the most 
consistent results pertaining to primary and secondary endpoints, no clear 
sifalimumab dosage effect was observed in this study (209).  
Of numerous anti-IFN therapies currently in development, the most promising 
agent is anifrolumab, an anti-IFN receptor mAb. Cell signalling by all type I 
IFNs including IFN-α, IFN-beta (IFN-β), IFN-epsilon (IFN-ε), IFN-kappa (IFN-
κ) and IFN-omega (IFN-ω) is mediated by the IFN-I receptor (IFNAR). In a 
phase II RCT of adults with moderate‐to‐severe SLE (severe lupus nephritis 
and neuropsychiatric excluded), patients were randomised to receive 
intravenous anifrolumab (300 mg or 1000 mg) or placebo, in addition to 
standard therapy for 48 weeks. Randomisation was stratified by SLEDAI-2K 
(<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day) and IFN-I gene 
signature test status (high or low) based on a 4‐gene expression assay. The 
primary endpoint was the SRI-4 rate at week 24 as well as sustained reduction 
of oral corticosteroids (<10 mg/day) from week 12 through 24. In this study, 
the primary endpoint was met in the anifrolumab (34.3% of 99 patients for 300 
mg and 28.8% of 104 patients for 1000 mg) than the placebo groups (17.6% 
of 102 patients); p=0.014 for 300 mg and p=0.063 for 1000 mg versus placebo 
respectively. Greater effect sizes were reported in patients with a high IFN 
signature at baseline (13.2% in placebo‐treated patients versus 36.0% 
[p= 0.004] and 28.2% [p = 0.029]) in patients treated with anifrolumab 300 mg 
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and 1000 mg respectively. In terms of safety, herpes zoster was more frequent 
in the anifrolumab‐treated patients (5.1% and 9.5% with anifrolumab 300 mg 
and 1000 mg respectively versus 2% in placebo), as were cases reported for 
influenza, consistent with the physiological role of IFN in viral immunity (210). 
The greater efficacy and broader impact demonstrated by anifrolumab were 
likely due to the result of achieving greater suppression of the IFN-I pathway 
by blocking the IFNAR. Phase III RCTs of anifrolumab are currently 
undergoing and their results are expected by the end of 2018.  
2.10.2. Interleukin-12/23 blocking therapy 
The interleukin 12/23 (IL-12/23) pathway has been implicated in the 
pathogenesis of SLE (277). In a phase 2 RCT of ustekinumab, a fully human 
IgG1κ mAb to interleukin IL-12/23 in autoantibody positive SLE, the primary 
endpoint, the SRI-4 at 26 weeks was met in the ustekinumab versus placebo 
groups; 60% and 31% respectively; p=0.0056, with a treatment effect 
favouring ustekinumab from the beginning of week 12. Most secondary 
endpoints were met apart from the BICLA response, although among BICLA 
non-responders, a greater proportion of ustekinumab group had no BILAG 
worsening versus placebo. Of particular interest, more patients with 
improvement of >50% in CLASI in the ustekinumab group versus placebo; 
59% vs 25% was reported (212). Safety events were consistent with the 
ustekinumab safety profile in other studied indications such as psoriasis and 
psoriatic arthritis. 
2.10.3. Janus kinase-signal transducer and activator of 
transcription (JAK-STAT) blockade therapy 
Recent advance in the JAK-signal transducer and activator of transcription 
(STAT) signalling pathway reveals aberrant STAT signalling in SLE. There are 
four JAKs; JAK1, JAK2, JAK3 and TYK2. Each involves in the signalling 
cascade of various cytokines. A theoretical advantage of modulating the JAK-
STAT pathway in SLE is the inhibition of pathogenic cytokines, hormones and 
growth factors regulating the key cellular processes such as survival, 
proliferation, and differentiation. 
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Baricitinib, an oral selective JAK1 and JAK2 inhibitor was investigated in a 
phase II RCT of non-renal SLE. Patients had to have positive ANA and clinical 
SLEDAI-2K≥4 including arthritis or rash. The primary endpoint was resolution 
of SLEDAI-defined arthritis or rash. At week 24, a significantly greater 
proportion of patients in the baricitinib 4mg group achieved resolution of 
SLEDAI-2K arthritis or rash compared to placebo; 67% versus 53%; as well 
as SRI-4 response rate; 64% versus 48% respectively; all p<0.05. No 
significant difference was observed in the baricitinib 2mg dose. The rates of 
discontinuation due to AE were higher in both baricitinib groups versus 
placebo. No other major safety signals apart from one case of deep venous 
thrombosis (in a patient with risk factors) reported in baricitinib 4mg group 
(211). 
2.10.4. Interleukin-6 blocking therapy 
Interleukin-6 (IL-6) is a highly pleiotropic cytokine that is overexpressed in 
SLE. Targeting IL-6 signalling may offer a novel therapeutic approach for SLE 
as supported by promising clinical and serological responses observed with 
the soluble IL-6 receptor inhibitor, tocilizumab in a small, open-label phase I 
study (278).  
Sirukumab, anti-IL-6 mAb was evaluated in a phase II RCT of patients with 
either class III or IV lupus nephritis, refractory to azathioprine or MMF. The 
primary endpoint, the change in proteinuria at week 24 was not met in the 
sirukumab-treated group (279). However, 20% of the sirukumab-treated group 
achieved meaningful reduction in proteinuria i.e. >50% from the baseline 
versus 0% in the placebo group. Nearly half of the sirukumab-treated group 




2.11. Tumour necrosis factor-blockade therapy 
2.11.1. Therapeutic indications for etanercept 
Etanercept in combination with methotrexate is indicated for the treatment of 
moderate to severe active RA, psoriatic arthritis (PsA). psoriasis and juvenile 
idiopathic arthritis (JIA), in patients with inadequate response to csDMARDs 
including methotrexate. It is also licensed for ankylosing spondylitis (AS) and 
non-radiographic axial spondyloarthropathy, in those with inadequate 
response to non-steroidal anti-inflammatory drugs (NSAIDs) (280).  
Despite the remarkable success of TNF-blockade therapies in the treatment 
of various ARDs above, there has been no completed RCT assessing efficacy 
of these agents in SLE. Two RCTs involving TNF- blockers in patients with 
lupus nephritis (one study each using infliximab and etanercept) were both 
aborted prior to study completion (281). The reason for this was because of a 
potential concern in the induction of pathogenic autoantibodies that might 
render SLE worse, thus both trials found difficulty to recruit patient. 
Approximately 0.5-1.0% of patients treated with systemic TNF-blockers 
developed high affinity IgG autoantibodies to anti-dsDNA, which were 
associated with mild lupus-like syndromes (282, 283). Nevertheless, data from 
open label use have demonstrated the efficacy and safety in both renal and 
non-renal manifestations (284, 285).  
2.11.2. Posology and Pharmacokinetic 
Treatment with etanercept should be initiated and supervised by specialist 
physicians experienced in the diagnosis and treatment of its licensed 
indications above. Patients should be given the Etanercept Patient Alert Card 
(280). 
Pfizer’s patent on the reference etanercept, Enbrel for its licensed indication 
had expired in the Europe in October 2012 but, in the US, a second patent, 
granting exclusivity for another 16 years i.e. 2028, has been granted (280). At 
the time of writing this chapter, two etanercept biosimilars; Benepali and Erelzi 
have gained marketing approvals in Europe.   
Enbrel is available in strengths of 10, 25 and 50 mg. 
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The recommended dose for the indications above (apart from JIA) are either 
25 mg etanercept, administered twice weekly or 50 mg administered once 
weekly. For JIA, the recommended dose is 0.4 mg/kg (up to a maximum of 25 
mg per dose), given twice weekly as a subcutaneous injection with an interval 
of 3-4 days between doses or 0.8 mg/kg (up to a maximum of 50 mg per dose) 
given once weekly (280). 
In terms of drug elimination, etanercept is cleared slowly from the body. The 
half-life is long, approximately 70 hours as well as slower clearance rate in 
patients RA compared to healthy volunteers (286, 287). The pharmacokinetics 
of etanercept are comparable between the different diseases as well as 
gender (288). 
2.11.3. Pharmacology of etanercept 
TNF is a dominant cytokine produced by lymphocytes and macrophages. It 
mediates the immune response by attracting additional white blood cells to 
the sites of inflammation, as well as through additional molecular mechanisms 
which initiate and amplify inflammation (289).  
Etanercept is a competitive inhibitor of TNF, binding to its cell surface 
receptors. TNF-α and TNF-β (lymphotoxin) are pro-inflammatory cytokines 
that bind to two distinct cell surface receptors; the 55-kilodalton (p55) and 75-
kilodalton (p75) TNF receptors. These receptors exist naturally in membrane-
bound and soluble forms; with the latter form is thought to regulate TNF 
biological activity. TNF and lymphotoxin exist as homotrimers. Their biological 
activity dependent on cross-linking of cell surface TNF receptors (280).  
Etanercept is developed by recombinant DNA technology in Chinese hamster 
ovary mammalian cell expression system. Etanercept is made from the 
combination of two naturally occurring soluble human 75-kilodalton TNF 
receptors linked to an Fc portion of an IgG1 (280). Etanercept is a dimeric 
molecule, and this dimeric structure exerts a higher affinity for TNF and are 
considerably more potent competitive inhibitors of TNF binding to its cellular 
receptors than other monomeric receptors. Moreover, its composition of an 
immunoglobulin Fc region as a fusion element in the construction of a dimeric 
receptor imparts a longer serum half-life (290). 
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2.11.4. Mode of action of etanercept 
Etanercept competitively inhibits the binding of both TNF and lymphotoxin to 
cell surface TNF receptors, rendering TNF biologically inactive (291). 
Etanercept also indirectly modulates several downstream molecules that are 
regulated by TNF, such as the expression of adhesion molecules E-selectin 
and to a lesser extent intercellular adhesion molecule 1 (ICAM-1), the 
production of interleukin-6 (IL-6), matrix metalloproteinase 3 (MMP-3) and IL-
1 (292). 
2.11.5. Immunogenecity of etanercept 
The currently available TNF-inhibitors have different molecular structures, 
dosing regimens, routes of administration, pharmacokinetic properties and 
immunogenicity. Etanercept is a TNF receptor–Fcγ1 fusion protein (as 
described in section 2.11.3). Infliximab is a chimeric mAb with a murine 
variable region fused to a human Fcγ1 Ig. Adalimumab and golimumab are 
fully human mAbs while certolizumab is a humanized Fab' fragment bound to 
polyethylene glycol molecules (293). The quantification and comparison of the 
immunogenicity of these TNF-inhibitors are largely dependent on the assay 
used to detect the anti-drug antibodies (ADAs). However, some general 
inferences can be drawn concerning their immunogenicity. 
Data from RCTs showed that etanercept had the lowest rate of ADA (range 0-
3%) (294, 295) compared to infliximab (range 7-53%) (296-298) and 
adalimumab (range 1-31%) (299, 300). Real-world data also concurred with 
the rates of ADA in etanercept, adalimumab and infliximab-treated patients 
were 0%, 17% and 31% respectively (301). Infliximab is the most 
immunogenic TNF-inhibitor, particularly when it is used without concomitant 
methotrexate (302, 303). ADAs can bind to the idiotope (e.g. the antigen-
binding region) of the fully human mAb such as adalimumab and golimumab 
and the chimeric mAb like infliximab. As a receptor construct, etanercept does 
not have an idiotype, which may explain the reason for reduced 
immunogenicity with therapy. The clinical implication of ADAs remains 




2.12. The unmet needs in SLE 
The management of SLE is challenging due to the heterogeneity in 
pathogenesis, clinical features and response to therapy. Despite treatment, 
SLE results in work disability and job loss (304, 305), reduced quality of life 
(306) and increased mortality with a Standardised Mortality Ratio of 2-3 (221, 
307). In addition, severe flare as a result of uncontrolled inflammation can 
increase the annual direct medical cost by two-folds to over £4500 per patient 
in the UK (3).   
Thus, there is a significant unmet need for therapies of proven efficacy and 
safety. Given the heterogeneity in immunopathogenesis, it may be that there 
is no one-size-fits-all therapy for SLE. Mechanistic studies concerning 
stratification and personalisation of therapy to individual patient and disease 
manifestations are currently limited. Lastly, in line with the principle of treat-
to-target in SLE (308), prevention of damage accrual should be a major 
therapeutic goal, which can be achieved through early recognition and 
intervention (309-311).  
2.13. Summary 
This review has described the importance of the interplay between innate and 
adaptive immunity in the pathogenesis of SLE. Immune dysregulation can 
occur several years before clinical onset. It appears that a ‘second hit’ is 
needed whether this may be environmental, hormonal or epigenetics effect for 
progression from benign autoreactivity to autoimmunity to occur. Currently, 
this factor is unknown. Should this and other potential biomarkers be 
identified, then early intervention can be employed to prevent from disease 
progression and reversible damage.   
Assessment of disease activity in SLE can be difficult owing to concurrent 
infection and multiple comorbidities often present in SLE patients. Of the 
currently available disease activity indexes, the BILAG requires adequate 
formal training and may be complex for the inexperienced clinicians while the 
SLEDAI may fail to capture partial response to therapy. Thus, the 
development of composite indices such as SRI and BICLA is welcomed with 
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interest. However, further work is needed to define a clinically meaningful 
response.  
This review also showed that results from RCTs in SLE demonstrated variable 
response rates ranging from 30-60%. Translating findings from bench to 
bedside has been problematic with many of the promising targeted therapies 
failing in clinical trials due to inefficacy, problem with trial design and/or safety 
issues. Belimumab is the only biologic licensed for autoantibody positive SLE 
but choosing the right patient for the therapy remains problematic. Better 
indication for use including the clinical phenotype that will respond to therapy 
may be identified from studies currently planned.  
Although RCTs of rituximab in SLE were negative, their methodology has 
been disputed and NHS England has agreed to commission rituximab based 
on strong open label evidence. Mechanistic studies to delineate predictors of 
B-cell depletion, rituximab resistance and stratification of therapy to lupus 
manifestations are needed but currently limited. With regards to safety, it is 
worth noting that another anti-CD20 mAb agent, ocrelizumab has failed in the 
trials due to safety issues. The effect of B-cell depletion and repeat cycles of 
treatment on immunoglobulin levels and infection risk is therefore of 
paramount importance. 
2.14. Key messages 
i. A period of ANA positivity and other immune dysregulation precedes 
clinically overt disease, thus provides a window of opportunity for early 
intervention. 
ii. The development of biologics targeting B-cells and non B-cell blockade 
represents a major advancement in SLE therapy, however many of 
these agents have failed in clinical trials due to inefficacy, problem with 
trial design and/or safety issues.  
iii. Although trials in rituximab have failed to meet their primary endpoints, 
their methodology has been disputed and rituximab is still widely used 




iv. Further studies to identify predictors of response to rituximab, 
mechanism of resistance and stratification of therapy to lupus 





Chapter 3. PRediction to allow Early interVENTion in 
At-Risk of autoimmune connective tissue disease 
(PREVENT-CTD) 
3.1. Introduction 
AI-CTD include SLE, primary Sjogren’s Syndrome (pSS), systemic sclerosis, 
inflammatory myopathies, mixed and undifferentiated CTDs. A hallmark of 
their pathogenesis is the loss of self-tolerance leading to autoreactivity and 
production of antibodies against numerous self-nuclear antigens. ANA can be 
detected in bloods up to 10 years before clinical features, representing a 
phase of subclinical autoimmunity (78). However, detecting ANA alone will not 
be sufficient to predict progression to disease. ANA is present in up to 25% of 
general population, of whom less than 1% develop clinical autoimmunity (167, 
312). Individuals with positive ANA therefore constitute At-Risk population of 
whom a minority will progress to AI-CTD (169, 313). The factors that dictate 
whether this autoreactivity develops into autoimmune disease are unknown. 
But if these were understood and predictable, then early and effective 
intervention could be employed, preventing the severe disease and heavy 
glucocorticoid use for remission induction of a newly diagnosed AI-CTD. 
Indeed, improved clinical outcome of patients with lupus nephritis, as 
diagnosed in the 1990s compared to 1980s, was attributed to early diagnosis 
and treatment (311) while failure to achieve lupus low disease activity state 
(LLDAS) six months after diagnosis was associated with early damage accrual 
in patients with SLE (309). 
Plausible biomarkers have not been investigated prospectively in At-Risk 
individuals. Variants in IFN-I pathway are prominent in the genetic 
susceptibility to AI-CTDs (as described in section 2.2.1) and therefore a focus 
for investigation (151, 314, 315). However, their role in disease initiation is 
unclear at present. IFN activity is difficult to measure but usually quantified 
using expression of interferon-stimulated genes (ISGs). Interpretation of ISG 
expression is complex with multiple IFN subtypes produced by different 
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tissues and cell types, as well as a transcriptional response in all nucleated 
cells with variation between cell types. Methods of measuring IFN-I activity 
are through indirect measurement of the expression of ISGs; either by 
assigning the patients into “High versus Low IFN signature” group (276, 316) 
or by combining level of protein expression of a set of ISGs of interest (317-
319). However, the former poorly differentiates IFN-I activity between 
individuals as the outcome is categorical while the latter may be affected by 
the weighting and selection of the genes, as some of them may have purely 
anti-viral properties and not necessarily pathogenic. In a paper for which I am 
the co-author, we recently described two continuous ISG expression scores 
(IFN-Score-A and IFN-Score-B) that in combination better identified clinically 
meaningful differences in IFN status between, and within ARDs and these 
scores were associated with certain features of SLE manifestations (320). 
In other ARDs such as RA, early evidence of progression to disease may be 
found at a target tissue level (321, 322). The tissues most commonly affected 
in AI-CTDs are skin and the joints. In a systematic literature review of which I 
am a co-author, we show that musculoskeletal ultrasound (MSK-US) can 
detect sub-clinical synovitis in SLE (194). However, this has not been 
assessed in At-Risk individuals. In skin, locally produced cytokines, which 
contribute to affected tissue injury and inflammation have been described in 
SLE. Previous studies comparing keratinocytes or skin biopsies that were 
isolated from cutaneous lupus patients and HCs found marked differences in 
interleukin-18 receptor (IL-18R) responsiveness (323), IFN- expression 
(324), as well as a role of IFN- in initiating a feed-forward loop which 
promoted exaggerated ISG activation in cutaneous lupus (325). IFN-I status 
in the skin has not been reported in At-Risk individuals. 
A wide range of targets for therapy are currently under investigation in 
established SLE (see section 2.4). However, there are no data on which of 





i. Risk of progression from At-Risk to SLE can be predicted using clinical, 
serological, histological or imaging parameters at presentation. 
ii. Immunological assessment of At-Risk individuals will provide a basis 
on the appropriate targeted therapy for disease prevention in a high 
risk population. 
3.1.2. Objectives 
i. To evaluate clinical, blood and tissue interferon and imaging 
biomarkers of progression from At-Risk to AI-CTD 
ii. To assess the relationships between blood interferon biomarkers and 
autoantibodies and routine immunological markers  
iii. To define biomarkers thresholds of progression to AI-CTD in At-Risk 
individuals  
3.2. Methods 
3.2.1. Candidate’s roles in this project 
In this work, the initial concept and design of the study were set by myself, Dr 
Psarras, Dr El-Sherbiny, Prof Emery and Dr Vital. I set-up and carried out the 
weekly pre-CTD clinic in Leeds under the supervision of Dr Vital, recruited and 
consented all 135 participants to the study, designed the proforma for data 
collection, performed a significant proportion of the clinical and 50% of the 
imaging assessments (the other half was done by Dr Zayat while I underwent 
training to perform MSK-US), undertaken all skin biopsy from consenting 
participants and was responsible to answer the enquiry line when contacted 
by the participants. The research blood and skin samples were processed and 
stored by members of my group; namely Dr Antonios Psarras, Dr Alase, Dr 
Shalbaf, Mrs Corscadden, Mrs Mbara and Ms Wigston. I organised and 
entered data onto the study database. In terms of statistical analysis, Dr 
Hensor  initially performed the single imputation of the missing ISG data as 
well as the factor analysis. I then performed the descriptive statistics analyses, 
multiple imputation of missing data and multivariable analyses of prognostic 
predictors of progression. My results were then checked by Dr Hensor. Finally, 
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I led the writing of the manuscript while other co-authors revised the draft 
critically for important intellectual content and final approval of the manuscript 
prior to submission to journal for publication. 
3.2.2. Design and Patient 
A prospective observational study was undertaken in consecutive individuals 
who were referred from primary care to Leeds Teaching Hospitals NHS Trust 
for a suspected AI-CTD between November 2014 and May 2017.  
Inclusion criteria were: (i) ANA-positive of at least 1:80 titre on indirect 
immunofluorescence and using multiplex immunoassays (excluding those 
with scleroderma [Centromere, Scl-70] or myositis-specific [PL-12, OJ, PL-7, 
Mi-2, Ku, Jo-1, PM-Scl75, PM-Scl100, SRP and EJ] antibodies only); (ii) ≤1 
clinical criterion based on 2012 SLICC (32) and not meeting classification 
criteria for other AI-CTDs (326-328) or RA (329); (iii) symptom duration <12 
months; (iv) glucocorticoid, antimalarial and immunosuppressive treatment-
naïve. Forty-nine HCs and 114 patients with SLE who met the SLICC criteria 
were used as negative and positive controls. 
3.2.3. Ethical approval  
All individuals provided informed written consent and this research was 
undertaken in compliance with the Declaration of Helsinki. The patients’ blood 
samples used for this study were collected under ethical approval, REC 
10/H1306/88, National Research Ethics Committee Yorkshire and Humber–
Leeds East, and HCs’ blood samples were collected under the study number 
04/Q1206/107. All experiments were performed in accordance with the 
relevant guidelines and regulations. The University of Leeds was contracted 
with administrative sponsorship. 
3.2.4. Assessment schedule and outcome 
Comprehensive assessments including clinical, laboratory, imaging, bloods 
and skin biomarkers were performed at baseline, 12 months, annually for 3 
years. Participants were given a helpline number to contact for an additional 




Progression was defined by meeting the 2012 SLICC classification criteria for 
SLE (32), 2016 ACR/EULAR classification criteria for pSS (326) or other 
relevant classification  criteria for AI-CTD (327, 328) at 12 months as 
assessed by rheumatologists. 
3.2.5. Clinical and laboratory assessment 
Age, gender, ethnicity, history of first or second degree relative(s) with ARDs, 
smoking history, SLICC criteria for SLE (32), signs or glandular symptoms 
criteria for pSS (326), patient and physician global health assessment using 
100mm VAS were recorded. 
ANA was tested using indirect immunofluorescence as well as a panel of 
nuclear autoantibodies including anti-dsDNA, extractable nuclear antigens 
(ENA, including Ro52, Ro60, La, Sm, Chromatin, RNP, Sm/RNP and 
Ribosomal P) and anti-phospholipid antibodies (Cardiolipin and B2-
Glycoprotein IgGs) using Bioplex 2200 Immunoassay. Lupus anti-coagulant 
tests including activated prolonged thromboplastin time (APTT), APTT-
synthetic peptide (APTT-SP) (with correction) and dilute Russell’s viper 
venom test (dRVVT) (with correction) were deemed positive if persistent when 
repeated at 12 weeks. Full blood count was processed at a single accredited 
diagnostic laboratory. Complement levels (C3 and C4) were measured by 
nephelometry. 
3.2.6. Musculoskeletal ultrasound 
MSK-US examination of wrists, metacarpophalangeal and proximal 
interphalangeal joints were performed by two rheumatologists, using General 
Electric S7 machine with a 6–15 MHz transducer. Outcome Measures in RA 
Clinical Trials (OMERACT) criteria (330) were used to define synovitis i.e. the 
presence of grey-scale (GS) ≥grade 2 and/or power Doppler (PD) ≥grade 1. 
3.2.7. Blood IFN Scores 
A two-score system of ISGs as previously described (320), was calculated 
without the knowledge of participants’ clinical status. 
Gene probe selection and gene expression 
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Ten genes were selected from each IFN-annotated module (M1.2, M3.4, 
M5.12) of a previous microarray study as reported by Chiche L et al. 2014 
(314), with addition of other common ISGs i.e. IFI27 and IFI6. Thus a total of 
31 ISGs were evaluated. Peptidylprolyl isomerase A (cyclophilin A) (PPIA) 
was used as a reference gene (confirmed not responsive to IFN-I).  
Peripheral blood mononuclear cells (PBMCs) were separated using density 
gradient method (LymphoprepTM, Alere Technologies, Norway) from 
ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood. Total 
ribonucleic acid (RNA) purification kit (Norgen Biotek, Canada) was used to 
extract RNA from PBMCs and sorted cell subsets. To obtain the 
complementary DNA (cDNA) synthesis from total RNA acquired, Fluidigm® 
Reverse Transcription Master Mix buffer was used including a mixture of 
random primers and oligo dT for priming. TaqMan assays (Applied 
Biosystems, Invitrogen) were used to perform the quantitative real-time 
reverse transcriptase-polymerase chain reaction (qRT-PCR) for the selected 
31 ISGs. These assays were performed using the BioMark™ HD System with 
appropriate cycling protocols for the 96.96 chip. Data were normalised using 
PPIA as the reference gene to calculate ΔCt. 
Factor analysis 
Factor analysis (FA) was performed to reduce the 31 ISGs into a smaller 
number of factors (331). Prior to FA, undetected ∆Ct values were singly 
imputed using the R package nondetects. The Kaiser-Meyer-Olkin measure 
was used to verify the sampling adequacy of the analysis. Principal factor 
extraction (without rotation) was used to identify the optimum number of 
factors, which was initially determined according to a parallel analysis (Monte 
Carlo simulation using 1000 replications). This indicated the maximum 
number of factors present. However, if a smaller number of factors were 
required to explain 80% of the variance and resulted in lower levels of cross-
loading (genes loaded by 2 or more factors at >0.4), a simpler structure was 
selected. Having identified the number of factors present, oblique (promax; 
kappa=4) rotation was used to obtain the final factor solution.  
In this present study, to calculate factor scores for each patient, median gene 
expression was calculated for genes loaded at ≥0.4 by each factor, provided 
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they did not cross-load onto more than one factor. The advantage of this 
approach was that it reflected the variability of the data and respected the 
within-patient ordinal scaling of ∆Ct values.  
As previously described (320), two factors explained 84% of the variance with 
limited cross-loading among the ISGs. Table 3-1 shows the ISGs that 
contributed to each factor; we called these IFN-Score-A (comprises 12 co-
clustered genes) and IFN-Score-B (comprises 14 co-clustered genes).    
Table 3-1 ISGs that constitute IFN-Score-A and IFN-Score-B    
Genes Modules from 
previous study 
using microarray 





ISG15 1.2 0.96*  
IFI44 1.2 0.80*  
IFI27 n/a 0.77*  
CXCL10 1.2 0.71*  
RSAD2 1.2 0.70*  
IFIT1 1.2 0.67*  
IFI44L 1.2 0.66*  
CCL8 3.4 0.58*  
XAF1 1.2 0.54*  
IFI6 n/a 0.51 0.45 
GBP1 3.4 0.46*  
IRF7 3.4 0.46*  
CEACAM1 3.4 0.45*  
HERC5 1.2 0.43 0.59 
EIF2AK2 3.4 0.42 0.64 
MX1 1.2 0.40 0.56 
LAMP3 1.2  0.40* 
IFIH1 3.4  0.45* 
PHF11 5.12  0.58* 
SERPING1 1.2  0.60* 
IFI16 5.12  0.64* 
BST2 5.12  0.74* 
SP100 5.12  0.74* 
NT5C3B 5.12  0.80* 
SOCS1 3.4  0.84* 
TRIM38 5.12  0.87* 
UNC93B1 5.12  0.88* 
UBE2L6 3.4  0.89* 
STAT1 3.4  0.94* 
TAP1 5.12  0.98* 
CASP1 5.12 <0.40 <0.40 
 
* Indicates genes that were included in the factor scores 
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3.2.8. Skin biopsy 
One 4 mm biopsy was obtained from non-lesional, non-sun-exposed areas 
(upper back or upper arms) of At-Risk individuals (n=10) and HCs (n=6), and 
from active lesions of SLE patients (n=10). Biopsies were snap frozen in 
optimum cutting temperature compound and sectioned at a thickness of 5 µm 
ensuring no remaining material contaminating subsequent RNA extraction/RT 
procedures. Total RNA were extracted using RNeasy mini kit (Qiagen, 
Manchester, UK). The RNA quantity was measured and assessed for purity 
and concentration using NanoDrop spectrophotometer, ND-1000, Heathfield, 
UK. Gene expression analysis and calculation of factor scores were 
conducted as for PBMCs. 
3.2.9. Missing data 
For 13 At-Risk individuals, gene expression data were missing at random due 
to samples not being processed on the day. For comparisons with HC and 
SLE groups, only At-Risk individuals with complete data were presented. For 
prediction of progression, multiple imputation by chained equations was used 
to create 20 complete datasets, results of which were combined according to 
Rubin’s rules (332). 
 
3.2.10. Statistical analyses 
Associations between categorical variables were tested by Fisher’s exact for 
independent samples and Stuart-Maxwell tests for paired samples. 
Continuous variables were compared either using Student’s T-tests or 
analysis of variance (ANOVA) followed by pairwise Tukey tests. For other 
associations, Kendall’s tau-b correlation was used if ties were present, 
otherwise using Pearson’s correlation.  
Receiver operator characteristic (ROC) curves were used to assess predictive 
strength and identify optimal thresholds for predicting progression to AI-CTD.  
To assess baseline predictors of progression to AI-CTD at 12 months, all 
(imputed) putative variables were first evaluated using univariable analysis at 
the 10% level of significance. Only variables with p-value of <0.1 were 
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included in the multivariable analysis, using backward-elimination as well as 
penalised logistic regression by Lasso method (333). Leave-one-out cross 
validation (R package cv.glmnet) (334) identified the largest penalty coefficient 
lambda within 1 standard error of the value that minimised deviance in each 
imputed dataset; average coefficients from the best models were calculated. 
All analyses of IFN Scores were conducted using ∆Ct scaling; results were 
then converted to relative expression (2-ΔCt) or fold difference (FD) (2-ΔΔCt). 
Statistical analyses were performed using Stata v.13.1 (StataCorp College 
Station, Texas, USA), R version 3.3.3 (335) and GraphPad Prism v.7.03 
(GraphPad, La Jolla, CA, USA) for Windows. 
3.3. Results 
3.3.1. Patient characteristics 
A total of 135 At-Risk individuals were recruited in this study. Of these, 118 
had at least 12 months follow-up and were analysed. Baseline characteristics 
are described in Table 3-2. The flowchart of participants is presented in Figure 
3-1. 
Table 3-2 Baseline characteristics of the 188 At-Risk of AI-CTD individuals   
Characteristic Values 
Age, median (range) years 48 (20 - 84) 
No. female patient (%) 104 (88) 
Ethnicity, N (%) 
     Caucasian 
     Indian/South Asian 
     African/Caribbean 





  1 ( 1) 
Positive ANA, N (%) 118 (100) 
No. of positive ANA specificities, median (range)   1 (1 – 4) 
Autoantibody positive specificities, N (%) 
     anti-dsDNA 
           10 – 20 IU/mL 
           21 – 50 IU/mL 









     anti-Ro  
           < 8 AI 
           ≥ 8 AI 
     anti-La  
     anti-Smith  
     anti-Chromatin  
     anti-RNP  
     anti-Ribosomal P  
     anti-Sm/RNP 




  9 (8) 
  5 (4) 
17 (14) 
  2 (2) 
  0 (0) 
16 (14) 
  5 (4) 
Positive Lupus Anti-Coagulant, N (%)   4 (3) 
Concurrent positive RF, N (%) 
     Low titre (< 50 iU/mL), N (%) 
     High titre (≥ 50 iU/mL), N (%) 
11 (9) 
  5 (4) 
  6 (5) 
*Concurrent positive anti-CCP antibody, N (%)   3 (3) 
Low complement levels (C3 or C4), N (%)   8 (7) 






Clinical criteria present, N (%) 
      **Acute or Sub-acute cutaneous lupus erythematosus 
Chronic cutaneous lupus erythematosus 







Leucopaenia or lymphopaenia 
Thrombocytopenia 
Glandular signs  
 
27 (24) 
  1 (1) 
  4 (3) 
  5 (4) 
43 (36) 
  1 (1) 
  0 (0) 
  0 (0) 
  0 (0) 
12 (10) 
  5 (4) 
  0 (0) 
***Family history of ARD, N (%) 43 (36) 




* All patients had low anti-CCP antibody titre (<50 U/mL); ** Only 1 patient had sub-
acute cutaneous lupus erythematosus lesion; *** First or second degree relative with 
autoimmune rheumatic disease. ANA: anti-nuclear antibody; ARD: autoimmune 








Figure 3-1 Flowchart of the participants in the PREVENT-CTD study in 
Leeds 
Adapted  with permission from the BMJ publishing group. Md Yusof MY et al. Prediction 
of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a 





3.3.2. Clinical outcomes at 12 months 
At 12 months, 19/118 (16%) At-Risk individuals progressed to meeting criteria 
for an AI-CTD; namely SLE (n=14; 74%) and pSS (n=5; 26%) (336). For those 
who progressed, all had 1 clinical criterion at baseline. The number of clinical 
SLE criteria increased to 2 in 4/19 (21%), 3 in 9/19 (47%) and 4 in 6/19 (32%) 
(Stuart-Maxwell Chi-square=20.0, p<0.001) at 12 months. These details are 
presented in Table 3-3 and illustrated in Figure 3-2. Two patients developed 
internal organ involvement; pleural effusion and class III lupus nephritis. 
On the other hand, 19/99 (19%) of the non-progressors had no clinical SLE 
criteria at both baseline and 12 months, 1/99 (1%) increased from 0 to 1, 41/99 
(42%) decreased from 1 to 0 (indicating a remission of autoimmunity) and 
38/99 (38%) had 1 criterion at both time-points (Stuart-Maxwell Chi-
square=38.1, p<0.001). 
Of note, 1/99 (1%) of non-progressors had ankylosing spondylitis (AS) while 





Table 3-3 Clinical characteristics of At-Risk progressors at 12 months  





          ACLE or SCLE 
          Mucosal ulcers 
















          Leucopaenia or lymphopenia 
          Thrombocytopaenia 
 
3/19 (16%) 




Glandular signs      0 6/19 (32%) 
Serositis 
         Pleural effusion 
   
     0 
   
1/19 (5%) 
Renal 
         Class III nephritis 
      










Figure 3-2 Mean number of clinical criteria at baseline and 12 months 
in the two At-Risk progressors groups 
Mean number of clinical criteria increased at 12 months or at time of progression in At-
Risk progressors as depicted in red-coloured graph while mean number of clinical 
criteria decreased at 12 months in At-Risk non-progressors (green). The error bars 








3.3.3. Blood IFN status in At-Risk differs from SLE 
At baseline, IFN-Score-A differed among HC, At-Risk and SLE groups 
(ANOVA F=40.26; p<0.001). The score was increased relative to HC (n=49) 
in both At-Risk [n=105; FD (95% CI) 2.21 (1.22, 4.00), p=0.005] and SLE 
[n=114; 7.81 (4.33, 14.04), p<0.001], and was increased in SLE relative to At-
Risk [3.54 (2.22, 5.63), p<0.001] (Figure 3-3A). On the other hand, although 
IFN-Score-B differed among these groups overall (F=63.35; p<0.001), the 
score did not differ between At-Risk and HC [0.98 (0.66, 1.46), p=0.993], but 
was increased in SLE to both HC [3.85 (2.60, 5.72), p<0.001] and At-Risk 
[3.93 (2.87, 5.37), p<0.001] (Figure 3-3B). 
3.3.4. Relationships of IFN scores with autoantibodies, complement 
and lymphopaenia 
Correlations between routine immunology markers (complement levels and 
lymphopenia) and IFN Scores were performed in observed data using 
reflected ∆Ct so that higher IFN Scores represented greater expression. At 
baseline, there was no association between count of positive ANA specificities 
(i.e. anti-dsDNA, Ro, RNP etc.) and IFN-Score-A (n=105, Kendall’s tau-b 0.13, 
p=0.084) or IFN-Score-B (tau-b 0.09, p= 0.234 (Figure 3-3C and 3-3D). 
There was a weak negative correlation between C4 levels and IFN-Score-A; 
n=97, Pearson’s r = -0.221, p=0.029 (Figure 3-3E) but not IFN-Score-B,   r = 
-0.089; p=0.385. There was a weak negative correlation between lymphocyte 
count and IFN-Score-A; n=105, r = -0.230; p=0.018 (Figure 3-3F) but not IFN-
Score-B; r = -0.127; p=0.195. 
With respect to the relationships of IFN scores with autoantibodies titres, the 
titres of two antibodies that were mostly prevalent using Bioplex; anti-dsDNA 
and anti-Ro were divided into 3 and 2 groups respectively. The results showed 
that there were no differences in both IFN Scores among the 3 anti-dsDNA 
groups (Figure 3-4A and 3-4B). However, elevated levels of IFN-Score-A (FD 
2.41 (95% CI 1.10–5.26) but not Score-B were found in the high titre ie: ≥8 AI 





Figure 3-3 Pattern of baseline blood IFN scores and their relationships 
with clinical immunology markers 
A) Baseline expression of IFN-Score-A was higher in At-Risk individuals compared to 
HC. B) However, there was no difference in IFN-Score-B between both groups. *** 
Highly significant (p<0.001), ** Moderate significant (0.001<p-value<0.01), *Significant 
(0.01<p-value<0.05). Error bars denote 95% confidence interval of the mean. C-D) Both 
IFN scores were not correlated with the count of positive ANA specificities and E-F) 
There were only weak correlations between IFN-Score-A and complement and 
lymphocyte count. Data for gene expression were expressed as reflected values for 
∆Ct so that higher IFN Scores represented greater expression. ANA: anti-nuclear 
antibody; C4: complement component 4; HC: healthy control; SLE: systemic lupus 
erythematosus. 
Reprinted with permission from the BMJ publishing group. Md Yusof MY et al. 
Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic 






Figure 3-4 Comparison of baseline blood IFN scores based on 
autoantibodies titres 
A-B) Anti-dsDNA titres were divided into 3 groups. IFN-Score-A and IFN-Score-B did 
not differ among the groups overall (p>0.1) at baseline C-D) Anti-Ro antibody titres 
were divided into groups. At baseline, IFN-Score-A was elevated in those with high titre 
i.e. ≥ 8 AI versus low titre; FD 2.41 (95% CI 1.10 – 5.26). There was a trend to increase 
in IFN-Score-B in those with high titre versus low titre; FD 1.52 (0.84 – 2.75). Error bars 
denote 95% confidence interval of the mean. ANOVA: analysis of variance; dsDNA: 
double stranded deoxyribonucleic acid; FD: Fold difference. 
Adapted with permission from the BMJ publishing group. Md Yusof MY et al. Prediction 
of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a 





3.3.5. Baseline IFN status in skin 
Similar to the results obtained for PBMC, at baseline, only IFN-Score-A was 
increased in non-lesional skin biopsies in At-Risk individuals (n=10) versus 
HC (n=6); FD 28.74 (1.29, 639.48), p=0.036. There was no difference in IFN-
Score-B; FD 1.82 (0.86, 3.86), p=0.100. As predicted, both IFN Scores were 
higher in SLE (active lesions) compared to either At-Risk or HC; all p<0.05. 
3.3.6. Comparison of baseline IFN status between blood and skin 
Expression of both IFN Scores were higher in At-Risk versus HC in both skin 
and PBMC, but FDs were greater in skin (Figure 3-5C). This could due to the 
small sample size for skin samples (paired skin-PBMC samples were not 
available). 
3.3.7. Prediction of AI-CTD using baseline IFN scores in blood 
When At-Risk were divided according to AI-CTD progression status at 12 
months, both IFN scores differed among the groups overall (p<0.001). Both 
were elevated in At-Risk progressors (n=19) versus non-progressors (n=86), 
to a greater extent for IFN-Score-B [FD 3.22 (1.74, 5.95), p<0.001] than IFN-
Score-A [2.94 (1.14, 7.54), p=0.018] (Figure 3-5A and B). Non-progressors 
did not differ from HC (n=49) for both scores; IFN-Score-B [0.79 (0.51, 1.23), 
p=0.520] and IFN-Score-A [1.82 (0.93, 3.53), p=0.096]. Neither IFN Score 
differed between At-Risk progressors and SLE (both p>0.1). 
As the number of skin biopsies obtained in At-Risk individuals was small 
(n=10), no formal association between IFN Scores and progression could be 
determined in this study.  
3.3.8. Baseline blood IFN-Score-B threshold of progression to AI-CTD 
ROC curve analysis was used to assess the prognostic ability of baseline 
blood IFN Scores to predict progression to AI-CTD at 12 months. The results 
showed that the area under the ROC (AUROC) was greater for IFN-Score-B 
[0.82 (95% CI 0.73 to 0.92)] than IFN-Score-A [0.70 (0.57, 0.83); Chi-
square=4.19, p=0.041. A cut-off of ≤5.01 ∆Ct for IFN-Score-B maximised the 
Youden’s index (sensitivity + specificity -1), which yielded 95% (95% CI 75% 
to 99%) sensitivity, 60% (50%, 70%) specificity, 35% (23%, 48%) positive 
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predictive value (PPV) and 98% (90%, >99%) negative predictive value 
(NPV). In order to design future prevention studies, for a rule-in biomarker, a 
high specificity indicator is warranted to exclude individuals with the lowest 
risk. Thus, we propose a cut-off of ≤3.90 ∆Ct, which yielded 68% (46%, 85%) 
sensitivity, 80% (70%, 88%) specificity, 43% (27%, 61%) PPV and 92% (84%, 







Figure 3-5 Baseline blood IFN scores as prognostic biomarkers 
A-B) Baseline expression of both IFN-Score-A and IFN-Score-B were higher in At-Risk 
individuals who progressed to AI-CTD compared to the non-progressors, but to a 
greater FD in the latter. *** Highly significant (p<0.001), ** Moderate significant 
(0.001<p-value<0.01), *Significant (0.01<p-value<0.05). C) FDs for both IFN scores 
between At-Risk and HC were greater in skin than bloods. Error bars denote 95% 
confidence interval. D) The AUROC was significantly greater for IFN-Score-B than IFN-
Score-A. The blue arrow denotes the optimal cut-off using Youden’s index while the red 
arrow denotes the proposed cut-off for prevention study. FD: fold difference; HC: 
healthy control; PBMC: peripheral blood mononuclear cell; SLE: systemic lupus 
erythematosus. 
Reprinted with permission from the BMJ publishing group. Md Yusof MY et al. 
Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic 






3.3.9. Baseline blood IFN Scores were lower in At-Risk without versus 
with one clinical criterion 
Of 20/118 (17%) At-Risk individuals who had no SLE clinical criterion at 
baseline, none  progressed to AI-CTD at 12 months. At baseline, FDs for both 
IFN scores differed among the groups overall (p<0.001). Both were lower in 
At-Risk with no criterion (n=17) versus with one criterion (n=88); all p<0.05 
(Figure 3-6A and B). 
 
 
Figure 3-6 Comparison of baseline blood IFN scores based on SLE 
clinical criterion 
A-B) At baseline, IFN-Score-A and IFN-Score-B differed among the groups overall 
(p<0.001) and both were elevated in At-Risk with one SLE clinical criterion versus 
without SLE criterion; FD 3.35 (95% CI 1.14 – 9.83); p=0.021 and 2.30 (1.11 – 4.78); 
p=0.018 *** Highly significant (p<0.001), ** Moderate significant (0.001<p-value<0.01), 
*Significant (0.01<p-value<0.05). Error bars denote 95% confidence interval of the 
mean. FD: fold difference; HC: healthy control; SLE: systemic lupus erythematosus.  
Reprinted with permission from the BMJ publishing group. Md Yusof MY et al. 
Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic 







3.3.10. Musculoskeletal ultrasound 
At baseline, one patient was not assessed using MSK-US. Of 117 At-Risk 
individuals with MSK-US available, 21(18%) had MSK-US-defined synovitis at 
baseline [GS≥2 only=13, PD≥1 with or without GS≥2=8]. Of 20 individuals who 
progressed, 7 (35%) had positive MSK-US at baseline versus 14% of non-
progressors; p=0.050; PPV (95% CI) =33% (17%, 55%), NPV 86% (78%, 
92%). 
In this study, 43/118 of At-Risk individuals had clinical arthritis based on 
SLICC criteria (32) [8/43 (19%) had ≥2 joints with swelling or effusion whereas 
34/43 (81%) had ≥2 joints with tenderness and early morning stiffness of ≥30 
minutes] while 75/118 had no arthritis. In those without arthritis, MSK-US-
defined synovitis was detected in 10/75 (13%) and 4/10 (40%) progressed to 
AI-CTD. On the contrary, in those with arthritis, only 11/42 (26%) had MSK-
US-defined synovitis and 3/11 (27%) progressed to AI-CTD at 12 months. 
Sensitivity and specificity of physician-judged arthritis with MSK-US-defined 
synovitis were 52% and 68% respectively.  
3.3.11. Analysis of baseline predictors of progression to AI-CTD 
All putative predictors were associated with progression to AI-CTD at 12 
months in imputed univariable analyses except for complement level and 
lymphocyte count (both p>0.1), which were excluded from multivariable 
analysis. In multivariable penalised logistic regression analysis, a family 
history of ARDs (OR 8.20, p=0.012) and IFN-Score-B (OR=3.79, p=0.005) 
were independently associated with progression to AI-CTD at 12 months. 
Penalised ORs remained substantive for these variables when all other 
variables were removed from model (Table 3-4). Results in complete data 





Table 3-4 Penalised logistic regression for predictors of progression to AI-CTD at 12 months  




Imputed Univariable  
OR (95% CI), P-value  
Imputed Multivariable  
OR (95% CI), P-value  
Penalised coefficient, 
OR 
Age, mean (SD) 49.0 (15.8) 39.6 (11.9) 0.96 (0.93, 0.99), p=0.016 0.97 (0.92, 1.02), p=0.232 0.000, 1.000 
Ever Smoked, (%)  41.8 %  20.0 % 0.35 (0.11, 1.12), p=0.076 0.34 (0.06, 1.91), p=0.222 0.000, 1.000 
Family history of ARDs, (%) 30.6 % 65.0 % 4.21 (1.53, 11.61), p=0.005 8.20 (1.58, 42.53), p=0.012 0.243, 1.275 
No. of positive ANA 
specificities,  median (IQR) 
1 (1 - 1) 1 (1 – 2) 2.07 (0.97, 4.40), p=0.060 2.41 (0.71, 8.20), p=0.161 0.000, 1.000 
Complement C4 level, 
mean (SD) 
0.29 (0.12) 0.26 (0.08) 0.06 (0.00, 8.05), p=0.264 Excluded Excluded 
Lymphocyte count, mean 
(SD) 
2.04 (0.77) 1.83 (0.67) 0.67 (0.34, 1.34), p=0.257 Excluded Excluded 
No. of Joints with MSK-US 
synovitis, median (IQR) 
0 (0 – 0) 0 (0 – 2) 1.20 (0.97, 1.47), p=0.086 1.44 (0.98, 2.11), p=0.061 0.002, 1.002 
Patient VAS, median (IQR) 36 (16 – 61) 47 (26 – 75) 1.02 (1.00, 1.04), p=0.079 1.01 (0.98, 1.04), p=0.484 0.000, 1.000 
Physician VAS, median 
(IQR) 
11 (3 – 31) 31 (15 – 47) 1.04 (1.01, 1.06), p=0.008 1.01 (0.97, 1.06), p=0.618 0.000, 1.000 
IFN-Score-A (-ΔCt), mean 
(SD)* 
-5.3 (1.9) -3.8 (2.26) 1.43 (1.11, 1.84), p=0.005 0.87 (0.54, 1.39), p=0.560 0.000, 1.000 
IFN-Score-B (-ΔCt), mean 
(SD)* 
-5.3 (1.4) -3.7 (1.0) 2.55 (1.60, 4.08), p<0.001 3.79 (1.50, 9.58), p=0.005 0.319, 1.376 
 
* Analysis was made based on reflected ∆Ct. Thus, the higher the number, the higher the gene expression to give positive values for odds ratio 




In this chapter, I have reported a unique cohort of At-Risk of AI-CTD 
individuals with longitudinal follow-up until progression to meeting 
classification criteria for clinical autoimmunity. My results show that IFN 
activity is strongly associated with progression independent of baseline clinical 
status, with measurement according to a two-score system we described 
being crucial. These results provide a rationale for diagnostic and preventative 
treatment pathways as well as assert the importance of IFNs in disease 
initiation. 
The number of referrals of ANA-positive individuals to rheumatologists has 
increased over the last decade (337). Concerns are that these At-Risk 
individuals may be discharged prematurely from clinic, or be observed in an 
inefficient “watch and wait” fashion until the diagnosis is clear, by which time 
the potential to prevent disease and confer the most benefit may be lost. 
Therefore, by undertaking the largest prospective study of At-Risk individuals, 
which is the first to integrate clinical, imaging and immunological assessments 
(including skin), my findings offer a novel approach, biomarkers and have 
implications for future development of targeted therapies for this group of 
patients. 
With regards to immunological assessment, within ANA-positive individuals, 
different immune phenotypes could be defined. At baseline, IFN-Score-A was 
elevated but not IFN-Score-B compared to HC. However, IFN-Score-B (and 
to a lesser degree, IFN-Score-A) were mostly elevated in individuals who 
progressed to AI-CTD. IFN-Score-A comprises many well-known ISGs that 
respond to various IFN-I subsets including IFN-α, -β –κ and -ω. In contrast, 
IFN-Score-B consists of ISGs that coincide with M3.4 and M5.12 modules of 
a previous microarray study (314). These ISGs were suggested to be 
responsive to IFN-II (IFN-gamma; IFN-γ), IFN-III (IFN-lambda; IFN-λ) as well 
as IFN-I. However, in our previous study, we could not demonstrate such a 
clear relationship between ISG subsets and subtypes of IFN, thus we could 
not exclude the influence of other inflammatory mediators on this pattern of 
gene expression (320). Some studies suggested that IFN-I contributes to 
priming cells to secrete IFN-II (338, 339). Conversely, a study that measured 
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IFN activity from serum postulated a sequential role of IFN-II augmentation 
that led to accumulation of autoantibody and subsequent elevations in IFN-α 
prior to SLE (340). Although this present study could not confirm which IFN 
pathways predominate, my findings suggested that progression to AI-CTD 
might not be exclusively driven by IFN-I but by a synergistic activation of ISGs 
induced by a range of IFNs and IFN-Score-B could act as a biomarker for 
more diverse immune activation. 
At the tissue level, this is the first study that reports IFN activity in non-lesional 
skin of At-Risk individuals. Similar patterns of immune dysregulation were 
observed between skin and blood. Interestingly, markedly greater FDs in both 
IFN scores were found in the former compared to the latter, thus highlighting 
skin as a potential site of AI-CTD initiation. 
Pertaining to imaging, only a third of the At-Risk individuals who had MSK-
US-defined synovitis at baseline progressed to AI-CTD within 12 months. My 
findings also highlighted discrepancy in the assessment of arthritis between 
clinical examination and imaging. Notably, a small number of asymptomatic 
individuals with MSK-US-defined synovitis were identified and some of them 
progressed to AI-CTD. Although there was a trend in association between the 
presence or number of joints with MSK-US-defined synovitis and progression 
to AI-CTD, further work including longitudinal analysis is required to determine 
the role of MSK-US in assessing At-Risk individuals. 
Together with a family history of ARD, IFN-Score-B from blood is 
independently predictive of progression as a prognostic biomarker. A cut-off 
level of IFN-Score-B with a moderate diagnostic accuracy in order to design 
future prevention study has been defined. 
This study has some limitations. First, the cohort was recruited from 
secondary care as well as positive ANA detected by both Bioplex and indirect 
immunofluorescence, which might contribute to moderate-to-high pre-test 
probabilities for progression to AI-CTD. Thus, our results might not be 
generalised to all ANA-positive cases detected in a primary care setting. 
However, our cohort was quite heterogenous in terms of ethnicity and 17% of 
the patients had no SLE criterion at baseline. Next, individuals with 
scleroderma or myositis-specific only autoantibodies were excluded, which 
might lead to preponderance of progression to SLE or pSS. Remarkably, one 
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patient had a severe AS and required biological therapy. Importantly, 4% of 
non-progressors had cancers thus highlighting the need to be vigilant of 
paraneoplastic manifestation in ANA-positive individuals as well as diverse 
alternative diagnoses in general. Lastly, although large in the context of 
existing studies in this field, sample size was still relatively small for 
multivariable analysis. However, penalised logistic regression was used to 
minimise the risk of overfitting of data. 
3.5. Conclusion  
To conclude, a novel ISG score, IFN-Score-B and a family history of ARD 
predict progression from ANA-positivity to AI-CTD. Longitudinal analyses are 
in progress as well as a validation cohort. Once this biomarker is validated, 
the predictive value of IFN scores may allow us to identify patients with 
imminent AI-CTD for earlier intervention either using therapies that block IFNs 
or conventional immunosuppressants, in order to avoid irreversible organ 
damage and glucocorticoid exposure. Furthermore, patients with benign 
autoreactivity can be better identified. 
3.6. Key messages 
i. In At-Risk of CTD individuals (ANA-positive and limited 
inflammatory symptoms), 16% progressed to meet AI-CTD criteria 
at 12 months. 
ii. Within these ANA-positive individuals, different immune 
phenotypes can be defined. 
iii. Blood IFN-Score-B and a family history of ARDs are independent 
predictors of AI-CTD at 12 months. 
iv. The predictive value of IFN scores may allow us to identify patients 
with imminent AI-CTD for earlier intervention to prevent from 




Chapter 4. Predicting and managing primary and 
secondary non-response to rituximab in systemic 
lupus erythematosus 
4.1. Introduction 
Rituximab, a chimeric anti-CD20 mAb remains an important treatment option 
for SLE patients with moderate to severe disease. A high degree of rituximab 
efficacy across a range of lupus manifestations has been reported in open 
label studies from single centre series (16, 341, 342), multicentre registries 
(14, 343, 344) and a systematic review of off-label use (13). Despite the 
success of these series, two phase III RCTs in non-renal lupus (204) and renal 
lupus (205) failed to meet their primary endpoints (defined in section 2.7.1) . 
The discrepancy in efficacy outcomes between RCTs and real world evidence 
has been attributed to aspects of trial design including the choice of 
appropriate and meaningful endpoints, the use of an active comparator, 
inclusion criteria and low statistical power, as detailed in section 2.6 previously 
(214).  
In the EXPLORER trial of rituximab in SLE, post-hoc analysis showed that the 
primary endpoint was met in Hispanic and African-American subgroups (204). 
Despite efficacy reported from open label evidences, there are limited data on 
predictors or biomarkers of response to rituximab. Using HSFC, a protocol 
that was optimised for the detection of plasmablasts, our group previously 
discovered that the depth of B-cell depletion predicted response in 37 
rituximab-treated SLE patients (16). Larger studies as well as identification of 
other clinical predictors of response to rituximab in SLE are needed to 
optimise its use and help design trials of alternative B-cell depleting strategies. 
The effect of B-cell depletion with rituximab is not long-lasting and majority of 
the patients experience a relapse following B-cell repopulation (albeit with a 
variable interval). After an initial response to rituximab, repeat treatment has 
been reported to be effective to treat clinical relapse (341). However, there 
are limited data on long-term outcomes of these patients. Moreover, we have 
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observed cases of SLE patients who had previously depleted and responded 
to rituximab but subsequently developed (i) a severe infusion reaction >24 
hours during the second infusion of a cycle; (ii) failure to deplete CD20+ (naïve 
and memory) B-cells and (iii) clinical non-response during repeat cycles. We 
called this phenomenon secondary non-depletion and non-response 
(2NDNR), which was suggestive of immunogenicity to rituximab. In this group 
of patients, further courses of rituximab would be detrimental in terms of safety 
and no longer be effective. Thus, alternative anti-CD20 mAbs, particularly 
humanised, could theoretically be used instead in order to overcome this anti-
drug antibody phenomenon.  
4.1.1. Hypotheses 
i. B-cell depletion is an independent predictor of clinical response to 
rituximab in SLE. 
ii. In patients who experience a clinical relapse after an initial response, 
repeat cycles of rituximab is effective and with no major safety signals. 
iii. 2NDNR is associated with anti-rituximab antibodies. 
iv. 2NDNR can be overcome using alternative humanised anti-CD20 
mAbs. 
4.1.2. Objectives 
i. To assess factors predicting primary and secondary non-response to 
rituximab in SLE 
ii. To validate B-cell depletion as a biomarker of response to rituximab in 
a second independent cohort 
iii. To evaluate the efficacy and safety of repeat cycles of rituximab  
iv. To evaluate management of 2NDNR using alternative humanised anti-
CD20 agents 
4.2. Methods 
4.2.1. Candidate’s roles in this project 
In this work, the initial concept and design of the study were set by myself, 
Prof Emery and Dr Vital. I carried out the weekly Lupus and Vasculitis clinic in 
Leeds under the supervision of Dr Vital and Prof Emery and performed a 
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significant proportion of the clinical assessments. Peripheral blood B-cell 
subsets were measured using HSFC at the Haematological Malignancy 
Diagnostic Service, Leeds Teaching Hospitals NHS Trust. I performed the 
ELISA test on research samples for anti-rituximab antibodies under the 
supervision of my laboratory supervisor, Dr El-Sherbiny. I organised and 
entered half of the data onto the study database (the other half was done by 
Dr Shaw). I performed all statistical analyses and  led the writing of the 
manuscript, while other co-authors revised the draft critically for important 
intellectual content and final approval of the manuscript prior to submission to 
journal for publication. 
4.2.2. Design and Patients 
A retrospective observational study was conducted of all patients with 
moderate to severe SLE who were treated with rituximab in Leeds between 
January 2004 and July 2016.  
Inclusion criteria were (i) adults (>16 years old); (ii) fulfilling the revised 1997 
ACR classification for SLE (31) and (iii) at least 6 months follow-up post-
rituximab. 
4.2.3. Ethical approval 
The use of rituximab, ofatumumab and ocrelizumab were all approved by 
Leeds Teaching Hospitals NHS Trust Drug and Therapeutic Committee. 
Analysis of samples for anti-rituximab antibody was approved by the Leeds 
(East) Research Ethics Committee (REC), 10/H1306/88, and the committee 
confirmed that other aspects of the study did not require ethical approval in 
accordance with the UK National Health Service REC guidelines. 
4.2.4. Treatment pathways 
All patients received a first cycle of treatment consisted of 100 mg of 
methylprednisolone and 1000 mg of rituximab given intravenously on days 1 
and 14. Further cycles of the same regimen were repeated on clinical relapse 
(as defined in section 4.2.4). 
Continuation of a stable or a reduced dose of concomitant csDMARDs 
(including oral corticosteroid), was left to investigators’ discretion with the aim 
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to stop glucocorticoid if MCR (as defined in section 4.2.4) was achieved at 6 
months. 
Of those who met the 2NDNR criteria (as defined in section 4.1), their 
treatment was switched from rituximab to humanised anti-CD20 mAbs either 
by using (i) 2x1000mg ocrelizumab (compassionate use from Roche UK) or 
(ii) 2x700mg ofatumumab (individual funding request to NHS England). 
4.2.5. Clinical Data and outcomes 
Disease activity was assessed using the BILAG-2004 index (172) at baseline 
and every 3 months thereafter. Clinical responses at 6 months were 
determined as follows: (i) MCR = improvement of all domains rated A/B to 
grade C/better and no A/B flare between baseline and 6 months; (ii) PCR = 
maximum of 1 domain with a persistent grade B with improvement in all other 
domains and no A/B flare and (iii) non-response (NR) = those not meeting the 
criteria for MCR or PCR. Relapse was defined as a new grade A or recurrence 
of ≥1 grade B following either MCR/PCR clinical response at 6 months. Global 
BILAG score was calculated as follows: grade A=12, grade B=8, grade C=1, 
and grades D and E=0 point (345).  
4.2.6. Protocol for peripheral B-cell analysis using Highly Sensitive 
Flow Cytometry (HSFC) 
As per standard of care for patients who received treatment with rituximab in 
Leeds, peripheral blood B-cell subsets (naïve, memory B-cells and 
plasmablasts) were measured using HSFC at the Haematological Malignancy 
Diagnostic Service, Leeds Teaching Hospitals NHS Trust at baseline, 6 
months and every 6 months without knowledge of patients’ clinical status other 
than time since rituximab. This accredited diagnostic clinical laboratory 
provides a regional and supra-regional diagnostic service and specialises in 
ARDs and haematological malignancies.  
B-cell numbers and subsets were enumerated following standard cell surface 
staining techniques using a sequential gating strategy with 6-colour flow 
cytometry, counting for 500,000 events. B-cells were first identified using 
gating strategy with peridinin chlorophyll A protein–Cy5.5–conjugated CD19 
and phycoerythrin–Cy7 (PECy7)–conjugated CD38 (BD Biosciences) 
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expression and light scatter characteristics. Fluorescein isothiocyanate–
conjugated CD3 and PE-conjugated CD14 (BD Biosciences) were used to 
exclude contaminating events. Subsequently, B-cells were classified 
according to the expression of PE-Cy7–conjugated CD38 and 
allophycocyanin (APC)–conjugated CD27 (BD Biosciences) as either naive B-
cells (CD19++CD27-), memory B-cells (CD19++CD27+) or plasmablasts 
(CD19+/-CD27++CD38++). APC-Cy7–conjugated CD45 (BD Biosciences) 
was used to identify total leukocytes for calculation of absolute B-cell subset 
numbers (234). The gating strategy for enumeration of B-cell subsets using 
HSFC is explained in Figure 4-1. 
Complete B-cell depletion was defined as counts <0.0001×109/L and 





Figure 4-1 Gating strategy for B-cell subsets enumeration using HSFC 
A) Plasmablasts have weaker CD19 expression. Therefore, the initial gate 
should be set around the MNCs rather than restrictive to lymphocyte. B-D) 
CD14 and CD3 markers were used to exclude contamination and T-cells 
respectively. Naïve B-cells were identified by MNC AND CD19+CD14- (Q1) 
AND CD3-CD27- (Q3-1). Memory B-cells were defined as MNC AND 
CD19+CD14- (Q1) AND CD3-CD27+ (Q4-1) AND CD38weak/negative. 
Plasmablasts were identified as MNC AND CD19+CD14- (Q1) AND CD3-





4.2.7. Other laboratory assessments 
Anti-dsDNA antibody titres were measured by ELISA until July 2012 and 
Bioplex 2200 Immunoassay (after July 2012). Complement levels (C3 and C4) 
and total serum immunoglobulin titres were measured by nephelometry.  
Anti-rituximab antibodies were tested on a subset of patients with 2NDNR 
using the Promonitor®-Anti-Rituximab ELISA and these titres were compared 
to those with continued response to rituximab. A concentration >140 AU/mL 
was deemed a positive test (as determined by the manufacturer). 
4.2.8. Safety 
Safety assessments included severe adverse events (SAEs) and SIEs were 
recorded irrespective of possible association with SLE and/or therapy. SAEs 
were defined as those resulted in either hospitalisation that lasted more than 
24 hours, flares requiring intravenous therapy, malignancies, life-threatening 
situations or death. Data for SIEs were gathered from hospital admission 
records using Patient Access Centre (PAS) system and was later confirmed 
with case notes. 
4.2.9. Statistical Analyses 
Descriptive statistics were summarised using mean with standard deviation or 
median with interquartile range for continuous variables where appropriate 
and proportion for categorical variables. The significance of the association 
between categorical variables was tested by Fisher’s exact test while for 
continuous variables using Mann-Whitney U test. Multiple imputation was 
used to handle missing data. The imputed univariable and multivariable 
analyses of predictors of any response (MCR/PCR) and MCR at 6 months 
post-rituximab were analysed using binary logistic regression. All statistical 
analyses was performed using Stata 13.1 (StataCorp College Station, Texas, 





4.3.1. Patient characteristics 
Of 125 SLE patients who were treated with rituximab at our unit over the 12 
years period, 117 patients with evaluable data at 6 months were studied. Eight 
patients were excluded (5 did not reach month 6 follow-up while 3 had left 
Leeds prior to the 6-month assessment).  
Baseline characteristics are described in Table 4-1. One hundred and twelve 
(96%) had refractory and active disease as defined by BILAG ≥1A score 
and/or ≥2B scores. The remaining 5 had BILAG B in 1 domain only but was 
refractory to other conventional therapies as well as on maintenance with oral 
prednisolone ≥10mg daily. Total follow-up was 492 patient-years (246).  
Table 4-1 Baseline characteristics of the 117 patients with SLE who were 
treated with rituximab  
Characteristic Values 
Age at first rituximab infusion, median (IQR) years 39 (26-52) 
No. female patient (%) 109 (93) 
Ethnicity, N (%) 
     Caucasian 
     Afro-Caribbean 
     South Asian 





 6 (5) 
SLE Disease duration at first rituximab, median (IQR) years 6 (2-11) 
Positive ANA at diagnosis, N (%) 117 (100) 
Antibody status at first rituximab infusion, N (%) positive 
     anti-dsDNA  
     anti-Ro  
     anti-La  
     anti-Smith  
     anti-Chromatin  
     anti-RNP  
     anti-Ribosomal P  














Cumulative dose of CyC, mean ± SD gram 6.6 ± 4.2 
Number of prior immunosuppressant failure (including CyC but 
excluding glucocorticoid), median (range) 
3 (0-9) 
Concomitant anti-malarials, N (%) 88 (75) 
Concomitant immunosuppressant, N (%) 







Prednisolone dose at first rituximab, median (IQR) mg 10 (3-20) 
ESR at first rituximab, median (IQR) mm/hour 29 (15-57) 
BILAG index score at baseline, N (%) 
       ≥1 A score  















Grade A Grade B 




  6 (5) 
  6 (5) 








  0 (0) 
  0 (0) 
  0 (0) 
12 (10) 
Global BILAG score, median (IQR) 21 (14-27) 
SLEDAI-2K score, median (IQR) 10 (6-14) 
SLICC Damage Index, median (IQR) 0 (0-1) 
 
ANA: antinuclear antibody; BILAG: British Isles Lupus Assessment Group; CYC: 
cyclophosphamide; dsDNA: double-stranded deoxyribonucleic acid; ESR: erythrocyte 
sedimentation rate; RNP: ribonucleic protein; RTX: rituximab; SLEDAI-2K: Systemic Lupus 
Erythematosus Disease Activity Index 2000; SLICC: Systemic Lupus International 




4.3.2. Treatment characteristics 
Three hundred and eighteen cycles of rituximab were administered in total. 
Median (range) duration of response in rituximab responders for cycles 1–4 
(C1–4) were 52 (26-423), 52 (26-299), 57 (27-184) and 50 (29-173) weeks 
respectively.   
Concomitant cyclophosphamide was used in only 5 patients who presented 
with life-threatening disease. 
4.3.3. Clinical and immunological response to first cycle rituximab 
In cycle 1, there was a good overall clinical response to rituximab; 58 (50%) 
patients had MCR, 38 (32%) PCR and 21 (18%) were non-responders. The 
median global BILAG scores had reduced from 21 (IQR 14-27) pre-rituximab 
to 8 (IQR 1-10) at 6 months; p<0.001.  
Responses in individual BILAG domains are shown in Table 4-2. Although 
majority of domains improved, responses were more variable in the 
mucocutaneous and haematological domains. Mucocutaneous responses to 
rituximab have been described in detail previously (17). These long-term data 
showed a more consistence major response in lupus erythematosus non-
specific lesions (LENS) and oral ulcers and non-response in chronic 
cutaneous lupus erythematosus (CCLE) [CCLE versus other lupus-specific 
lesions; p=0.022] 
The median serum anti-dsDNA titre had reduced from 109 (IQR 16-300) IU/ml 
pre-rituximab to 32 (IQR 7-116) IU/ml at 6 months; p<0.001. Of 46 patients 
with low complement (C3 and/or C4) levels pre-rituximab, levels had 
normalised in 25/46 (54%) at 6 months.  
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Table 4-2 Responses in individuals BILAG domains at 6 months post-rituximab (cycle 1)  
Domains No cases at 
baseline (Grade 
A/B) 






Worsening New Flare 
General 21 (9/12) 19 (90) 0 2 (10) 0 0 0 
Mucocutaneous 55 (23/32) 35 (64) 5 (9) 3 (5) 11 (20) 2 (4)* 3 (5) 
     ACLE/SCLE 34 (10/24) 24 (71) 3 (9) 2 (6) 4 (12) 2 (6)* 1 (3) 
     CCLE 12 (5/7) 3 (25) 2 (17) 1 (8) 6 (50) 0 2 (17) 
     LENS 7 (5/2) 7 (100) 0 0 0 0 0 
     Oral ulcers 12 (2/10) 11 (92) 0 0 1 (8) 0 0 
     Alopecia 13 (0/13) 9 (69) 0 0 4 (31) 0 0 
Neurological 34 (17/17) 22 (65) 7 (21) 0 5 (14) 0 0 
Musculoskeletal 54 (30/24) 41 (76) 8 (15) 4 (7) 1 (2) 0 0 
Cardiorespiratory 19 (6/13) 17 (89) 0 0 2 (11) 0 0 
Gastrointestinal 6 (6/0) 5 (83) 0 0 1 (17) 0 0 
Ophthalmic 0  0 0 0 0 0 0 
Renal  34 (34/0) 24 (71) 8 (24) 2 (5) 0 0 0 
Haematology 23 (11/12) 17 (73) 2  (9) 2 (9) 2 (9) 2 (9) 0 
 
* One patient with BILAG B for ACLE rash pre-rituximab had worsening of psoriasiform lesions (BILAG A) at 6 months post-rituximab. Hence, the total percentage for MCR, PCR, 
severe and moderate persistence in the mucocutaneous and ACLE/SCLE domains did not add up to 100% 
ACLE: acute cutaneous lupus erythematosus; BILAG: British Isles Lupus Assessment Group; CCLE: chronic cutaneous lupus erythematosus; LENS: lupus erythematosus non-
specific lesions; MCR: major clinical response; PCR: partial clinical response 
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4.3.4. Predictors of major clinical response to first cycle rituximab 
Only B-cell depletion at 6 weeks post-rituximab increased the odds of any 
BILAG response (MCR/PCR) in multivariable analysis; adjusted imputed OR 
13.93 95% CI 3.11-62.37; p=0.001 (Table 4-3). 
As there was a high degree of response to rituximab in this cohort, we 
analysed predictors for MCR separately in order to identify patients who would 
respond best to therapy. In imputed univariable analysis, only younger age 
was associated with MCR to rituximab (OR 0.97 95% CI 0.95-0.99; p=0.031). 
While in imputed multivariable model, younger age (OR 0.97 95% CI 0.94-
1.00; p=0.045) and B-cell depletion at 6 weeks post-rituximab (OR 3.22 95% 




Table 4-3 Multivariable analysis of predictors of any BILAG response (major/partial) to first cycle rituximab  





Univariable OR (95% CI),  
P-value 
(with multiple imputation) 
Multivariable OR (95% CI), 
P-value 
(with multiple imputation) 
Age, mean (SD) years 39 (14) 40 (16) 1.00 (0.97-1.03), p=0.833 per year 0.99 (0.95-1.04), p=0.785 
White, N (%) 14 (67) 66 (69) 0.91 (0.33-2.48), p=0.852 0.56 (0.13-2.44), p=0.440 
Anti-dsDNA titres, mean 
(SD) IU/ml 
121 (217) 149 (233) 1.00 (0.99-1.00), p=0.464 per unit 1.00 (0.99-1.00), p=0.243 
Anti-ENA positivity, N (%) 19 (90) 60 (62) 0.18 (0.04-0.84), p=0.028 0.21 (0.04-1.21), p=0.080 
Low C3 and/or C4 titres, N 
(%)* 
8 (38) 42 (44) 1.26 (0.48-3.33), p=0.640 - 
ESR, mean (SD) mm/hour 45 (33) 39 (34) 1.00 (0.98-1.01), p=0.618 per unit 0.99 (0.97-1.01), p=0.525 
Concomitant DMARDs, N 
(%)** 
14 (67) 62 (65) 0.91 (0.34-2.47), p=0.856 - 
Daily Prednisolone dose, 
mean (SD) mg 
16 (13) 14 (13) 0.98 (0.95-1.02), p=0.390 per mg 0.98 (0.93-1.03), p=0.511 
Total BILAG score, mean 
(IQR) 
21 (11) 23 (11) 
1.02 (0.97-1.07), p=0.486 per 
point 
1.02 (0.96-1.09), p=0.487 
Total B-cell counts, mean 
(IQR)*** 
132 (103) 116 (128) 1.00 (0.99-1.00), p=0.727 per unit 1.00 (0.99-1.01), p=0.986 
B-cell depletion at 6 weeks 
post-rituximab, N (%) 
3 (14) 65 (68) 11.07 (2.97-41.20), p<0.001 13.93 (3.11-62.37), p=0.001 
 
*   As there were high collinearity between concomitant DMARDs and B-cell depletion, low complement and Total B-cell counts and concomitant DMARDs and low complement, 
the last two variables were excluded in the multivariable analysis  
* * Concomitant DMARDs was defined as either using methotrexate, azathioprine, mycophenolate mofetil and/or other disease modifying anti-rheumatic drugs but excluded anti-
malarials 
***(count x 109 cells/L) for each subset multiply by 1000 prior to analysis 
BILAG: British Isles Lupus Assessment Group; C3/C4: complement 3 or 4; DMARDs: disease modifying anti-rheumatic drugs; dsDNA: double-stranded deoxyribonucleic acid; 
ENA: extract nuclear antigen; ESR: erythrocyte sedimentation rate 
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Table 4-4 Multivariable analysis of predictors of major clinical response to first cycle rituximab  






Univariable OR (95% CI),  
P-value   
(with multiple imputation) 
Multivariable OR (95% CI), 
P-value     
(with multiple imputation)                                      
Age, mean (SD) years 43 (17) 37 (14) 0.97 (0.95-0.99), p=0.031 per year 0.97 (0.94-1.00), p=0.045 
White, N (%) 43 (73) 37 (64) 1.53 (0.70-3.34), p=0.292 0.92 (0.34-2.47), p=0.870 
Anti-dsDNA titres, mean 
(SD) IU/ml 
147 (230) 142 (230) 1.00 (0.99-1.00), p=0.879 per unit 1.00 (0.99-1.00), p=0.632 
Anti-ENA positivity, N (%) 40 (68) 38 (66) 0.91 (0.42-1.99), p=0.812 0.90 (0.37-2.22), p=0.821 
Low C3 and/or C4 titres, N 
(%) 
25 (42) 24 (41) 0.97 (0.46-2.04), p=0.937 1.14 (0.41-3.13), p=0.801 
ESR, mean (SD) mm/hour* 40 (32) 41 (36) 1.00 (0.99-1.01), p=0.827 per unit - 
Concomitant DMARDs, N 
(%)** 
41 (69) 35 (60) 0.67 (0.31-1.43), p=0.301 0.43 (0.17-1.09), p=0.075 
Daily Prednisolone dose, 
mean (SD) mg 
13 (11) 16 (14) 1.02 (0.99-1.05), p=0.207 per mg 1.00 (0.97-1.04), p=0.713 
Total BILAG score, mean 
(IQR) 
21 (8) 24 (13) 
1.03 (0.99-1.07), p=0.093 per point 
1.02 (0.97-1.07), p=0.371 
Total B-cell counts, mean 
(IQR)*** 
101 (95) 138 (150) 1.00 (1.00-1.01), p=0.161 per unit 1.00 (1.00-1.01), p=0.137 
B-cell depletion at 6 weeks 
post-rituximab, N (%) 
29 (49) 39 (68) 2.10 (0.95-4.62), p=0.065 3.22 (1.24-8.33), p=0.016 
 
*   As high collinearity was observed between ESR and Total B-cell counts, only the latter was included in the multivariable analysis 
** Concomitant DMARDs was defined as either using methotrexate, azathioprine, mycophenolate mofetil and/or other disease modifying anti-rheumatic drugs but excluded anti-
malarials 
***(count x 109 cells/L) for each subset multiplied by 1000 prior to analysis 
BILAG: British Isles Lupus Assessment Group; C3/C4: complement 3 or 4; DMARDs: disease modifying anti-rheumatic drugs; dsDNA: double-stranded deoxyribonucleic acid; 
ENA: extract nuclear antigen; ESR: erythrocyte sedimentation rate
116 
 
4.3.5. Validation of association between complete B-cell depletion and 
clinical response 
The published discovery cohort included 37 SLE patients (16). In this 
validation cohort, 67 subsequent and consecutive patients (with B-cell data 
available) were analysed. Similar to the discovery cohort, higher response rate 
was achieved in complete depletion compared to incomplete depletion 
groups; 93% versus 68%; p=0.011 in this validation cohort (Figure 4-2A). 
4.3.6. Relationships between B-cell depletion and routine 
immunological markers 
While there was no difference at baseline, patients with complete B-cell 
depletion had significantly lower anti-dsDNA antibody titres at 14 weeks 
(p=0.030) and 26 weeks (p=0.041) compared to those with incomplete 
depletion. Additionally, in the former, C3 and C4 levels were not different at 
14 weeks (p=0.064 and p=0.148 respectively) but were higher at 26 weeks 
(p=0.020 and p=0.022 respectively) compared to the latter group. There was 
no difference in the count of anti-ENA specificities between the two groups at 
14 and 26 weeks; all p>0.10. 
4.3.7. Retreatment of first cycle non-responders 
In RA, we showed that retreatment of incomplete depleters who were initial 
non-responders led to improved response rate in cycle 2 (240). In this present 
study, of 21 SLE patients who were cycle 1 non-responders, 9 were retreated 
with rituximab. The domains that persisted at grade A or B in cycle 1 were 
mucocutaneous (n=4), musculoskeletal (n=3), renal (n=2) and haematology 
(n=3). After retreatment, none of these patients responded. Moreover, 4 
patients had clinical features that were suggestive of immunogenicity.  
4.3.8. Retreatment of first cycle responders 
Of the 96 SLE patients who were cycle 1 responders, 77 (with complete data 
on 72) were retreated on clinical relapse. Of these, 61/72 (85%) responded in 
cycle 2 (Figure 4-3). Numerically higher rate of B-cell depletion was achieved 
in cycle 2 compared to C1, 68% versus 58% respectively; p=0.206 and 
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depletion improved over subsequent cycle; cycle 3 versus cycle 1, 79% versus 
58% respectively; p=0.022 (Figure 4-2B). 
Twelve out of thirty-eight patients with PCR in cycle 1 were retreated at 6 
months. Of these, MCR was achieved in 10/12 (83%) in cycle 2. One patient 
had worsening of arthritis while another had 2NDNR in cycle 2. 
Of the 11 SLE patients who were cycle 2 non-responders, 9 met 2NDNR 
criteria. Therefore, the incidence of 2NDNR in this cohort was 9/77 (12%). In 






Figure 4-2 B-cell depletion as a biomarker of response and depletion 
over successive cycles 
A) Similar to the discovery cohort, a higher response rate was achieved 
in complete depletion compared to incomplete depletion groups; 93% 
versus 68%; p=0.011 in the validation cohort B) There was an 
incremental increase in the rates of B-cell depletion over 3 cycles of 














Figure 4-3 Efficacy of repeat cycles with rituximab in SLE 
A high rate of initial clinical response to rituximab was observed in this cohort, 96/117 (82%). 77 responders who had clinical relapse were retreated in cycle 
2. Of these, 61/72 (85%) continued to response in cycle 2. Of the cycle 2 non-responders, 9/11 met 2NDNR criteria. Five were switched to ocrelizumab or 
ofatumumab, resulted in depletion and response in all. 2NDNR: secondary non-depletion and non-response. 
Reprinted with permission from the BMJ publishing group. Md Yusof MY et al. Predicting and managing primary and secondary non-response to rituximab 




4.3.9. Association of 2NDNR with anti-rituximab antibody 
Anti-rituximab antibodies were tested in post-rituximab sera of 5/9 patients 
with 2NDNR. Of these, all 5/5 (100%) were tested positive. In contrast, of the 
16 patients who were cycle 2 responders, 9/16 (56%) were also tested positive 
for anti-rituximab antibodies. The median anti-rituximab levels were higher in 
the former, 562 (IQR 394-9670) AU/ml compared to the latter group, 217 (IQR 
0-409) AU/ml; p=0.024 (Figure 4-4). 
 
Figure 4-4 Patients with 2NDNR had higher anti-rituximab levels than 
those with continued response 
The phenomenon 2NDNR was associated with anti-rituximab antibody. 
Y-axis represents logarithmic scale with base 10 of the median anti-
rituximab antibody level. Error bars denote interquartile range. The 
dotted red line represents normal cut-off of the anti-rituximab antibody 
ELISA test. 2NDNR: secondary non-depletion and non-response; 






4.3.10. Factors associated with 2NDNR 
Risk factors for 2NDNR were lack of concomitant DMARDs (p=0.023) and 
higher pre-rituximab plasmablasts (p<0.001) (Table 4-5). Concomitant 
corticosteroid dose, duration of response in cycle 1, clinical response category 
in cycle 1, pre-rituximab global BILAG score, pre-rituximab naïve- and 
memory B-cells were not associated with 2NDNR; all p>0.10. 
Table 4-5 Factor associated with 2NDNR to rituximab  
Characteristics prior 
to repeat rituximab  
Continued response 
(n=61) 





 41 (67) 2 (22) 0.023 
Prednisolone, median 
(IQR) mg 
5 (0-10) 5 (0-17.5) 0.729 
Duration of response, 
median (IQR) weeks 
50 (36-107) 62 (52-164) 0.239 
Total BILAG score, 
median (IQR) 
16 (12-21) 24 (12-27) 0.209 
Partial clinical response 
in cycle 1, N (%) 
24 (39) 3 (33) 0.731 
Naïve B-cells, median 





















2NDNR: secondary non-depletion and non-response; BILAG: British Isles 
Lupus Assessment Group; DMARDs: disease modifying anti-rheumatic drugs; 




4.3.11. Efficacy of switching to alternative humanised anti-CD20 
antibodies 
Following 2NDNR, treatment for 5 SLE patients were switched to humanised 
anti-CD20 mAbs (ocrelizumab=3 and ofatumumab=2). Post-treatment, 
complete depletion of total CD20+ cells were achieved in 4/5 patients while 
the remaining 1 had substantially low counts; 0.0016 x 109/L.  
The median global BILAG scores had reduced from 24 (IQR 18-45) pre-
treatment to 1 (IQR 0-8) post-treatment; p=0.008 (Figure 4-5A). The individual 
BILAG response is shown in Figure 4-5B and described in Table 4-6. One 
patient with class IV-G (active with moderate scarring) who had progressed 
into end-stage renal failure was treated with ofatumumab, mainly for severe 
thrombocytopenia with a view for renal transplantation preparation. Post-
ofatumumab, her platelet had normalised from 45 x 109/L (pre-treatment), 

















Figure 4-5 Efficacy of switching to humanised anti-CD20 antibodies 
A) Global BILAG score and CD20+ B-cells are plotted for each patient. The black vertical line in the CD20+ B-cells figure represents the median. B) An 
example of a case where proteinuria was normalised following a switch to ocrelizumab. ‘RR’ represents 2 x infusions of rituximab, ‘R’ represents a single 
infusion as the patient cannot not complete the second due to severe infusion reaction and ‘OO’ represents 2 x infusions of ocrelizumab. Total B-cell counts 
were transformed to natural log. 2NDNR: secondary non-depletion and non-response; BILAG: British Isles Lupus Assessment Group; PCR: protein creatinine 
rato 
Reprinted with permission from the BMJ publishing group. Md Yusof MY et al. Predicting and managing primary and secondary non-response to rituximab 
using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017 Nov;76(11):1829-1836  
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cells x 10 9/L 
Post-Treatment 
Total CD20+ B-
cells x 10 9/L 
01 OCR B – General 
A – Mucocutaneous 
B – Musculoskeletal 
A – renal 
 
40 D – General 
C – Mucocutaneous 
D – Musculoskeletal 
D – Renal 
 
1 0.0032 0 
02 OCR B – General 
A – Renal 
 
20 D – General 
D – Renal 
 
0 0.1481 0 
03 OCR B – Neurological 
B – Musculoskeletal 
 
16 D – Neurological 
C – Musculoskeletal 
 
1 0.0724 0.0016 
04 OFA A – Renal 
A – Haematology 
 
24 B – Renal 
C – Haematology 
 
13 0.0369 0 
05 OFA B – General 
A – Mucocutaneous 
B – Neurological 
B – Musculoskeletal 
A – Renal 
C – Haematology 
 
49 D – General 
C – Mucocutaneous 
D – Neurological 
D – Musculoskeletal 
C – Renal 
C – Haematology 
 
3 0.0286 0 
Note: 1 patient with severe SLE who had incomplete B-cell depletion and non-responder in cycle 1 was retreated with rituximab but subsequently developed 
immunogenicity. She was treated with ocrelizumab, resulted in enhanced depletion, biological response i.e. normalisation of anti-dsDNA and complement levels, 
as well as was able to be discharged home (after 3 months of prolonged hospitalisation). Unfortunately she died 5 months later due to multi-organ failure. This 
patient was not included in the above as she did not meet 2NDNR criteria. 





138 SAEs were recorded in 54 patients who were treated with rituximab. Of 
these, 130 were hospitalisation episodes (median duration 5 (IQR 3-9) days), 
3 malignancies and 5 deaths (Table 4-7). The causes of deaths were 
intracranial/subarachnoid haemorrhage=2, pneumonia=1, urinary sepsis=1 
and multi-organ failure=1.  
33 SIEs (6.7/100 patient-years) were recorded in 23 rituximab-treated 
patients, mostly due to chest infection (n=15). The 5 opportunistic infections 
recorded were mycobacterium avium complex=1, pneumocystis jiroveci 
pneumonia=1 in a patient who was simultaneously diagnosed as having 
human immunodeficiency virus (HIV) infection, cytomegalovirus=1, 
disseminated varicella zoster=1 and disseminated candidiasis. 36% (n=12) 
and 64% (n=21) of the SIEs occurred within 3 and 6 months respectively from 
the last rituximab infusion in any cycle. No cases of progressive multi-focal 
leukoencephalopathy (PML) were observed. 
6 SAEs were recorded in 3 patients who were treated with ocrelizumab. Of 
these, 4 were SIEs (14/100 patient-years) which included one opportunistic 
infection with cytomegalovirus. One death occurred in a patient with severe 
SLE who died of multi-organ failure at 5 months post-ocrelizumab. No serious 












All severe adverse events 
No. of severe adverse events 












All serious infection, no. events  
       Pneumonia 
       Urinary tract infection 
       Opportunistic infections 
       Cellulitis/Skin abscess 
       Intra-abdominal abscess 
       Infectious diarrhoea 
       Necrotising fasciitis 




























All other hospitalisation, no. events 
       SLE flare 
       Infusion reaction/serum sickness 
       Viral illness 
       Acute kidney injury 
       Bowel surgery/Hernia repair 
       Thromboembolism 
       Diverticulitis/Perforated colon 
       Orthopaedics surgery (Elective) 
       Kidney transplant 
       Acute coronary syndrome  
       Intracerebral haemorrhage 
       Palpitation/Atrial fibrillation 
       Avascular necrosis 
       Seizure 
       Kidney stones 




















































All malignancy, no. events 
       Renal transitional cell carcinoma 
       Thymoma 










4.3.13. B-cell depletion and associated serious infection 
As most of the SIEs occurred in cycles 1 and 2, (n=23 in 15 patients), we 
analysed the association between complete B-cell depletion and SIEs. After 
two cycles, there were no difference in the serious infection rates between 
complete and incomplete depletion groups; 8/98 (8.2%) and 7/73 (9.6%) 
respectively; p=0.789. 
4.4. Discussion 
The clinical challenges in the use of rituximab in SLE include defining 
subgroups of patients likely to respond to initial, subsequent cycles and 
establishing optimal repeat treatment strategy. By capturing data of all SLE 
patients who are treated with rituximab in this largest reported cohort as well 
as long-term follow-up to date, this study offers insights into pragmatic use of 
rituximab and has implications for the future development of targeted 
therapies.  
In this study, the only consistent predictor of any and MCR to rituximab was 
B-cell depletion (as measured using HSFC) at 6 weeks post-rituximab. I have 
now validated this biomarker in an independent cohort. This underscores the 
immunomodulatory action of rituximab in terms of normalising autoantibody 
titres and complement levels without increasing the risk of severe infection. 
From treatment stratification perspective, my results provide the rationale for 
B-cell monitoring for as a biomarker for response prediction during therapy.  
In this study, a high degree of clinical and immunological initial response to 
rituximab was confirmed in a wide range of SLE manifestations. Thus although 
not formally licensed, rituximab should remain an option in the treatment of 
patients with severe and refractory SLE. However, given the heterogeneity in 
clinical phenotype, it may be that there is no one-size-fits-all therapy. Clinical 
response was more varied for mucocutaneous manifestation and depended 
on the subtypes. In particular, CCLE was associated with poor clinical 
response. Although immune complex deposition is a common feature, non B-
cell mechanisms through activation and apoptosis of keratinocytes and 
production of inflammatory cytokines and chemokines (274, 346, 347) are also 
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responsible in the pathogenesis of this lesion and consequently, should be 
targeted. 
Regardless of initial response, about 12% subsequently developed 2NDNR in 
cycle 2. This phenomenon was associated with anti-rituximab antibodies. 
However, measuring anti-rituximab antibody alone was not enough to classify 
patients as 2NDNR as over half of the patients who were tested positive 
responded in that particular cycle. Instead, clinical features including severe 
infusion reaction, non-response and measuring B-cells were more 
meaningful. Lack of concomitant csDMARDs (excluding hydroxychloroquine 
only) and higher pre-rituximab plasmablasts predicted 2NDNR. Oral 
csDMARDs was decided at physicians’ discretion but my data suggest they 
might have a role in preventing immunogenicity. The exact mechanism for the 
association of 2NDNR with plasmablast number is unknown but plasmablasts 
are markers for overall B-cell activation. Following initial depletion with 
rituximab, BAFF levels increase and promote the formation of plasmablasts 
(248). This early increase in plasmablasts enhances the formation of follicular 
T-helper cells, thus creating a positive feedback loop that perpetuates 
antibody-driven inflammation and may explain why some patients become 
refractory to rituximab in SLE (348).  
Following 2NDNR to rituximab, switching to humanised alternative anti-CD20 
mAbs restores depletion and response in SLE. Ocrelizumab and ofatumumab 
are both type 1 anti-CD20 mAbs. The primary endpoint was met in 
ocrelizumab-treated groups in RA trials (252) and was investigated in SLE 
(253). However, development in these indications was halted after an increase 
in opportunistic infections, some of which fatal were reported (254). All 3 
patients in our study had MCRs and prolonged remission for over 5 years’ 
period post-ocrelizumab. Ofatumumab is licensed for resistant CLL and has 
demonstrated efficacy in RA (255). Both patients in this present study 
responded well to ofatumumab included one who achieved complete 
depletion for the first time from B-cell depleting therapy. Moreover, a few case 
series have recently reported on its efficacy in non-renal and refractory lupus 
nephritis (349, 350). Alternatively, other anti-CD20 agents with enhanced 
ADCC may be more effective in SLE. In vitro obinutuzumab demonstrated that 
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enhanced depletion was achieved with this type 2 mAb, compared to rituximab 
(351). 
This study has some limitations. First, an inter-observer variability could have 
occurred in BILAG assessments due to the lengthy follow-up duration as well 
as a cohort that was highly heterogeneous in lupus manifestations. However, 
the BILAG scores reflected the clinicians’ intention-to-treat and the patients 
were managed in a dedicated single centre, thus allowing for consistency in 
assessment. Second, B-cells and laboratory data were missing in some 
cases. As these were deemed missing at random, multiple imputation was 
used to reduce potential bias in parameter estimation as well as enhancing 
generalisability of the results. Next, concomitant therapy with csDMARDs 
were used in more than 60% of the patients, thus efficacy could not be 
attributed to rituximab alone. Lastly, the lack of control group limits 
interpretation of efficacy and safety of rituximab. 
4.5. Conclusion 
In conclusion, treatment with anti-CD20 agents should be guided by B-cell 
monitoring with the aim of achieving complete depletion. 12% of the SLE 
patients lose depletion on repeat cycles of rituximab regardless of prior 
response and secondary non-depletion is associated with anti-rituximab 
antibodies. Concomitant csDMARDs may help to prevent this. If 2NDNR 
occurs, switching to humanised anti-CD20 mAbs restores depletion and 
response. Therefore, alternative humanised anti-CD20 antibodies may be 
more consistently effective in SLE treatment and several ongoing trials are 
addressing these issues.   
4.6. Key messages 
i. Rituximab is effective for a wide range of SLE manifestations as well 
as no major safety signals were observed in long-term follow-up of this 
cohort study. 
ii. B-cell depletion (as measured at 6 weeks post-rituximab) is an 
independent predictor of any or major clinical response to rituximab, 
which has been validated in a second cohort. 
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iii. 12% of patients with SLE lose depletion and response on repeat cycles 
regardless of prior response, and this 2NDNR phenomenon is 
associated with anti-rituximab antibodies. 
iv. If 2NDNR occurs, switching to alternative humanised anti-CD20 






Chapter 5. B-cell biomarkers in systemic lupus 
erythematosus and other B-cell mediated 
autoimmune rheumatic diseases  
5.1. Introduction 
Clinical efficacy of rituximab in RA has been associated with the level of both 
synovial membrane B-cell depletion (352, 353) and early peripheral blood 
plasmablast depletion as measured using sensitive assays (234); the latter 
possibly functioning as a surrogate marker. Following depletion with rituximab, 
repopulation of B-cells lead to a relapse in most patients (albeit after a variable 
interval after repopulation). However, the optimal retreatment strategy has not 
been clearly defined. The most common strategy is to give repeat cycles on 
clinical relapse. However, these relapses may give rise to further structural 
deterioration or, in severe CTD, may cause life- or organ-threatening disease 
for patients. An alternative approach is to use pre-emptive using fixed-
intervals strategy (e.g. biannually), but this potentially exposes the patient to 
overtreatment and enhances the risk of adverse events as well as being 
expensive. Moreover, the time-to-relapse is specific to each patient and can 
be difficult to predict prior to treatment. To overcome this, one potential 
strategy may be to guide treatment decisions based on B-cell biomarkers; 
specifically monitoring for the depth of B-cell depletion and regeneration 
kinetics of B-cell subsets after rituximab administration.  
In SLE, our group previously showed that initial complete B-cell depletion was 
associated with better initial clinical response (16), which was validated in my 
thesis (section 4.3.5) and subsequently published (246). However, factors 
leading to complete depletion is unclear. If this could be predicted, then 
modification of therapy to improve depletion would be made possible. 
Additionally, our group also reported that following B-cell depletion, there was 
a bimodal pattern of relapse i.e. earlier (within 18 months of first cycle 
rituximab) versus later relapse (>18 months).  Earlier relapse requiring further 
rituximab therapy was predicted by a plasmablast count of >0.0008 × 109/L at 
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6 months (the time of initial clinical response) whilst those with lower 
plasmablasts at 6 months had sustained response without retreatment. 
Validation of this as a biomarker is therefore needed to determine whether B-
cell enumeration using HSFC can be used in clinical practice to guide 
retreatment decisions. 
Simiarly, in RA, our group previously reported that the initial depth of B-cell 
depletion (measured after the first infusion of rituximab) was associated with 
clinical response; 96% complete versus 74% incomplete depletion at 6 
months (p=0.020) (234). Furthermore, retreatment of initial non-responders 
with incomplete depletion led to 72% response rate in cycle 2 (240). These 
two aspects also need validation in a second cohort for this biomarker to be 
used in clinical practice. 
Rituximab has been licensed by US FDA and EMA for remission induction in 
AAV since 2011 (258, 259). For this indication, retreatment strategy remains 
problematic. The fixed-intervals strategy either by administering 1g rituximab 
every 6 months or 2g rituximab every 12 months had led to secondary 
hypogammaglobulinaemia, increased rates of infection and cessation of 
therapy (261, 354). Despite evidence for the pathogenicity of ANCA (355), 
serum levels of these antibodies do not appear to be clinically useful as a 
biomarker of relapse. A meta-analysis of 18 studies demonstrated that ANCA 
titres were only modestly predictive of relapses (356). Thus, a reliable 
biomarker for relapse prediction is warranted and B-cells had not previously 
been analysed. 
5.2. Hypothesis 
Enumeration of B-cell subsets using HSFC will predict clinical response and 
relapse in SLE, RA and AAV patients treated with rituximab. 
5.3. Objectives 
i. To validate B-cell depletion after the first infusion as a predictor of 
response to rituximab (Project 1) 
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ii. To assess outcome of retreatment of first cycle non-responders in RA 
(Project 2) 
iii. To assess factors contributing to complete B-cell depletion in first cycle 
rituximab for the treatment of SLE (Project 3) 
iv. To validate the association of repopulation of plasmablasts at 6 months 
post-rituximab with clinical relapse in SLE (Project 4) 
v. To assess the association of repopulation of B-cell subsets at 6 months 
post-rituximab with clinical relapse in AAV (Project 5) 
vi. To compare utility of B-cell biomarkers to guide rituximab treatment 
decisions in RA, SLE and AAV 
5.4. Methods 
5.4.1. Candidate’s roles in this project 
In this work, the initial concept and design of the study were set by myself, 
Prof Emery and Dr Vital. I carried out the weekly Biologics, Lupus and 
Vasculitis clinic in Leeds under the supervision of Dr Vital and Prof Emery. I 
performed a significant proportion of the clinical assessments. Peripheral 
blood B-cell subsets were measured using HSFC at the Haematological 
Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust. I 
organised and entered half of the data (over 1000 patients) onto the study 
database (the other half was done by Dr Das, Dr Baptiste Candelier, Dr 
Eugenio and Dr Garcia-Montoya). I performed all statistical analyses and  led 
the writing of the manuscript, while other co-authors revised the draft critically 
for important intellectual content and final approval of the manuscript prior to 
submission to journal for publication. 
5.4.2. Design and patients 
A retrospective observational study was conducted of all patients with ARDs, 
who were treated with at least a course of rituximab in Leeds between Jan 
2002 and July 2016.  
Inclusion criteria were (i) adults (>16 years old); (ii) fulfilling the classification 
criteria for RA (329), SLE (32) and AAV (357) and (iii) at least 3 months follow-
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up post-rituximab. The published discovery cohorts included 60 RA patients 
in Project 1 (234) and 25 RA patients in Project 2 (240). For this validation 
study, we analysed the subsequent consecutive 180 patients with RA treated 
with rituximab in Leeds.  
The published discovery cohort included 37 patients with SLE in Project 4 
(16). For this validation study, the subsequent consecutive 78 patients with 
SLE treated with rituximab in Leeds were studied (see details and 
characteristics of patients in section 4.3.1). The total cohort was used to 
analysed predictors of complete B-cell depletion in SLE (Project 3).  
For Project 5, the patients received rituximab if there was active severe 
disease despite either a course of cyclophosphamide lasting 3–6 months or 
maximum cumulative cyclophosphamide dose of 25g (358) or in 
circumstances where cyclophosphamide could not be given because of 
previous toxicities associated with therapy i.e. profound leukopenia and 
haemorrhagic cystitis and other relative contraindications such as a history of 
solid malignancy and issues with fertility (359). Blood from HCs were used as 
a negative control for comparison among diseases.  
5.4.3. Ethical approval 
This study did not require ethical approval because all treatment decisions 
were made prior to evaluation of data, in accordance with the UK National 
Health Service Research Ethics Committee guidelines. Peripheral B-cell 
analyses were performed as standard of care of patients receiving treatment 
with rituximab in Leeds and results were reported in the Trust server. The HCs’ 
blood samples used for this study were collected under ethical approval, 
04/Q1206/107, National Research Ethics Committee Yorkshire and Humber–
Leeds East. The off-label use of rituximab prior to its approval in RA and AAV 
and commissioning by NHS England for SLE was all approved by the Leeds 
Teaching Hospitals NHS Trust Drug and Therapeutic Committee. 
5.4.4. Treatment protocol 
All patients received a first cycle of treatment consisted of 100 mg of 
methylprednisolone and 1000 mg of rituximab given intravenously on days 1 
and 14. Further cycles of the same regimen were repeated on clinical relapse. 
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For Project 2, patients who had incomplete B-cell depletion and non-response 
in cycle 1 were given a further course of rituximab (using the same regimen 
as above) at 6 months.   
Continuation of a stable or a reduced dose of concomitant DMARDs (including 
oral corticosteroid), was left to investigator’s discretion with the aim to stop 
glucocorticoid if clinical response was achieved at 6 months. 
5.4.5. Assessment schedule and follow-up arrangements 
Comprehensive assessments including clinical, laboratory and B-cell 
biomarkers were performed at baseline, 3 months, 6 months and every 6-
monthly then after. Participants were given a helpline number to contact for 
an additional flare visit to be organised if they had new or worsening 
inflammatory symptoms. 
5.4.6. Clinical data and outcomes 
For RA, disease activity was assessed using DAS-28 at baseline and every 3 
months. Response at 6 months was defined according to the criteria of the 
European League Against Rheumatism (EULAR) (360). 
For SLE, disease activity was assessed using the BILAG-2004 index at 
baseline and every 3 months thereafter. Criteria for clinical responses at 6 
months were described in section 4.2.4.  
For AAV, disease activity was assessed at baseline and every 3 months post-
therapy using Birmingham Vasculitis Activity Score (BVAS 3.0) (361) without 
knowledge of B-cell results. Complete response (CR) was defined as BVAS = 
0 while partial response (PR) was defined as 50% improvement in BVAS from 
baseline, both assessed at 6 months. Relapse was defined as an increase in 
the BVAS ≥ 1. 
5.4.7. Peripheral B-cell analysis using HSFC 
Peripheral blood B-cell subsets (naïve, memory B-cells and plasmablasts) 
were measured using HSFC at the Haematological Malignancy Diagnostic 
Service, Leeds Teaching Hospitals NHS Trust at baseline, 6 months and 
every 6 months without knowledge of patients’ clinical status other than time 
since rituximab. The protocol for analysis is detailed in section 4.4.5. 
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Complete B-cell depletion was defined as counts <0.0001×109/L and 
repopulation as ≥0.0001×109/L. 
5.4.8. Other relevant laboratory assessments 
Full blood count and C-reactive protein (CRP) were processed at a single 
accredited diagnostic laboratory. 
The ANCA staining pattern; cytoplasmic (cANCA) or perinuclear (pANCA) was 
determined by indirect immunofluorescence. Measurement of antigen 
specificity for myeloperoxidase (MPO), proteinase-3 (PR3), anti-dsDNA and 
anti-ENAs were made using ELISA (until July 2012) and Bioplex 2200 
Immunoassay (after July 2012). Complement levels (C3 and C4) and total 
serum immunoglobulin titres were measured by nephelometry. 
5.4.9. Statistical analyses 
Descriptive statistics were summarised using mean with standard deviation or 
median with interquartile range for continuous variables where appropriate 
and proportion for categorical variables. The significance of the association 
between categorical variables was tested by Fisher’s exact test while for 
continuous variables using either Student’s T-test or Mann-Whitney U test 
where appropriate. B-cell subsets over time among the three B-cell mediated 
diseases were compared ANOVA followed by pairwise Tukey tests. To 
account for missing data, multiple imputation by chained equations was used 
to create 20 complete datasets, results of which were combined according to 
Rubin’s rules. The imputed multivariable analyses of predictors of complete 
B-cell depletion post-rituximab in SLE were analysed using binary logistic 
regression. Relapse-free survival time (measured in weeks) was calculated 
from the date of first rituximab infusion to either the date of rituximab re-
treatment or the date of data last updated (July 2016). ROC curve analysis 
was used to measure sensitivity and specificity of optimal thresholds for 
investigations predicting time-to-clinical relapse in SLE. For AAV, relapse-free 
survival analysis for seven continuously distributed variables and six 
categorically distributed variables were analysed using univariate Cox-
regression analysis. Analysis for other categorically distributed variables that 
were relevant for relapse prediction was calculated using Kaplan–Meier plot 
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and log-rank test. All statistical analyses was performed using Stata 13.1 
(StataCorp College Station, Texas, USA) GraphPad Prism v.7.03 (GraphPad, 
La Jolla, CA, USA) for Windows. 
5.5. Results 
5.5.1. Project 1: Validation of depletion as a predictor of response in 
RA 
Patient characteristics 
Following the publication of the discovery cohort (234), data for the 
consecutive 180 patients with RA who were treated with rituximab were 
analysed (362). There was no difference in key clinical characteristics 
between the two cohorts. Baseline characteristics are summarised in Table 5-
1.  
Table 5-1 Comparison of clinical characteristics between the discovery and 
validation cohorts of RA patients treated with rituximab 
 
Characteristics Discovery Cohort  
(n=60) 
Validation Cohort  
(n=180) 
Mean age (SD), years  59.0 (15.2) 59.9 (13.7) 
Female, n (%) 45 (75) 147 (81) 
Median RA disease duration 
(IQR), year 
12 (6 – 18) 10 (5 - 18) 
RF and/or CCP antibodies 
positivity, n (%) 
60 (100) 175 (97) 
Previous TNF-inhibitors 
exposure, n (%) 
40 (67) 108 (60) 
 
CCP: cyclic citrullinated peptide; IQR: interquartile range; RA: rheumatoid 




Validation of association between complete B-cell depletion and clinical 
response in RA 
Similar to the discovery cohort, higher EULAR response (Good or Moderate) 
rate was achieved in complete B-cell depletion compared to incomplete 
depletion groups in RA; 77% versus 61%; p=0.036 in this validation cohort 
(Figure 5-1). Overall, combining results from both cohorts (n=240), we had 
confirmed in a large cohort of rituximab-treated RA patients that complete B-
cell depletion after the first infusion of rituximab was associated with EULAR 
response in RA; 79% complete depletion versus 61% incomplete depletion 





Figure 5-1 Association of complete B-cell depletion and EULAR 
response in RA 
Similar to the discovery cohort, a higher EULAR response rate was 
achieved in complete depletion compared to incomplete depletion 
groups; 77% versus 61%; p=0.036 in the validation cohort. EULAR: 





5.5.2. Project 2: retreatment of first-cycle non-responders in RA 
Outcome of retreatment of first cycle non-responders in RA 
Of 180 patients with RA who were treated with rituximab in this validation 
cohort, 30 patients who were cycle 1 non-responders and had incomplete 
depletion were retreated at 6 months. Of these, 20/30 (67%) had complete 
depletion and responded in cycle 2. This rate was about similar to the 
discovery cohort (240). In this validation cohort, non-responders in cycle 2 had 
a trend to higher plasmablasts at retreatment than responders; median count 
0.0027 ×109/L and 0.0012 ×109/L respectively; p=0.145. 
5.5.3. Project 3: Predictors of complete B-cell depletion to first cycle 
rituximab in SLE 
Data for B-cell subsets were available for 104/117 (89%) of the patients. In 
imputed univariable analysis, higher anti-dsDNA titre (OR 1.00, 95% CI 0.99 
to 1.00; p=0.038), normal complement levels (OR 0.41, 95% CI 0.18 to 0.91; 
p=0.028) and lower pre-rituximab plasmablasts (OR 0.88, 95% CI 0.80 to 
0.98; p=0.015) were associated with complete B-cell depletion in cycle 1. 
While in the imputed multivariable model, only normal complement levels (OR 
0.29, 95% CI 0.09 to 0.90; p=0.032) and lower pre-rituximab plasmablasts 
(OR 0.86, 95% CI 0.78 to 0.96; p=0.007) predicted complete B-cell depletion 










Table 5-2 Predictors of complete B-cell depletion post-first cycle rituximab in SLE 






Univariable OR (95% CI),  
P-value 
(with multiple imputation) 
Multivariable OR (95% CI),  
P-value 
(with multiple imputation) 
Anti-dsDNA titres, 
mean (SD) IU/ml 
200 (282) 101 (166) 1.00 (0.99-1.00), p=0.038 1.00 (0.99-1.00), p=0.105 
Anti-ENA positivity,       
N (%) 
31 (70) 36 (60) 0.63 (0.27-1.44), p=0.273 0.75 (0.27-2.07), p=0.579 
Low C3 and/or C4 
titres, N (%) 
25 (57) 21 (35) 0.41 (0.18-0.91), p=0.028 0.29 (0.09-0.90), p=0.032 
Concomitant DMARDs, 
N (%) 
25 (57) 43 (72) 1.92 (0.85-4.36), p=0.118 2.66 (0.98-7.27), p=0.055 
Corticosteroid dose, 
mean (SD) mg 
15 (11) 13 (14) 0.99 (0.96-1.02), p=0.339 1.02 (0.97-1.06), p=0.429 
Total BILAG score, 
mean (IQR) 
23 (11) 23 (11) 
1.00 (0.97-1.04), p=0.938   
 per point 
1.05 (1.00-1.11), p=0.064 
Naïve B-cell counts, 
mean (SD)* 
101 (105) 74 (79) 0.99 (0.99-1.00), p=0.202 0.99 (0.99-1.00), p=0.111 
Memory B-cell counts, 
mean (SD)* 
29 (31) 27 (70) 1.00 (0.99-1.01), p=0.889 1.00 (0.99-1.01), p=0.658 
Plasmablast counts, 
mean (SD)* 
8 (10) 3 (5) 0.88 (0.80-0.98), p=0.015 0.86 (0.78-0.96), p=0.007 
 
*(count x 109 cells/L) for each subset multiply by 1000 prior to analysis. BILAG: British Isles Lupus Assessment Group; C3/C4: complement 3 or 4; DMARDs: disease modifying 
anti-rheumatic drugs; dsDNA: double-stranded deoxyribonucleic acid; ENA: extract nuclear antigen
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5.5.4. Project 4: Validation of the association of repopulation of 
plasmablasts at 6 months post-rituximab with clinical relapse in SLE 
At 6 months, B-cells were detectable in 81% of the C1 responders to 
rituximab. This time-point preceded all clinical relapses. As the median of 
duration of response to rituximab was 52 weeks, we divided the patients in 
this validation cohort (n=25 with B-cells data available) into two groups: (i) 
earlier relapse (≤12 months from first rituximab) and (ii) later relapse (>12 
months). A 12-month relapse time was clinically significant as it indicated that 
a 6-monthly retreatment might not be necessarily needed in these patients. 
Similar to the discovery cohort (16), the ROC curve analysis indicated that a 
plasmablast count of >0.0008 x 109/L at 6 months yielded 73% (95% CI 45-
92%) sensitivity and 90% (95% CI 56-99%) specificity in predicting earlier 
relapse; the AUROC of 0.86 (Figure 5-2A).  
Of patients with plasmablasts >0.0008 x 109/L at 6 months, relapse rates 
within the next 6 and 12 months were 90% and 100% respectively. While of 
patients with plasmablasts ≤0.0008 x 109/L at 6 months, relapse rates within 
the next 6 and 12 months were 33% and 73% respectively (Figure 5-2B). 
There were no differences in anti-dsDNA titres, the total BILAG score and 
memory B-cells at 6 months between the earlier versus later relapse groups, 






Figure 5-2 Predictive values of plasmablast repopulation at 6 months 
with clinical relapse to rituximab in SLE 
A) ROC curve analysis indicated that a plasmablast count of >0.0008 x 109/L at 6 
months demonstrated 73% sensitivity and 90% specificity in predicting earlier relapse. 
B) Similar to the discovery cohort, detection of plasmablasts >0.0008 x 109/L at 6 
months predicted earlier relapse in this validation cohort. ROC: receiver operating 
characteristic 
Adapted with permission from the BMJ publishing group. Md Yusof MY et al. Predicting 
and managing primary and secondary non-response to rituximab using B-cell 






5.5.5. Project 5: association of B-cell subsets with relapse in AAV 
Patient characteristics 
A total of 37 consecutive patients with active severe AAV received treatment 
with rituximab. Only 35 patients were included in the analysis as two patients 
subsequently followed a pre-emptive re-treatment strategy guided by rising 
ANCA levels (162 patient-years follow-up). Baseline characteristics are 




Table 5-3 Baseline characteristics of the 35 patients with AAV treated with 
rituximab 
Characteristic Values 
Median age at first rituximab infusion (IQR), years 56 (38-65) 
Female patient, n (%) 18 (51) 
Median AAV disease duration from diagnosis to first rituximab 
(IQR), months 
27 (12-60) 










Positive ANCA at first rituximab infusion, n (%) 23 (66) 
Prior CyC therapy, n (%) 
Cumulative dose of CyC, mean ± SD gram 
CyC contraindicated, n (%) 
31 (89) 
12.9 ± 11.7 
4 (11) 












Median No. prior DMARDs including CyC but excluding steroid 
(IQR) 
2 (1-2) 
Organ system involvement at first rituximab infusion, n (%) 
Musculoskeletal and General (fever and myalgia) 
Mucocutaneous 
Eyes 














BVAS at first rituximab infusion, mean ± SD 10.5 ± 6.0 
 
ANCA: Anti-neutrophil cytoplasmic vasculitis; BVAS: Birmingham Vasculitis Activity Score; C-
ANCA: cytoplasmic ANCA; CYC: cyclophosphamide; DMARDs: disease modifying anti-
rheumatic drugs; GPA: Granulomatosis with polyangiitis; IQR: inter-quartile range; P-ANCA: 




Response rates at 6 months (Complete/Partial) were high; above 83% in all 
first five cycles of rituximab. Response rates for cycles 1-5 were 33/35 (94%), 
28/28 (100%), 17/20 (85%), 11/13 (85%) and 5/6 (83%) respectively. All BVAS 
non-responders responded to a subsequent cycle when retreated at minimum 
retreatment time. No patient had to permanently switch therapy due to non-
response. 
Association of complete B-cell depletion with BVAS response in AAV 
There was a weak trend to association between complete peripheral B-cell 
depletion at 6 weeks post-rituximab and clinical response (major/partial) at 6 
months, although this analysis was limited by the small number of non-
responders; 97% complete versus 86% incomplete depletion; p=0.187 (Figure 
5-3).  
 
Figure 5-3 Association of complete B-cell depletion with clinical 
response in AAV 
Despite a trend to association, there was no significant difference in the 
proportion of AAV patients who achieved a BVAS response according to 
their B-cell depletion status. AAV: anti-neutrophil cytoplasmic antibody-





Comparison of B-cell kinetics in AAV with RA and SLE 
Peripheral B-cells, which were measured before and after rituximab, were 
compared among age-matched RA (n=95), SLE (n=44) and AAV (n=35) 
patients (Figure 5-4). 
At baseline, there was no difference in total B-cell counts among RA, SLE and 
AAV groups (ANOVA F=2.89; p=0.059) although there was a trend to higher 
total B-cell counts for RA relative to AAV [mean difference 0.0645 x 109/L 
(95% CI -0.0003 to 0.1292); p=0.051]. At 2 weeks post-rituximab, B-cell 
numbers were generally low and there was no difference in total B-cell counts 
among RA, SLE and AAV groups (ANOVA F=0.08; p=0.920).  
At 6 weeks post-rituximab, although a large proportion of patients had 
complete B-cell depletion, there were differences among RA, SLE and AAV 
groups (ANOVA F=6.17; p=0.003). The total B-cell counts were higher for SLE 
relative to RA [mean difference 0.0060 x 109/L (95% CI 0.0018 to 0.0103); 
p=0.003] and for SLE relative to AAV [mean difference 0.0063 x 109/L (95% 
CI 0.0002 to 0.0124); p=0.040]. The rates for complete B-cell depletion for 
SLE, RA and AAV were 49%, 58% and 59% respectively.  
At 26 weeks post-rituximab, there was no difference in total B-cell counts 
among RA, SLE and AAV groups (ANOVA F=2.89; p=0.059) although there 
was a trend to higher total B-cell counts relative to AAV in both SLE [mean 
difference 0.0182 x 109/L (95% CI -0.0017 to 0.0382); p=0.080] and RA [mean 
difference 0.0163 x 109/L (95% CI -0.0011 to 0.0337); p=0.070]. The rates for 
B-cell repopulation at 26 weeks for SLE, RA and AAV were 88%, 84% and 






Figure 5-4 Comparison of B-cell kinetics before and after rituximab 
across the three B-cell mediated diseases 
At baseline and 2 weeks post-rituximab, there were no differences in total 
B-cell counts among RA, SLE and AAV groups (ANOVA p=0.059 and 
p=0.920 respectively. However at 6 weeks post-rituximab, although a 
large proportion of patients had complete B-cell depletion, the total B-cell 
counts were higher for SLE relative to RA [mean difference 0.0060 x 10 
9/L (95% CI 0.0018 to 0.0103); p=0.003] and for SLE relative to AAV 
[mean difference 0.0063 x 10 9/L (95% CI 0.0002 to 0.0124); p=0.040]. 
** Moderate significant (0.001<p-value<0.01), *Significant (0.01<p-
value<0.05). Bar charts represent mean total B-cell counts while error 
bars denote standard error of mean. AAV: anti-neutrophil cytoplasmic 







Predictors of relapse in AAV based on baseline characteristics 
In AAV, using univariate cox-regression, only higher baseline memory B-cell 
numbers was a significant predictor of earlier relapse (HR: 1.01, 95% CI [1.00-
1.03]) with p=0.040 (Table 5-4). However, this association was not reproduced 
in the subsequent cycles. Multivariable analysis was not performed since 
there was only 1 baseline significant predictor and a small sample size to 
prevent from overfitting of data. 
Before the first rituximab infusion, AAV was characterised by naïve and 
memory B-lymphopenia compared to HCs, all p<0.05. These features which 
were suggestive of abnormal B-cell homeostasis or trafficking, were more 









p-value 95% Confidence 
Interval 
Baseline Clinical Characteristics 
Age at baseline, years 0.995 0.635 0.903 – 1.017 
Disease duration at baseline, months 1.005 0.170 0.998 – 1.012 
BVAS, per point increase in score 1.001 0.964 0.939 – 1.038 
CRP at baseline, mg/L 1.005 0.359 0.994 – 1.016 
ANCA positivity at baseline (Y/N)** 1.038 0.918 0.508 – 2.121 
Concomitant DMARDs (Y/N) 1.036 0.926 0.494 – 2.174 
Clinical Characteristics at 26 weeks 
BVAS, per point increase in score 1.152 0.160 0.946 – 1.404 
CRP, mg/L 0.976 0.152 0.944 – 1.009 
ANCA positivity (Y/N) 1.258 0.550 0.555 – 3.021 
PR3 titre, U/mL 1.007 0.695 0.973 – 1.042 
MPO titre, U/mL 1.055 0.208 0.970 – 1.148 
B-cell subsets, depletion and repopulation 
Naïve B-cells at baseline, cells/L* 1.004 0.329 0.996 – 1.012 
Memory B-cells at baseline, cells/L* 1.014 0.040 1.001 – 1.028 
Plasmablasts at baseline, cells/L* 0.884 0.187 0.736 – 1.062 
Complete depletion at 6 weeks (Y/N) 1.088 0.813 0.540 – 2.192 
Naïve B-cell repopulation at 26 
weeks (Y/N) 
0.326 0.036 0.114 - 0.930 
Memory B-cell repopulation at 26 
weeks (Y/N) 
0.570 0.212 0.236 – 1.377 
Plasmablasts repopulation at 26 
weeks (Y/N) 
1.413 0.439 0.588 – 3.391 
 
*(count x 109 cells/L) for each subset multiply by 1000 prior to analysis 
ANCA: anti-neutrophil cytoplasmic antibody-associated vasculitis; BVAS: Birmingham 
Vasculitis Activity Score; CRP: C-reactive protein; DMARDs: disease modifying anti-





Figure 5-5 Comparison of B-cell subsets and their relationships with 
CRP levels  
Prior to rituximab, active AAV was characterised by naïve and memory 
B-lymphopenia compared to healthy controls. This dysregulation was 
more marked in patients with severe systemic inflammation; raised CRP 
(CRP>10 mg/dL). Error bars denote interquartile range. AAV: anti-
neutrophil cytoplasmic antibody-associated vasculitis; CRP: C-reactive 
protein; HC: healthy control 
Reprinted with permission from the BMJ publishing group. Md Yusof MY 
et al. Repeat cycles of rituximab on clinical relapse in ANCA-associated 
vasculitis: identifying B cell biomarkers for relapse to guide retreatment 





Predictors of relapse post-rituximab 
After the first cycle of rituximab, the median time to relapse (IQR) in patients 
with CR and PR were 94 (73-132) and 79 (62-91) weeks respectively. Patients 
with CR had a weak trend to time-to-relapse (albeit not clinically significant) 
compared to patients with PR (Log-rank (Mantel–Cox) test, x2 = 1.675, df = 
1, p=0.196). The time-to-relapse for C1 and C2 of RTX showed moderately 
significant correlation (r=0.490, p=0.020).  However, duration of C1 rituximab 
alone did not appear clinically useful in estimating duration of C2; the second 
cycle was >12 weeks longer than the first in 30% of cases, and >12 weeks 
shorter than the first in 45% of cases. 
At 6 months, as reported above, B-cells were detectable in 70% of the 
patients. This time point preceded all clinical relapses. In order to analyse the 
effect of B-cell repopulation and relapse, we compared the time-to-relapse 
according to the presence or absence of each B-cell subset (naïve, memory, 
plasmablast). 
There was a significant association between repopulation of naïve B-cells at 
6 months and relapse; p=0.010 (Figure 5-6), but no association between 
memory B-cell (p=0.399) or plasmablast repopulation (p=0.262) and relapse. 
In order to better understand these results, we compared the baseline clinical 
characteristics of patients based on the presence or absence of naïve B-cells 
at 6 months. AAV patients without detectable naïve B-cells at 6 months had 
lower naïve B-cells and significantly higher CRP (p=0.015) at baseline, but no 
difference in age, disease duration, BVAS 3.0, PR3 or MPO titres. The relapse 
rates for this group at 12 and 18 months were 31% and 54% respectively. 
On the other hand, of patients with detectable naïve B-cells at 6 months, the 
relapse rates at 12 and 18 months were 0% and 14% respectively. Similar 
trend was observed in subsequent cycles; C2 (n=12) and C3 (n=8): 0% 
relapse rates for both at 12 months. 
The relationship between repopulation of naïve (CD19+CD27-) cells and later 
relapse, in a subset of patients (n=6) was further evaluated. We divided these 
cells into CD19+CD27-CD38- “mature naïve B-cells” and CD19+CD27-
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CD38+ “transitional B-cells.” Two distinct groups of transitional B-cell 
repopulation were observed; low frequency (1.5-5.0%) and high frequency 
(20.8-84.3%). Due to sample size, we were unable to confirm the association 















Figure 5-6 Association of naive B-cell repopulation at 6 month with later 
clinical relapse 
Relapse-free survival according to repopulation of naïve B-cells at 6 
months post-rituximab. Early repopulation of naïve B-cells at 6 months 




5.5.6. Summary of evidence on the utility of B-cell biomarkers to guide 
treatment decisions with rituximab in SLE, RA and AAV. 
For a biomarker to be used in clinical practice, it needs to be validated and 
reproduced (363). Based on the results presented in section 4.3.5 and in this 
chapter, the potential uses of B-cell biomarkers as measured using HSFC for 
response and relapse prediction in SLE, RA and AAV are summarised in 




















Table 5-5 Current evidence and the proposed schedule for B-cell monitoring during rituximab treatment in SLE, RA and AAV 
Disease Discovery of Biomarkers Validation of Biomarkers  Proposed monitoring in clinical practice 
SLE The depth of depletion (i.e.: depletion after 
the 2nd infusion) was associated with clinical 
response at 6 months; 100% complete vs 
68% incomplete depletion; p=0.012. 
(n=38 patients) Ref: (16) 
Validated in the subsequent n=46 patients. 
Confirmed association of complete depletion 
and response; 93% complete vs 65% 
incomplete depletion after 2nd infusion; p=0.014. 
Ref: (246) 
Peripheral B-cell to be checked at 0 (first 
infusion), 2 weeks (2nd infusion), 6 weeks 
and 6 months post-rituximab. 
 
 
Earlier relapse post-rituximab was 
associated with plasmablast repopulation 
>0.0008 x 109/L at 6 months (p=0.024). 
(n=28 patients) Ref: (16) 
Validated in the subsequent n=25 patients.  
Confirmed association of plasmablast 
repopulation (>0.0008 x 109/L) at 6 months 






Initial depth of B-cell depletion i.e. depletion 
after the first infusion was associated with 
clinical response at 6 months; 96% complete 
vs 74% incomplete depletion; p=0.020. 
(n=60 patients) Ref: (234) 
Validated in the subsequent n=180 patients.  
Confirmed association of complete depletion 
and response: 77% complete vs 61% 
incomplete; p=0.036. Ref: (362) 
Peripheral B-cell to be checked at 0 (first 







Retreatment of initial non-responders with 
incomplete depletion in C1 led to 72% 
response rate in C2.  
(n=25 patients) Ref: (240) 
Validated in the subsequent n=30 patients. 
Confirmed the strategy to re-treat patients who 
had incomplete depletion and  non-response to 
C1. Response rate in C2 was 67%.  Ref: (362) 
AAV Naïve B-cell repopulation at 6 months was 
associated with a reduced risk of relapse 
(HR: 0.33, 95% 0.11-0.93, p=0.036). 
Relapse rates at 12 and 18 months were 0% 
and 14% with naïve repopulation and 31% 
and 54% without naïve repopulation.  
(n=35) Ref: (364) 
Data collection for validation study is still 
ongoing. 
Peripheral B-cell to be checked at 0 (first 





In this chapter, I presented data on the use of B-cell biomarkers in terms of 
response and relapse prediction in RA, SLE and AAV, which had been 
validated in a second cohort for the first two indications. These data also 
offered insights about B-cell kinetics before and after treatment with rituximab 
and provided the rationale for B-cell monitoring to guide treatment decisions 
for efficient use of therapy. 
Early studies indicated no correlation between the total B-cell numbers and 
clinical response to rituximab when they were measured using conventional 
cytometry (365). This could be attributed to the failure in enumerating 
persistence of plasmablasts in some patients, which required specialised flow 
cytometry protocols. This is important because their continuing presence in 
the blood indicates continuing B-cell activity at other sites (352). However, 
HSFC validated that patients who had complete B-cell depletion were 
associated with better outcome in RA. Moreover, the validation study, which 
demonstrated efficacy of retreatment of patients who had persistence B-cells 
and poor response to first cycle rituximab, provided an alternative strategy to 
manage this challenging group of RA patients who would otherwise be 
switched to a different agent, with uncertain efficacy and side effects. The 
assumption that patients who exhibited initial non-response to rituximab had 
a B-cell-independent disease was not supported by the results. Indeed, these 
findings highlighted that the full potential of B-cell depleting therapies was not 
maximised and that more RA patients than previously thought might benefit 
from rituximab if its use was refined. 
In SLE, the degree of complete B-cell depletion (after the second infusion) as 
measured using HSFC was the least efficient in SLE compared to RA and 
AAV patients. This could be contributed to insufficient rituximab dose used 
(237) or intrinsic resistance to therapy (238). From treatment stratification 
perspective, by assessing patients (prior to rituximab) for higher plasmablasts 
and low complement levels, treatment  modification could be employed to 
improve depletion either by increasing the dose or adding an extra infusion, 
as we previously showed in RA (236) for the former. While for those with low 
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complement levels pre-rituximab, treatment could be modified by combining 
rituximab with complement correction therapy such as fresh frozen plasma, 
as demonstrated in CLL (8, 9) or using other anti-CD20 mAb with enhanced 
ADCC such as obinutuzumab. At 6 weeks post-rituximab, complete depletion 
is a marker of good response to therapy. For those with incomplete depletion, 
close monitoring for response is required. At 6 months post-rituximab, 
repopulation of plasmablasts of >0.0008 x 109/L increased the risk of clinical 
relapse within the following 6 months. Therefore, these patients could be 
considered for early retreatment in order to reduce the higher burden of B-cell 
numbers and enhance depletion in the subsequent cycle. Importantly, for 
those with plasmablasts of ≤0.0008 x 109/L at 6 months, monitoring for clinical 
relapse would appear to be an acceptable strategy. 
In AAV, the results showed that active vasculitis was characterised by naïve 
lymphopenia compared to HCs, RA and SLE patients at baseline. There was 
no significant difference in lymphocyte count or relative B-cell numbers 
between patients who had received initial remission induction with 
cyclophosphamide versus rituximab, or comparing patients with or without 
concomitant csDMARDs at baseline (data not shown). Furthermore, the 
dysregulation of naïve B-cells was more marked in patients with more severe 
systemic inflammation (high CRP). These observations suggest that naïve 
lymphopenia is a biomarker of disease-associated B-cell activity rather than 
an effect of immunosuppressive therapy on B-cell homeostasis (366). 
Patients with early relapse failed to repopulate with naïve B-cells in AAV. This 
differed to our results in SLE (16). In SLE, we observed sustained suppression 
of memory B-cells and plasmablasts despite repopulation of naïve B-cells that 
predicted longer responses to rituximab. Thus, undetectable naïve B-cells at 
26 weeks in AAV might be an early indication of the recurrence of the naïve 
lymphopenia that characterised more severe disease before rituximab, and 
therefore served as an early sign of disease-associated B-cell activity. 
Alternatively, this subset might contain a population of regulatory B-cells 
(Bregs) that helped to maintain disease in remission. These have previously 
been described within transitional B cell subsets, CD19+CD24hiCD38hi27- cells 
(367). Wilde et al. (368) demonstrated that interleukin (IL-10) competency was 
diminished during active and remission in AAV patients. Todd et al. (369) 
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concurred, but also reported an increase in frequency of the Bregs following 
rituximab despite 5 years of therapy. This hypothesis needs to be assessed 
in a prospective cohort study.  
These studies have some limitations. First, the repopulation pattern of naïve 
B-cells at 6 months as a biomarker for relapse in AAV has not yet been 
validated in a second cohort for this to be applied in clinical setting. This is 
currently in progress as well as studies on the potential role of Bregs in AAV 
patients treated with rituximab. Second, although our cohort was one of the 
largest at a single centre reported in AAV, the sample size was still relatively 
small for a multivariable analysis to be conducted to identify the independent 
predictors of response and relapse to rituximab. Nevertheless, by linking 
analyses of B-cell subsets with clinical data in this longitudinal follow-up, this 
study was the first to report a B-cell biomarker for use in relapse prediction 
and that naïve lymphopenia might be a marker of B-cell-associated activity in 
AAV. Next, B-cell subsets were only measured in peripheral blood in the 
studies of RA, SLE and AAV. Therefore, this could explain the reason for a 
minority of patients with complete depletion in blood but exhibited poor 
response since persistence of B-cells could occur at other inflamed tissues 
(370, 371). Lastly, the lack of widespread availability of enumeration of B-cell 
numbers using HSFC may limit the generalisability of our findings. However, 
this flow protocol has been increasingly adopted in many institutions, which in 
turn strengthens its clinical applicability (372-374). Therefore, cost-
effectiveness analysis of treatment decision based on these biomarkers is 
needed and may help its implementation in a wider population.  
5.7. Conclusion 
In conclusion, treatment of RA, SLE and AAV with B-cell depleting agents 
should be guided by B-cell monitoring using HSFC with the aim of achieving 
complete depletion. Close monitoring for clinical response is required for those 
with incomplete depletion post-rituximab. These patients may benefit from 
either an additional infusion or retreatment at 6 months in order to reduce the 
burden of high B-cell numbers. Following a clinical response to rituximab in 
SLE and AAV, relapse can be predicted by the repopulation of plasmablasts 
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of >0.0008 x 109/L and the absent of naïve B-cell repopulation at 6 months 
respectively. Therefore, these patients with imminent relapse should be 
considered for early retreatment while monitoring may be all that required for 
those without these prognostic these biomarkers in order to promote judicious 
use of rituximab.  
5.8. Key messages 
i. Enumeration of B-cells (before and after therapy) using HSFC should 
be carried out in RA, SLE and AAV patients who are treated with 
rituximab. 
ii. In RA, the association of complete depletion and clinical response and 
efficacy of retreatment of initial non-responders who had incomplete 
depletion in the previous cycle were validated in a second cohort.  
iii. In SLE, repopulation of plasmablasts of >0.0008 x 109/L at 6 months 
as biomarker of imminent relapse was validated in a second cohort. 
iv. In AAV, relapse post-treatment may be predicted by absence of naïve 
B-cell repopulation at 6 months and that naïve B-lymphopenia may be 
a biomarker of disease activity.
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Chapter 6. Candidate predictors for safety and 
rationale for immunoglobulin monitoring during 
rituximab treatment in systemic lupus erythematosus 
and other autoimmune rheumatic diseases 
6.1. Introduction 
Rituximab has been licensed for the treatment of moderate to severe RA for 
over a decade as well as approved for remission induction in AAV (223). 
Despite failure of RCTs in SLE (204, 205), pSS (375, 376) and autoimmune 
inflammatory myopathies (377) in meeting their respective primary endpoints, 
rituximab is commonly used in these indications and other various ARDs 
based on open label use, often in cases of severe, organ-threatening and 
refractory to other systemic therapies (16, 341, 378, 379). However, the 
immunomodulatory properties of biological DMARDs (bDMARDs) in general 
including rituximab have naturally raised safety concerns prompting careful 
evaluation in clinical trials and intensive post-marketing surveillance. 
Observations from these also provide insight into pathogenic basis of 
infectious disease (8). As described in section 2.7, long-term data from RCTs 
and LTE studies of rituximab in various ARDs had shown no major safety 
signals (204, 205, 256, 259, 380). However, these data need to be interpreted 
with caution since RCTs and their LTE studies selected patients who could 
tolerate the therapy while those with comorbidities were often excluded from 
trials. Therefore, real-world data from large cohort study is needed. 
Infection events are frequent in the initial months after rituximab infusions, 
which may be secondary to the initial bolus of glucocorticoid given as pre-
treatment (381). Subsequent cycles have either similar or lower rates of 
infections (382). However, data pertaining risk factors for infection identified 
through multivariable analysis are lacking and needed to discern patients at 
greatest risk. 
B-cell depletion targeted at the CD20 molecule is temporary due to the sparing 
of stem cells.  An initial expectation was that temporary clearance of B-cells 
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would be sufficient to eliminate pathogenic clones leading to sustained 
remission after repopulation with a new diverse population of B-cells.  
However for most ARDs, patients ultimately relapse albeit after a variable 
interval following B-cell repopulation, requiring repeat cycles to recapture 
response. Repeat cycles with rituximab is effective. However, attrition of 
plasma cells and low immunoglobulin levels may occur with repeat cycles. 
Data from the French registry reported that low IgG pre-rituximab increased 
the odds of SIE over the 12 months post-rituximab (262). Nevertheless, there 
is limited data on repeat treatment and outcome of patients with secondary 
hypogammaglobulinaemia. Additionally, evidence for immunoglobulin 
monitoring during rituximab treatment is also scarce.  
Another potential concern is alteration of the B-cell repertoire during depletion 
with rituximab. The reconstitution of B-cell compartment following each cycle 
of depletion may not fully recapitulate the previous repertoire (although long-
lived plasma cells are mostly spared from depletion). It is possible that long-
term perturbation of the immune system in this fashion may lead to impaired 
host defence. Moreover, over the long run, the failure to mount adequate 
responses to variants of current pathogens or to new pathogens may put 
chronically B-cell depleted patients at risk for infection. Although the lack of 
association  between depletion and SIE in the first 2 cycles of treatment for 
SLE was described in section 4.3.13, longer-term follow-up is needed.  
6.1.1. Hypotheses 
i. Low immunoglobulin subsets pre-rituximab are associated with 
increased odds of SIEs during the first 12 months of therapy and with 
repeat cycles. 
ii. Low B-cell numbers pre-rituximab and B-cell depletion post-rituximab 





i. To evaluate risk factors for SIEs within the first 12 months of therapy 
and with repeat cycles of rituximab for the treatment of SLE and other 
ARDs 
ii. To assess the effect of attrition in immunoglobulin levels and B-cell 
depletion on the rates of SIEs 
iii. To evaluate infection outcomes of patients with 
hypogammaglobulinaemia 
iv. To assess efficacy of immunoglobulin replacement therapy in those 
with secondary hypogammaglobulinaemia  
6.2. Methods 
6.2.1. Candidate’s roles in this project 
In this work, the initial concept and design of the study were set by myself, 
Prof Emery, Dr Vital and Dr Savic. I carried out the weekly Biologics, Lupus 
and Vasculitis clinic in Leeds under the supervision of Dr Vital and Prof Emery. 
I performed a significant proportion of the clinical assessments. Peripheral 
blood B-cell subsets were measured using HSFC at the Haematological 
Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust. For 
safety data, I spent two months reviewing medical notes and results for all 700 
patients single-handedly. I organised and entered all data onto the study 
database. In terms of statistical analyses, I carried out the descriptive statistics 
analyses, multiple imputation of missing data and multivariable analyses of 
prognostic predictors of serious infection in the first 12 months of therapy. Prof 
McElvenny checked my results and performed the complex mixed-effect 
logistic regression analyses. I am currently leading the writing of the 
manuscript, while other co-authors will revise the draft critically for important 
intellectual content and final approval of the manuscript prior to submission to 




6.2.2. Design and patients 
A retrospective observational study was conducted of the first 700 consecutive 
patients with ARDs, who were treated with at least a course of rituximab in 
Leeds between Jan 2002 and May 2015. 
Inclusion criteria were (i) adults (>16 years old); (ii) fulfilling the classification 
criteria for any ARD including RA (329), SLE (32), AAV (383), pSS (326), 
autoimmune inflammatory myopathies (328), systemic sclerosis (327) and 
others (384, 385) and (iii) at least 3 months follow-up post-rituximab. 
6.2.3. Ethical approval 
This study did not require ethical approval because all treatment decisions 
were made prior to evaluation of data, in accordance with the UK National 
Health Service Research Ethics Committee guidelines. The off-label uses of 
rituximab in non-licensed indications were all approved by Leeds Teaching 
Hospitals NHS Trust Drug and Therapeutic Committee.  
6.2.4. Treatment protocol 
All patients received a first cycle of therapy consisted of 100 mg of 
methylprednisolone and 1000 mg of rituximab given intravenously on days 1 
and 14. Further cycles consisted of the same regimen were repeated on 
clinical relapse. For RA, 19% of the patients received repeat treatment with 
half-dose regimen (500mg x 2) following a EULAR response in the previous 
cycle (360). This decision was left to investigator’s clinical judgement.   
Prior to approval of rituximab by NICE for remission induction in AAV in 2014 
(386) and its commissioning by NHS England for SLE in 2013 (233), 
intravenous cyclophosphamide was commonly used as a remission induction 
agent for severe and refractory AAV and SLE cases. This was typically given 
for 3-6 months, adjusted for age, body weight and renal function. Following a 
subsequent relapse or non-response to cyclophosphamide, patients were 
treated with rituximab for remission induction in SLE and AAV.  
Continuation of a stable or reduced dose of concomitant csDMARDs 
(including oral corticosteroid) was left to investigators’ discretion with the aim 
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to stop glucocorticoid if clinical response for the respective disease was 
achieved at 6 months.  
6.2.5. Clinical data and outcomes 
Age, gender, disease duration, diagnosis, comorbidities including previous 
history of any type of cancer, chronic lung disease such as interstitial lung 
disease, bronchiectasis and asthma (with recurrent exacerbations), heart 
failure, diabetes, previous history of severe infection, number of previous 
csDMARDs, number of previous bDMARDs, previous treatment with 
cyclophosphamide, concomitant corticosteroid, corticosteroid dose, 
concomitant csDMARDs (excluding anti-malarials only), rituximab dose and 
time-to-rituximab retreatment were recorded.  
SIEs were recorded irrespective of possible association with ARDs and/or 
therapy. Serious infections were defined as those resulted in hospitalisation 
for > 24 hours or required intravenous antibiotics. Data for SIEs were gathered 
extensively from hospital admission records using the PAS system, pathology 
results server and confirmed with case notes. 
6.2.6. Laboratory assessments 
Total serum immunoglobulin levels were measured by nephelometry before 
and after treatment with intravenous cyclophosphamide, at rituximab baseline 
and at 4-6 months after each cycle (normal range for IgM: 0.5-2.0 g/L; IgA: 
0.8-4.0 g/L and IgG: 6.0-16.0 g/L). Secondary hypogammaglobulinaemia was 
defined as a level of IgM, IgA or IgG which was below its respective lower limit 
of normal (LLN) for at least 4 months following rituximab.  
Peripheral blood B-cell subsets were measured using HSFC (as previously 
described in section 4.2.5) at baseline, week 2, week 6, months 6, and every 
6 months without knowledge of patients’ clinical status other than time since 
rituximab. Complete B-cell depletion was defined as counts ≤0.0001×109 
cells/L and repopulation as counts >0.0001×109 cells/L. 
6.2.7. Missing data 
Some data for immunoglobulin levels and B-cells were missing at random due 
to samples not being processed on the day. Multiple imputation by chained 
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equations was used to create 10 complete datasets, results of which were 
combined according to Rubin’s rules (332). 
6.2.8. Statistical analyses 
Descriptive statistics were summarised using mean with standard deviation or 
median with interquartile range for continuous variables where appropriate 
and proportion for categorical variables. Percentage change for each 
immunoglobulin classes between 4-6 months post-rituximab and pre-
rituximab level of each cycle was calculated for cycles 1-5. The significance 
of the association between categorical variables was tested by Fisher’s exact 
test while for continuous variables using either Student’s T-test or Mann-
Whitney U test.   
To assess baseline predictors of SIEs in the following 12 months post-
rituximab, all (imputed) putative variables were first evaluated using 
univariable analysis. Only variables with p-value of <0.25 were included in the 
multivariable analysis. The final model included variables that showed p-
values <0.10 using a stepwise backward elimination method, and the 
respective ORs and 95% CIs were reported.   
To analyse predictors of SIEs in repeat cycles of rituximab (cycles 1-5), mixed-
effect logistic regression, a statistical model comprised both fixed and random 
effects were used to account for repeated measurements made on the same 
individual or statistical unit in this long-term follow-up (387). Only variables 
with p-value of <0.25 in univariable analysis were included in the multivariable 
analysis. The final model included variables that showed p-values <0.10 using 
a stepwise backward elimination method. 
Statistical analyses were performed using Stata v.13.1 (StataCorp College 
Station, Texas, USA) and GraphPad Prism v.7.03 (GraphPad, La Jolla, CA, 
USA) for Windows. 
6.3. Results 
6.3.1. Patients and characteristics 
Of 700 patients with ARDs who were treated with rituximab in Leeds, 550 
patients were female, median age (IQR) at rituximab initiation was 58 (46–68) 
167 
 
years and median disease duration (IQR) 7.9 (3.4–15.0) years. Most patients 
had RA, n=506 (72%). Total follow-up: 2880 patient-years. Baseline 
characteristics are described in Table 6-1.  
Table 6-1 Baseline characteristics of the 700 patients with ARDs treated with 
rituximab 
Characteristic Values 
Median Age (IQR) in years 58 (46-68) 
Female : Male 550 : 150 
Median Disease duration (IQR) in years (IQR) 7.9 (3.4-15.0) 
Diagnosis, n (%) 
     Rheumatoid arthritis 
     Systemic lupus erythematosus 
     ANCA-associated vasculitis  
     Autoimmune myopathies 
     Primary Sjogren’s syndrome 
     Systemic sclerosis 
     Anti-Phospholipid antibody syndrome (APS) 
     Mixed connective tissue disease 
     Cryoglobulinaemic vasculitis 
     IgG4-related sclerosing disease 






 9 (1.3) 
 6 (0.9) 
 5  (0.7) 
 4 (0.6) 
 2 (0.3) 
 2 (0.3) 
 9 (1.3) 
Biologic naïve, n (%) 364 (52) 
Prior Cyclophosphamide, n (%) 142 (20.3) 
Concomitant anti-malarials, n (%)   85 (12.1) 
Concomitant csDMARDs, n (%) 
     Methotrexate 
     Mycophenolate mofetil 
     Azathioprine 
     Leflunomide 
     Cyclophosphamide 
     Sulfasalazine 
515 (73.6) 
389 (55.6) 
  54 (7.7) 
  35 (5.0) 
  26 (3.7) 
    7 (1.0) 
    4 (0.6) 
Concomitant prednisolone, n (%) 303 (43.2) 
Median daily prednisolone dose (SD), mg 5 (7) 




Median Immunoglobulin (IQR) g/L  
     IgM (0.5-2.0) 
     IgA (0.8-4.0) 






ANCA: anti-neutrophil cytoplasmic antibody-associated vasculitis; csDMARDs: 
conventional synthetic disease modifying anti-rheumatic drugs; CTD: connective 
tissue disease; IQR: interquartile range; SD: standard deviation 
 
6.3.2. Rate and sources of serious infection events 
Overall, there were 284 SIEs recorded in 179 patients (9.9/100 PY) from this 
long-term follow-up study of over 13 years. The rates of SIEs were slightly 
lower in AI-CTD (9.4/100 PY) compared to RA (10.1/100 PY). The rates of 
SIEs generally remained stable over time and with multiple treatment courses 
(Figure 6-1).  
Most SIEs were due to lower respiratory tract infection (LRTI); n=170 (61%). 





Figure 6-1 Serious infection events over time and with multiple cycles of 
rituximab 
The rates of serious infection events were comparable and stable over 
time and with multiple cycles of rituximab with the exception of at 7-8 




Figure 6-2 Sources of serious infection events 
The pie chart above demonstrates the distribution of the sources of 
serious infection events, each is represented with different colours. The 
most common source for serious infections in this cohort was lower 




6.3.3. Opportunistic infections 
There were 8 opportunistic infections recorded in this study. These were 
disseminated varicella zoster=2, mycobacterium=2, cytomegalovirus=2, 
disseminated candidiasis=1 and pneumocystis jiroveci pneumonia (PCP)=1. 
The last was observed in a patient who was subsequently diagnosed as 
having HIV infection. This was in the year 2005 when HIV test was not 
routinely tested in patients receiving rituximab at our unit.  
6.3.4. Baseline predictors of serious infection within 12 months of 
rituximab initiation 
Data for immunoglobulin levels were available for 667/700 (95%) while for B-
cells were 597/700 (85%) of the patients. In the following 12 months from 
rituximab initiation, 89 SIEs were recorded in 75 patients. Univariable analysis 
with multiple imputation showed older age, ever smoked, previous history of 
cancer, chronic lung disease, diabetes, previous history of severe infection, 
concomitant corticosteroid, higher corticosteroid dose, low IgM, low IgA and 
low IgG increased odds of SIEs. While female gender reduced the risk of SIEs. 
In multivariable analysis with multiple imputation, only previous cancer, 
chronic lung disease, previous history of severe infection and low IgG 
increased odds of SIEs in the following 12 months from first cycle rituximab. 




Table 6-2 Baseline predictors of serious infection within 12 months of first 
cycle rituximab 
 No severe 
infection 
N = 625 
Severe 
infection 
N = 75 
Univariable OR 




(95% CI), P-value 
(with multiple 
imputation) 







Per 10 years of 
age, P = 0.005 
 
Female, n (%) 
   
 
497 (79.5) 53 (70.6) 0.62 (0.36-1.06), 











 P = 0.517 
 
 
Ever smoked, n 
(%) 











P = 0.032 
2.85 (1.23-6.64) 
P = 0.015 
 
Chronic lung 
disease, n (%) 






P < 0.001 
1.68 (0.92-3.08) 
P = 0.092 
Heart failure, n (%) 










Diabetes, n (%) 










Diagnosis of RA vs 
CTDs, n (%) 






P = 0.249 
0.46 (0.24-0.86) 
P = 0.015 
Previous severe 
infection, n (%) 
58 (9.3) 40 (53.3) 
 
11.17 (6.59-
18.94), P < 0.001 
10.65 (5.82-





     
123 (19.7) 
 
19 (25.3) 1.38 (0.79-2.42) 




    0 
    1 
    2 
    3 


















Per number of 
previous biologics 

















0 (0-7.5) 5 (0-10) 1.04 (1.01-1.07) 





DMARDs, n (%) 












 No severe 
infection 
N = 625 
Severe 
infection 
N = 75 
Univariable OR 




(95% CI), P-value 
(with multiple 
imputation) 
Low IgM (<0.5g/L), 
n (%) 
     
42 (6.7) 
 
15 (20.0) 3.47 (1.82-6.63) 
P < 0.001 
 





4 (5.3) 3.14 (0.98-10.14) 
P = 0.055 
 
Low IgG (<6.0g/L), 
n (%) 
     
20 (3.2) 14 (18.7) 7.28 (3.48-15.25) 
P < 0.001 
3.56 (1.47-8.63) 
P = 0.005 
Median naïve B-
























1.9 (0.9-) 1.016 (0.991-
1.043), P = 0.215 
 
 
*(count x 109 cells/L) for each subset multiply by 1000 prior to analysis 
CTD: connective tissue disease; DMARDs: disease modifying anti-rheumatic drugs; IQR: 




6.3.5. Predictors of low IgG prior to first cycle rituximab 
Since low IgG pre-rituximab was independently predictive of SIE, risk factors 
for development of low IgG were evaluated. In univariable analysis with 
multiple imputation, older age, previous history of cancer, previous history of 
severe infection, previous therapy with cyclophosphamide, concomitant 
corticosteroid and higher corticosteroid dose increased odds of low IgG at 
baseline. While a diagnosis of RA, biologic naïve or lower number of previous 
biologics, concomitant DMARDs, higher plasmablast counts reduced the risk 
of low IgG. 
In multivariable analysis with multiple imputation, only older age, previous 
cancer, previous history of severe infection and previous therapy with 
cyclophosphamide increased the odds of low IgG at baseline. While a 





Table 6-3 Predictors of low IgG prior to first cycle rituximab 










(95% CI), P-value 
(with multiple 
imputation) 







per 10 years of 
age, P = 0.018 
1.48 (1.10-1.99) 
P = 0.010 
Female, n (%) 27 (29.4) 498 (78.7) 1.03 (0.44-2.41) 











P = 0.224 
 
Ever smoked, n 
(%) 
17 (50.0) 273 (43.1) 1.30 (0.64-2.61) 
P = 0.464 
 
 





49 (7.7) 2.65 (1.05-6.72) 
P = 0.040 
3.44 (1.19-9.94) 
P = 0.022 
Chronic lung 




143 (22.6) 1.48 (0.69-3.17) 
P = 0.317 
 
Heart Failure, n (%) 1 (2.9) 
 
11 (1.7) 1.69 (0.21-13.38) 
P = 0.620 
 
 
Diabetes, n (%) 
 
 
3 (8.8) 34 (5.4) 
 
1.74 (0.51-5.97) 
P = 0.375 
 
Diagnosis of RA vs 




471 (74.4) 0.27 (0.13-0.54) 
P < 0.001 
0.31 (0.09-1.06) 
P = 0.062 
Previous Severe 







P < 0.001 
5.46 (2.25-13.22) 










P < 0.001 
5.22 (1.64-16.64) 

























Per number of 
previous biologics 

















5 (0-15) 0 (0-7.5) 1.04 (1.01-1.09) 
P = 0.024 
 
Concomitant 





















































P = 0.068 
 
*(count x 109 cells/L) for each subset multiply by 1000 prior to analysis 
CTD: connective tissue disease; DMARDs: disease modifying anti-rheumatic drugs; 




6.3.6. Effect of previous treatment with cyclophosphamide followed by 
rituximab on immunoglobulin levels 
Immunoglobulin levels for patients with SLE and AAV who had received initial 
remission induction with intravenous cyclophosphamide followed by rituximab 
(after second relapse) were compared and illustrated in Figure 6-3. Remission 
induction with cyclophosphamide led to a profound decline in almost all 
immunoglobulin classes for both diseases (except IgM for SLE) at 6 months 
post-therapy. Mean IgA and IgG levels for SLE and AAV remained 
substantially lower than pre-cyclophosphamide levels at 18 months.  
Following a second relapse, subsequent remission induction and 
maintenance were given using rituximab. As described in section 6.2.3, repeat 
treatment with rituximab was given using retreatment-on-relapse strategy in 
our cohort. Using this strategy, IgM, IgA and IgG levels remained stable up to 
3 cycles in AAV. While in SLE, progressive reduction in all immunoglobulin 
classes over the 3 rituximab cycles were observed albeit their levels were still 





Figure 6-3 Trends of immunoglobulin levels following remission 
induction with cyclophosphamide and rituximab in SLE and AAV  
Remission induction with cyclophosphamide led to a profound decline in 
almost all immunoglobulin classes for both diseases (except for IgM in 
SLE) at 6 months post-therapy. Mean IgA and IgG levels for SLE and 
AAV remained substantially lower than pre-cyclophosphamide levels at 
18 months. Following a second relapse, subsequent remission induction 
and maintenance were given using rituximab, based on retreatment-on-
relapse strategy at our unit. Using this strategy, IgM, IgA and IgG levels 
remained stable up to 3 cycles in AAV. While in SLE, progressive 
reduction in all immunoglobulin classes over the 3 rituximab cycles were 
observed albeit their levels were still above the LLN. *** Highly significant 
(p<0.001), ** Moderate significant (0.001<p-value<0.01), *Significant 
(0.01<p-value<0.05), ns: non-significant. The graphs for all 
immunoglobulin classes represent mean concentration and the error 
bars denote standard error of the mean. AAV: anti-neutrophil cytoplasmic 
antibody-associated vasculitis; C1-3: cycles 1-3; CyC: 
cyclophosphamide; LLN: Lower limit of normal, RTX: rituximab; SLE: 




6.3.7. Infection outcomes in patients with low immunoglobulin levels 
To assess infection risk in patients with ARDs who had 
hypogammaglobulinaemia, we divided them into 3 groups: i) low Ig levels prior 
to first cycle rituximab; ii) low Ig levels during rituximab therapy and iii) never 
developed low Ig. Only IgM and IgG were evaluated since frequency of 
IgA<LLN was the lowest; 32/670 (4.8%).  
For IgM, rates of SIEs were similar in those with low IgM prior to first cycle 
rituximab, before development of low Ig (during therapy) and never developed 
low Ig. While the highest rate of SIEs was observed in those who developed 
IgM during rituximab therapy.  
In contrast, the rates of SIEs were markedly higher in those with low IgG prior 
to first cycle rituximab and who developed low IgG during rituximab therapy 




Table 6-4 Summary of serious infection rates in patients with IgM and IgG levels <LLN for at least 4 months  
 Group 1: Ig<LLN 
before 1st rituximab 
(n=57) 
Group 2: Patients who developed Ig<LLN during 
rituximab (n=196) 
Group 3: Those who 
never developed Ig<LLN 
during rituximab (n=482) Before Ig<LLN During/After Ig<LLN 
IgM 
Total Exposure (PY) 235.5 
 
538.1 528.2 1700.9 
No of SIE 25 53 74 156 
Rate of SIE/100 PY 
(95% CI) 
10.6 (6.9 to 15.7) 9.8 (7.4 to 12.9) 14.0 (11.0 to 16.6) 9.2 (7.8 to 10.7) 
IgG 
Total Exposure (PY) 122.1 123.5 136.0 2457.1 
No of SIE 20 15 29 238 
Rate of SIE/100 PY 
(95% CI) 
16.4 (10.0 to 25.3) 12.1 (6.8 to 20.0) 21.3 (14.3 to 30.6) 9.7 (8.5 to 11.0) 
 
LLN: lower limit of normal; PY: patient-year; SIE: serious infection event
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6.3.8. Relationship between percentage of change in immunoglobulin 
level and serious infection 
In addition to pre-rituximab Ig<LLN of any cycle as a predictor, for analysis of 
repeat cycles with rituximab, I also assessed the relationship between 
percentage change in immunoglobulin level and SIE. In cycles 1-5, higher 
percentage of change in all three immunoglobulin classes were associated 
with increased rates of SIEs (Figure 6-4). 
 
Figure 6-4 Percentage of change in IgM, IgA and IgG levels with serious 
infection 
Higher percentage of change in all three immunoglobulin classes could 
be associated with increased rates of SIEs over multiple cycles of 





6.3.9. Predictors of serious infection during repeat cycles of rituximab 
For cycles 2-5, all plausible variables were analysed using mixed-effect 
logistic regression analysis. In multivariable analysis, baseline comorbidities 
including previous cancer, chronic lung disease and previous history of severe 
infection as well as pre-rituximab variables of any cycle such as higher 
corticosteroid dose, longer time-to-rituximab retreatment and larger 
percentage of change in IgM increased odds of with SIEs. Lower B-cell 
subsets numbers and depletion status were not associated with SIEs (Table 
6-5). 






(95% CI), P-value 
 
Mean age (SD), 
years 
59.7 (15.3) 55.7 (14.5) 1.02 (1.00-1.04) 
P = 0.108 
 
Female (%) 75.6 79.8 - 
 




49 (7.7) 2.35 (1.10-5.00) 
P = 0.026 




19.8 2.04 (1.16-3.56) 
P = 0.013 
Heart Failure (%) 4.9 
 
1.3 3.05 (0.79-11.72) 








P = 0.119 





8.7 5.71 (2.79-11.68) 




36.6 63.4 - 
Mean corticosteroid dose, 
(SD) mg 
 
4.22 (6.19) 2.05 (3.96) 1.07 (1.02-1.12) 
P = 0.006 
Median time-to-rituximab 
retreatment (IQR), weeks 
53.9 (39.0-86.4) 49.1 (36.1-64.0) 1.01 (1.00-1.01) 
P = 0.013 
Median percentage of 
change in IgM (IQR), g/L 
-18.5% (-36.3 to 
-2.6) 
-15.4% (-25.8 to -
5.9) 
1.01 (1.00-1.02) 
P = 0.027 
Median percentage of 
change in IgA (IQR), g/L 
-10.0% (-20.3 to 
-1.9) 




Median percentage of 
change in IgG (IQR), g/L 
-8.9% (-20.8 to 
2.63) 




Median naïve B-cell 
(IQR)* 
 




Median memory B-cell 
(IQR)* 
 





0.8 (0-2.4) 1.0 (0.3-2.1) - 
B-cell depletion at 6 
weeks post-rituximab (%) 
 
73.2 74.0 - 
*(count x 109 cells/L) for each subset multiply by 1000 prior to analysis 




6.3.10. Efficacy of immunoglobulin replacement therapy 
Of 700 patients with ARDs who were treated with at least a cycle of rituximab, 
only 7 (1%) required immunoglobulin replacement therapy due to secondary 
hypogammaglobulinaemia and infection. These were RA=3, SLE=2, AAV=1 
and APS=1. Median time (range) from first cycle rituximab to immunoglobulin 
replacement was 3.7 (0-7.2) years. Post-immunoglobulin replacement, 6/7 
had IgG normalised, 3/7 had normal IgA and 2/7 had normal IgM. Number and 
severity of infection reduced in all patients. Median duration (range) of therapy 
was 3.7 (0.5-10) years. Cessation of immunoglobulin replacement was 
achieved in 1/7 of the patient. 
6.4. Discussion 
This report presents fundamental safety data on the use of rituximab for 
various ARDs from a real-world perspective. By carefully reviewing records of 
every patient to capture all infection episodes in the largest single centre 
cohort study to date, my findings provide insights on candidate predictors of 
SIEs as well as safety monitoring of rituximab.    
In this study, a high rate of SIEs (9.9/100 PY) was observed. This is in 
comparison with data from RCTs and LTE studies of rituximab in RA (3.94/100 
PY) (256), registries of rituximab in ARDs (ranging from 5.0 to 6.6 PY) (262, 
388, 389) and other bDMARDs used in RA (ranging from 3.0 to 5.2/100 PY) 
(390-392). This high rate of SIE was contributed to a cohort which comprised 
patients with multiple comorbidities including chronic lung disease, previous 
history of cancer and previous history of serious infection. The presence of 
these could lead to channelling away of patients from using other bDMARDs 
to rituximab, thus led to an increase in reports of adverse events. Moreover, 
efficacy RCTs (and meta-analyses derived from them) are of limited value in 
identifying adverse events while LTE studies are not powered to and sub-
select populations that tolerate therapy (393). For registry study, patients with 
recurrent infections were censored at the time of their first infection (262) while 
my study accounted for all recurrent episodes in the calculation of the rate of 
SIEs.   
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The finding from the French registry (262) that low IgG at baseline was 
associated with increased risk of SIE within 12 months of rituximab initiation 
was validated in this study. However, other important risk factors such as 
previous history of cancer and previous serious infection were not reproduced 
from their dataset. Importantly, my study offers advantages compared to this 
registry in terms of longer duration of follow-up, methods of dealing with 
missing data were better defined and the majority of data for immunoglobulin 
levels were available (95% versus 49% in registry). This study is also the first 
to identify predictors of SIEs with repeat cycles of rituximab including 
concomitant higher corticosteroid dose, longer time-to-rituximab retreatment, 
previous cancer and previous serious infection. Moreover, my findings 
provided a rationale for immunoglobulin monitoring, not only for below or 
above LLN as per consensus statement on the use of rituximab in RA (263), 
but also for percentage of change in immunoglobulin level with reduction in all 
Ig classes (in particular IgM) being associated with increased risk of post-
treatment infection.  
Other studies reported risk factors for secondary hypogammaglobulinaemia 
including lower pre-rituximab hypogammaglobulinaemia (394) and total dose 
of prior cyclophosphamide therapy (354). This study identified older age, 
previous cancer, previous history of severe infection and previous therapy with 
cyclophosphamide as predictors of low IgG at baseline. These factors as well 
as other predictors of SIEs as described in section 6.3.5 need to be taken into 
account when counselling patients before commencing therapy with rituximab 
from the perspective of safety. It is also important to note that development of 
secondary hypogammaglobulinaemia could not be solely attributed to 
rituximab. This study showed that remission induction for severe AAV and 
SLE with intravenous cyclophosphamide led to a marked decline in all 
immunoglobulin classes up to 36 months. Venhoff et al. demonstrated a single 
cycle of rituximab following cyclophosphamide further worsened the decline 
in IgM and IgG to below LLN levels (264). In contrast, using retreatment on 
clinical relapse strategy, IgM, IgA and IgG levels remained stable over time in 
AAV in this study. Meanwhile, reduction in all immunoglobulin classes from 
the use of rituximab in SLE (albeit their levels were still above the LLN) could 
be attributed to efficacy of rituximab. Overall then, retreatment on clinical 
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relapse strategy as implemented in this cohort led to a lower rate (1%) of 
patient who subsequently required immunoglobulin replacement therapy 
compared to fixed retreatment strategy i.e. every 6 to 12-monthly (ranging 
from 4-11%) (261, 354). Thus, this is an important consideration in guiding 
judicious use of retreatment with rituximab.  
The continued efficacy of B-cell depletion in SLE and other ARDs depends on 
repeated cycles of rituximab to maintain depletion or low levels of B-cells. This 
is the first study to show that in a fully adjusted model, this significant 
manipulation of the humoral immune system appears safe pertaining to 
serious infection with repeated cycles of treatment. 
This study has some limitations. First, this was a retrospective study, thus 
detailed information with regards to serious infections could be under-reported 
particularly those who lived outside the region. However, records for all 
patients were thoroughly reviewed in a systematic way and using various 
sources in order to enhance collection of data. Second, the lack of control 
group limits interpretation of safety of rituximab. Another potential limitation 
was heterogeneity of the patients, although this could also improve the 
generalisability of my findings. Next, multivariable analysis of predictors of 
SIEs based on repeated measurements, made on the same individual were 
complex to undertake. Nevertheless, this was overcome by using mixed effect 
logistic regression, which accounted for random effects on data. Lastly, 
concomitant therapy with csDMARDs and daily oral corticosteroid were used 
in 74% and 43% of the patients respectively, thus safety could not be 
attributed to rituximab alone. 
6.5. Conclusion 
In conclusion, risk factors that informed rituximab initiation were identified 
including previous cancer, chronic lung disease, previous history of severe 
infection and low IgG while a diagnosis of RA was associated with lower risk 
of SIEs. For repeat cycles of rituximab, risk factors that might inform cessation 
of therapy or modify using half-dose regimen from safety perspective were 
baseline comorbidities (similar as above) as well as pre-rituximab variables in 
any cycle such as higher corticosteroid dose, longer time-to-rituximab 
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retreatment and larger percentage of change in IgM. Finally, based on the 
data presented, immunoglobulin levels should be monitored at least 4-6 
monthly and before any retreatment, particularly in those with comorbidities 
and low baseline immunoglobulin levels in order to identify those with the 
greatest risk for infection and who may require treatment with immunoglobulin 
replacement therapy. 
6.6. Key messages 
i. Patients with a previous history of cancer, chronic lung disease, 
previous severe infection and low IgG should be counselled regarding 
the risk of serious infection prior to commencing rituximab. 
ii. Immunoglobulin levels should be monitored at least 4-6 monthly and 
before rituximab retreatment particularly in those with comorbidities, 
higher corticosteroid dose, longer time-to-rituximab retreatment and 
larger percentage of change in IgM in any cycle. 
iii. Low B-cell subsets pre-rituximab and the degree of B-cell depletion 
post-rituximab were not associated with SIEs. 
iv. More intensive B-cell depleting regimens have indicated the potential 
for more significant infection risk, thus an important consideration in 




Chapter 7. TARGeted therapy using intradermal 
injection of Etanercept for remission induction in 
Discoid Lupus Erythematosus (TARGET-DLE) 
7.1. Introduction 
DLE is a chronic, autoimmune inflammatory skin condition and a form of 
CCLE. Chronic discoid lesions develop in up to 25% of patients with SLE but 
may also occur in the absence of any other clinical features of SLE (395, 396). 
Patients with DLE usually have only a negative or low-titre ANA (397). In these 
patients with positive autoantibodies, there is approximately 5 to 10% risk of 
eventually progressing to SLE, which usually tends to be mild (398). Hence 
the pathogenesis of DLE appears to be different from other systemic features 
of SLE, with a less clear role for circulating autoantibodies. 
There is an unmet need for new therapies to control inflammation in DLE. A 
significant proportion of DLE patients (with or without SLE) are resistant to 
conventional therapies (272). There is no clinical guideline or algorithm on 
how to manage DLE patients who have refractory disease to the first line 
agents, i.e. anti-malarials. Combination therapy of anti-malarial agents and 
high dose oral steroid may be effective, but will lead to unacceptable 
complications from excess corticosteroid use including osteoporosis, 
metabolic consequences and increased risk of major cardiovascular events. 
Importantly, if left untreated, uncontrolled inflammation in DLE will lead to 
permanent disfiguring and irreversible scarring, thus posing a major cosmetic 
issue for the patient, which will significantly impair their quality of life (273, 
399).  
Targeted therapy based on immunopathogenesis of DLE is an attractive 
approach. As discussed in section 2.8, DLE may be exacerbated by B-cell 
depletion therapy (17). Moreover, the common occurrence of DLE in ANA-
negative patients without lupus in other organs also suggests that B cell-
targeted therapy may not be effective for this manifestation.  
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TNF is highly expressed in discoid lupus lesions and is implicated in the 
pathogenesis of DLE (400-402). A concern with systemic TNF-blocker 
administration is induction of pathogenic autoantibodies and flare of disease. 
Approximately 0.5-1.0% of patients treated with systemic TNF-blockers 
develop high affinity IgG autoantibodies to anti-dsDNA, that were associated 
with mild lupus-like syndromes (282). This could be overcome using a low-
dose intra-lesional injection, which might be sufficient to neutralise the TNF in 
lesions. TNF-blockers have been administered using an intra-lesional 
injection in other TNF-mediated diseases such as Crohn’s (403-405) and AS 
patients with refractory Achilles enthesitis (406), and appear safe and similarly 
effective to systemic administration.  
Another important challenge is the problem with outcome measures as 
highlighted by the discussion around the negative clinical trials in SLE (214). 
The assessment of disease activity may be difficult owing to the concurrent 
infection and multiple comorbidities often present in these patients. 
Additionally, currently available instruments  rely on subjective assessment 
(as described in section 2.3). Potential objective outcome measures to assess 
tissue response to therapy including an histology score of skin biopsy, optical 
coherent tomography (OCT), LDI (as described in section 2.3.8) and infrared 
thermography have not been utilised in a clinical trial. 
Therefore, the TARGET-DLE trial addressed these problems by (i) 
administering an existing TNF-blocker, etanercept using a novel route of 
administration (intra-dermal), which would provide local concentration to 
neutralise TNF in tissue whilst minimised the effect to systemic immunity and 
(ii) measuring tissue response using the existing outcome measure; the 
modified limited SADDLE (ML-SADDLE) as well as objective measures such 
as skin biopsy, OCT, LDI and thermography. The concept and rationale of this 















Figure 7-1 Concept and rationale of TARGET-DLE 
TNF is implicated in the pathogenesis of DLE, thus should be targeted (green arrow). However, prolonged systemic administration 
of TNF-blockade therapy may activate B-cells (red arrow pointing upwards) by suppressing the production of Th1 cytokines, thereby 
driving the immune response towards Th2 cytokine production, IL-10, and IFN-α, a hypothesis called cytokine shift (407, 408). 
These cytokines then activate B-cells and lead to increase production of autoantibodies, which may render lupus worse or trigger 
a lupus-like syndrome. Therefore, I hypothesised that this induction of systemic autoimmunity could be minimised using intra-
dermal injection of etanercept in DLE lesion. DLE: discoid lupus erythematosus; IFN-α: interferon-alpha; IL-10: interleukin-10; TNF: 




Targeting TNF using an intra-dermal injection of etanercept is effective and 





To assess the proportion of patients with active DLE that achieved the ML-
SADDLE response (defined as reduction ≥20% in total activity from 
baseline) in the index lesion at Week 12 following treatment with weekly 
intra-dermal injection of etanercept. 
Secondary 
i. To assess other efficacy variables including higher hurdle endpoints 
such as ML-SADDLE 50 and 70 response rates, physician’s VAS of 
global assessment of disease activity and daily oral corticosteroid 
requirement 
ii. To evaluate patient-reported outcomes including Dermatology Life 
Quality Index (DLQI) and Patient’s VAS 
iii. To assess change in lesional OCT, LDI, thermography and 
histopathology score 
iv. To report the safety of therapy in terms of AEs, adverse reactions (AR), 
serious adverse events (SAEs), serious adverse reactions (SARs), 
suspected unexpected serious adverse reaction (SUSAR) 
v. To evaluate the effect of therapy to systemic immunity through 
development of SLE in patients with DLE only or worsening of SLE 
disease activities in patients with established SLE 
vi. To assess whether intra-dermal delivery of administration is associated 





7.2.1. Candidate’s roles in this project 
In this work, the initial concept and design of the study were set by myself, 
Prof Goodfield, Dr Wittmann, Prof Emery and Dr Vital. As the principal 
investigator of this trial, I led the set-up of the study by writing the study 
protocol, preparing and submitting the appropriate documents for ethical, 
MHRA and research and innovation department approvals under the 
guidance of CTRU Leeds, trial coordinators (James and Huma) and chief 
investigator, Prof Emery. I recruited and consented all 25 participants to the 
study. I performed almost all clinical assessments including intra-dermal 
injection of etanercept, OCT, LDI, thermography and skin biopsy. The results 
for OCT were analysed by Dr Abignano while the skin biopsy was scored by 
Dr Edward. I designed the case report forms and entered a quarter of the data 
on the study database (the other three quarters were done by data entry 
personnel). In terms of statistical analysis, I performed all the statistical 
analyses, which were then checked by Dr Wilson. I am currently leading the 
writing of the manuscript, while other co-authors will revise the draft critically 
for important intellectual content and final approval of the manuscript prior to 
submission to journal for publication. 
7.2.2. Study design 
A prospective single arm, Simon’s 2-stage minimax design with Hybrid 
adaptation, phase II open label trial was conducted in Leeds from 1 February 
2016 to 31 December 2017. This study was registered with ClinicalTrials.gov, 
number NCT02656082.  
Simon’s 2-stage minimax design was chosen due to the advantage of allowing 
the minimum total number of patients needed to be treated with a new 
treatment that might be ineffective (409). While a hybrid adaptation of the 2-
stage design was implemented to allow for recruitment to continue while the 
results of the first stage of recruitment were generated in the interim analysis 
(410). 
7.2.3. Ethical approval 
All patients provided informed written consent and this study was conducted 
in accordance with the principles of the Declaration of Helsinki. They also 
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consented for their images to be included in the study reports and 
publication.as long as their identities are protected (see Consent Form version 
3.0 in Appendix). Ethical approval was gained from the National Research 
Ethics Committee Yorkshire and Humber, Sheffield [15/YH/0257] and the 
Medicines and Healthcare products Regulatory Agency [16767/0279/001-




i. Adults aged 18-80 years old. 
ii. Had at least one active DLE lesion, either diagnosed by skin biopsy or 
confirmation by Dermatologist/ Rheumatologist. 
iii. Patients with DLE only and SLE patients with DLE were included.  
iv. Had refractory disease to an anti-malarial for at least 3 months as 
assessed by Dermatologist or Rheumatologist. 
v. Patients receiving anti-malarials must had been receiving them for at 
least 3 months prior to Screening, with a stable dose regimen for at 
least 28 days (±1 day) prior to Baseline (the first study drug 
administration)   
vi. Ability to provide an informed consent. 
vii. All male and female patients biologically capable of having children 
agreed to use a reliable method of contraception for the duration of the 
study and for a period of 3 weeks after their final dose of study drug. 
Acceptable methods of contraception were surgical sterilisation, oral, 
implantable or injectable hormonal methods, intrauterine devices or 
barrier contraceptives. 
Exclusion criteria 
i. Any prior treatment with TNF-blockade therapies. 
ii. Intramuscular or intra-dermal corticosteroid within 28 days of the 
Screening visit. 
iii. Corticosteroid of greater than 10mg prednisolone daily equivalent, or 
change in oral steroid dose within 28 days prior to Baseline Visit. 
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iv. A change in the dose of other immunosuppressant including 
methotrexate, azathioprine and mycophenolate mofetil within 28 days 
(±1 day) prior to Baseline Visit. 
v. Concomitant therapies with any alkylating agents (e.g. 
cyclophosphamide, chlorambucil), other immunosuppressant including 
sulfasalazine and leflunomide, other biological agent particularly 
anakinra and abatacept and other experimental drug. If patients were 
on any of these, they needed to be off therapies for at least 28 days 
prior to Baseline Visit to allow for washout. 
vi. Evidence of an immunosuppressive state, including an active HIV 
infection, agammaglobulinaemias, T-cell deficiencies or Human T cell 
Lymphotrophic Virus Type 1 (HTLV-1). 
vii. Chronic active infection such as hepatitis B or hepatitis C and 
tuberculosis. Patients with latent tuberculosis could be included if 
treated with chemoprophylaxis for at least 2 months before starting the 
study, and to continue chemoprophylaxis for a total of 6 months.  
viii. A history of cancer within the last 5 years except for squamous or basal 
cell skin carcinoma, which had been completely excised and treated 
cervical carcinoma in situ. 
ix. Demyelinating diseases. 
x. Moderate to severe heart failure based on New York Heart Association 
(NYHA) functional class III and IV. 
xi. Pregnancy.  
xii. Breastfeeding. 
xiii. Planned surgery within the study period which was expected to require 
omission of study medication of 28 days or more. 
xiv. Receipt of live attenuated vaccine within 28 days prior to Baseline Visit. 
7.2.5. Treatment 
The investigational medicine product (IMP) used in this study was etanercept 
(Enbrel). Etanercept is a recombinant human TNF-receptor fusion protein. It 
interferes with the inflammatory cascade by binding to TNF, thereby blocking 
its interaction with cell-surface receptors. The usual route of administration in 
its licensed indications i.e. RA, juvenile idiopathic arthritis, psoriatic arthritis, 
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psoriasis and axial spondyloarthropathies is via subcutaneous injection, given 
every week (280). However in this study, a novel route of administration using 
an intra-dermal delivery of the drug to DLE lesion for remission induction was 
investigated. 
The non-IMP used was any anti-malarial agent including hydroxycholoroquine 
200mg daily, chloroquine 150mg daily or combination therapy with 
hydroxychloroquine 200mg and mepacrine 100mg (alternate days). Patients 
would have had to receive any of the therapy above for at least 3 months. This 
non-IMP was continued during the trial as well as after the study had been 
completed at 12 weeks, for maintenance of disease control.   
One index lesion was identified (i.e. the lesion with the highest ML-SADDLE 
score at baseline) and treated with weekly intra-dermal injection of etanercept 
for up to 12 weeks. The same lesion was injected at each time point. 
If remission (as defined by modified limited SADDLE activity score = 0) was 
achieved earlier than expected, the study treatment would be ceased. The 
injection was administered by the investigators or qualified research nurses at 
the Day Case Unit (Ward 5), Chapel Allerton Hospital, Leeds. 
Selection of dose and dose modification 
The usual dose of an intradermal administration of a therapy such as  
corticosteroid is 0.2ml per injection, with repeated injections used to cover a 
larger lesion. Etanercept was available in a 10mg vial, which was made up to 
1ml so that each 0.2ml dose would contain 2mg.    
We estimated that this dose would adequately neutralise typical 
concentrations of TNF in DLE lesion. The estimated TNF concentration in an 
inflamed tissue would be up to 500-5000 ng/mL (411). The dose of TNF-
blocker required to neutralise this would be 100 times the concentration of 
TNF. We estimated that a dose of 500µg of etanercept would be adequate to 
treat 1ml of inflamed tissue. When adjusting for residual volume retained in 
the syringe and backflow of volume out of the skin, the following dosing guide 
(Table 7-1) was used, with multiple injections spread across a larger lesion.  






















1 1.57 0.80 0.1 0.5 
1.5 3.53 1.80 0.2 1 
2 6.28 3.14 0.3 1.5 
2.5 9.81 4.90 0.5 2.5 
3 14.14 7.10 0.7 3.5 
3.5 19.24 9.62 1.0 5.0 
 
For safety and tolerability purposes, the first dose acted as a test dose using 
etanercept 1mg dose irrespective of the size of the lesion. As etanercept was 
used for an unlicensed condition in this study, we had capped a ceiling therapy 
of 10mg per injection at one treatment visit for a discoid lesion ≥3.5 cm radius. 
This is in line with clinical practice where up to 10mg of triamcinolone 
(corticosteroid) is injected intra-lesionally to discoid lupus at one session 
(412). 
Prior and concomitant medications 
Concomitant medications were kept to a minimum during the study. However, 
if these were considered necessary for the patients’ welfare and were unlikely 
to interfere with the investigational products, they could be given at the 




Prohibited prior medications 
 Any prior treatment with TNF blockade therapies. 
 Intramuscular or intra-dermal corticosteroid within 28 days of the 
Screening visit. 
Permitted concomitant medications 
If the patients were prescribed oral prednisolone for maintenance, the dose 
must had been ≤10mg (or equivalent) and were stable for at least 28 days 
prior to Baseline visit. 
Those who were prescribed anti-malarials must had been receiving them for 
at least 3 months prior to Screening, with a stable dose regimen for at least 
28 days (±1 day) prior to Baseline visit. 
Permitted other concomitant csDMARDs include methotrexate, azathioprine 
and mycophenolate mofetil. The patients must had been on a stable dose of 
this DMARDs for at least 28 days (±1 day) prior to Baseline visit. 
Prohibited concomitant medications 
 Any topical corticosteroid preparation 
 Any alkylating agents (e.g. cyclophosphamide, chlorambucil). 
 Certain csDMARDs including sulfasalazine and leflunomide.  
 Any other bDMARDs particularly anakinra and abatacept. 
 Any experimental drug. 
7.2.6. Vaccination with live attenuated vaccines.Assessment 
Study schematic 
The study schematic of TARGET-DLE trial is summarised in Figure 7-2. 
Summary schedule of study assessments 





Figure 7-2 Study schematic of TARGET-DLE trial 
A flow chart of the trial from pre-screening to screening, baseline, 






Table 7-2 Summary schedule of study assessments for TARGET-DLE trial 
Assessment (Procedure/Activity) Screening Visit 1 Baseline Visit 2 Clin. Visit 3 Clin. Visit 4 Clin. Visit 5 Clin. Visit 6 Clin. Visit 7 Clin. Visit 8 Clin. Visit 9 Clin. Visit 10 Clin. Visit 11 Clin. Visit 12 Clin. Visit 13 Clin. Visit 14 Clin. Visit 15
Week (Wk) Wk -4 (-28 days) Wk 0 Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6 Wk 7 Wk 8 Wk 9 Wk 10 Wk 11 Wk 12 Wk 15
Treatment - Etanercept intra-dermal injectiona x x x x x x x x x x x
Informed Consent x
Inclusion / Exclusion Criteria x x
Demographic Data x
Medical/Surgical History x x x x
Concomitant Medication x x x x x x x x x x x x x x x
Adverse Event check x x x x x x x x x x x x x x
Physical examination & Vital signs x x x x x x x x x x x x x x x
Urinalysis x x x x
Pregnancy test (urine) x x x x x x x x x x x x x x x




Immunology (ANA,anti-dsDNA, ENAs and ACA) x x x
Complement (C3 and C4) x x x
Immunoglobulins x x x
Haematology x x x
Biochemistry x x x
Etanercept levelb x x
Blood for exploratory biomarkers x
Medical photography of the skin lesionsc x x x
Skin Biopsyd x x
Optical Coherence Tomography (OCT) x x
Infrared thermography x x
Laser Doppler Imaging (LDI) x x
Modified Limited SADDLE x x x x x x x x x x x x x x
BILAG 2004 (for SLE patients with DLE) x x x
SLEDAI (for SLE patients with DLE) x x x
Physician's Global Assessment (VAS) x x x
Patient's Global Assessment (VAS) x x x




7.2.7. Primary efficacy variable 
SADDLE score (189) was chosen as the primary efficacy variable instead of 
other instruments such CLASI (183) because it accounted for the three 
important morphologies of DLE; erythema, scaling and induration (413). This 
instrument has been described in details in section 2.3.6. 
In this study, a ML-SADDLE score was used; limited to only one index lesion 
and the efficacy was judged based on total score in activity only.   
7.2.8. Secondary efficacy variables 
Physician’s VAS for global assessment of disease activity 
The investigator rated the overall disease activity status of the patient on the 
day of the visit, with respect to the DLE signs and symptoms and the functional 
capacity of the patient, using a 100mm VAS where 0 was “very good, 
asymptomatic, and no limitation of normal activities” and 100 was “very poor, 
very severe symptoms which were intolerable, and inability to carry out all 
normal activities.” 
Requirement for daily oral corticosteroid 
The patients reported daily oral prednisolone intake at each visit. Tapering of 
oral corticosteroids after Week 3 (Visit 5) to a target dose of ≤5 mg/day 
prednisolone equivalent was encouraged during the study. Steroid dose 
adjustments should be avoided during Weeks 9 to 12 (Visit 11 to 14).  
A temporary increase in oral corticosteroids up to a maximum of 25% above 
Baseline levels was allowed, if needed, at the discretion of the investigator 
should the patients develop skin flare with therapy. Flare was defined as an 
increase in disease activity in skin compared to previous assessment in a 
patient previously improving or stable, requiring a change in treatment. Those 
who had increment in oral corticosteroids >25% of Baseline levels were 




BILAG-2004 (For SLE patients with DLE) 
This index had been described in details in section 2.3.1. This assessment 
was only undertaken in SLE patients with DLE at Baseline, Week 7 and Week 
15.  
SLEDAI-2K (For SLE patients with DLE) 
This index had been described in details in section 2.3.2. Similar to BILAG-
2004 index, this assessment was only undertaken in SLE patients with DLE 
at Baseline, Week 7 and Week 15.   
Dermatology Life Quality Index (DLQI) 
The DLQI was the first dermatology-specific health-related quality of life 
(HRQoL) questionnaire developed in 1994 (414). This instrument consisted of 
10 questions concerning patients’ perception regarding the impact of skin 
diseases on different aspects of their health related quality of life over the last 
one week. The items of the DLQI encompassed aspects such as symptoms 
and feelings, daily activities, leisure, work or school, personal relationships 
and the side effects of treatment. 
Each question was scored on a 4-point Likert scale: Not at all/Not relevant=0, 
A little=1, A lot=2 and Very much=3. Scores of individual items (0-3) were 
added to yield a total score (0-30). 
Patient’s global health assessment (VAS) 
The patients rated the global assessment of their DLE disease activity on the 
day of the visit in response to the question “Considering all the ways your DLE 
affects you, please mark a vertical line on the scale below for how are you 
feeling today?” using a 100mm VAS where 0 was “very good, no symptoms” 
and 100 was “very poor, very severe symptoms.”  
Immunological assessments 
Blood samples for measurement of immunological parameters were collected 






 anti-ENAs (anti-SM, anti-RNP, anti-Ro, anti-La and anti-chromatin 
antibodies)  
 anti-cardiolipin antibody (ACA) 
 Complement levels (C3 and C4) 
Optical Coherence Tomography 
“Virtual skin biopsy” using OCT, is a quantitative imaging biomarker that is 
useful for monitoring disease activity in inflammatory skin diseases (415-417). 
This test produces two-dimensional (2D) images of optical scattering from 
internal tissues, that enable visualisation of micromorphological structures at 
the epidermis and the upper dermis, thus provides information on the severity 
of the disease and on treatment effects (417, 418). The reasons for choosing 
OCT as a secondary efficacy variable in this trial were because it provided an 
instant, direct imaging of tissue morphology at much higher resolution (~ 10 
µm) than other imaging modalities such as magnetic resonance imaging (MRI) 
or ultrasound, a non-invasive and non-contact test, as well as no ionising 
radiation was involved (419, 420).  
In this study, the OCT scans were performed by a rheumatologist using the 
VivoSight machine (Michelson Diagnostics) which comprised four parallel 
Swept-Source OCT systems, using a laser with central wavelength of 1310 
and 150 nm laser sweep. For each index lesion that was scanned, the 
handheld OCT probe was used to capture 100 OCT 6 mm B-scans with an 
inter-frame spacing of 4 μm. The resulting image (4×0.4×2 mm) was reviewed 
in real-time before being stored for later analysis. 
Previous studies have shown that the OCT parameters correlated with the 
histopathology of cutaneous lupus in skin biopsy: (i) thickening and disruption 
of the entrance signal correlated with hyperkeratosis (ii) thinning of layer below 
the entrance signal correlated with atrophy of epidermis (iii) patchy 
hyporeflective zones in the epidermis correlated with lymphocytic infiltrates in 
the upper dermis and (iv) wide signal free cavities in the upper dermis 
correlated with dilated vessels in the upper dermis (421). At the end of this 
study, the OCT images were scored by an independent rheumatologist, who 
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was blinded to the patient’s clinical status. These four OCT parameters were 
graded using a scale of 0-3; 0=none, 1=slight, 2=moderate and 3=strong.   
Laser Doppler Imaging 
This objective outcome measure had been described in section 2.3.8. An area 
with the highest ML-SADDLE score and non-lesional area were evaluated 
using a high resolution LDI system (moorLDI2-IR, Moor Instruments UK) by a 
rheumatologist; who was trained in the operation of the LDI and was blinded 
to the patient’s clinical information.  
All scans were performed in a designated assessment room after the patients 
were acclimatised to room temperature (22º Celcius) for 15 minutes. Images 
were acquired at a distance between 40-70 cm from the selected areas using 
a bandwidth between 250Hz-15KHz and the scan speed of less than 
5ms/pixel. The region of interests were selected and analysed using Moor 
LDI2-IR version 5.0 software. The relative difference in the mean perfusion 
between active and non-active CLE lesions was calculated and expressed in 
perfusion unit (PU). 
In a previous study for which I am the first author, we reported that LDI 
correlated better with histology score compared to ML-RCLASI and 
physician’s VAS of photograph. LDI was also shown to be responsive to 
clinical change with a cut-off of 20% reduction in the relative difference in the 
mean perfusion PU to be the most predictive (198).  
Infrared thermography 
Thermography is a non-invasive technique that detects infrared radiation to 
provide an image of the temperature distribution across skin surface. This skin 
temperature image is influenced by the state of the skin vasculature or heat 
generated in deeper tissues (inflamed). This tool has been used to assess 
disease activity in cutaneous manifestation of connective tissue disease 
(422).  
The protocol for thermography and LDI was nearly identical, so these two tests 
were done at the same time. The only difference was that the former detected 
the temperature of the skin whereas the latter studied blood flow (perfusion) 
to the skin. Two areas were evaluated using the FLIR C2 compact thermal 
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imaging system; active DLE lesion and non-lesion areas by a rheumatologist, 
who was blinded to the patient’s clinical information. The temperature 
difference between these lesions was calculated in real-time and expressed 
in Celcius.  
Histology score from skin biopsy  
The patients were invited to undergo skin punch biopsies at Baseline and 
post-treatment (Visit 14, Week 12). A separate section in the Consent Form 
was provided for the consenting patients.  
Two x 4mm biopsies were obtained from the DLE lesion of the consenting 
patients, of which ½ x 4mm was fixed in 10% formalin before staining with 
haematoxylin and eosin whilst another ½ x 4mm was kept in Michel’s transport 
medium for immunofluorescence staining. The samples were rated in real-
time by a histopathologist, with over 10 years’ experience in reporting DLE 
cases and who was blinded to the patient’s clinic status. Since there was no 
standardised histological scoring system for DLE, the histopathologist scored 
the biopsy based on their classic histological features  including (i) interface 
dermatitis; (ii) inflammatory cell infiltrate in a perivascular, periappendageal or 
subepidermal location; (iii) vacuolar alteration of the basal layer; (iv) thickening 
of the basement membrane; (v) follicular plugging; (vi) the presence of 
immunofluorescence  and (vii) dermal mucin deposition (423). The first two 
parameters were rated using a graded scale of 0-2; 0=absent, 1=mild and 
2=strong while the remaining five parameters were rated using a binary scale; 
0=absent, 1=present, with a maximum total score possible of 9. Finally, since 
these parameters were not weighted for clinical significance, an overall grade 
of activity score was then assigned for each biopsy sample using a graded 
scale of 0-2; 0=non active, 1=mild and 2=active. This histology grade was 
used as a gold standard for measuring DLE activity and for comparison with 
other instruments.  
The remaining 4.0 mm biopsy sample was cryopreserved using the optimum 
cutting temperature compound and stored at the University laboratory, Chapel 




Photograph of DLE 
The photograph of the index lesion was taken at baseline and post-therapy 
using a macro digital camera, Canon EOS 600D. 
Pharmacokinetics 
The pharmacokinetic (PK) profile of etanercept was assessed to determine 
whether intra-dermal route drug delivery led to accumulation of etanercept in 
systemic circulation. Blood samples for determination of serum etanercept 
were collected at two time points: (i) before the first dose at Baseline and (ii) 
trough levels (prior to treatment at Week 4) as specified in the schedule of 
study procedures (section 7.2.5.2). These bloods were stored as serum at the 
University laboratory, Chapel Allerton Hospital. At the end of the study, these 
serum were tested for etanercept concentration using the Promonitor® 
Etanecept ELISA according to the manufacturer’s instructions.  
Safety  
Safety variables including AEs, ARs, SAEs, SARs and SUSARs were 
recorded at each visit throughout the study period. All AEs were graded 
according to the National Cancer Institute’s Common Terminology Criteria 
(version 4.0) (424).  
Laboratory measurements 
In addition to the blood obtained for immunological tests, other laboratory 
measurements collected in this study were haematology, biochemistry, urine 
pregnancy testing (for women of child bearing potential) and urinalysis. 
7.2.9. Withdrawal criteria 
The patients were permitted to withdraw from the study at any time, without 
prejudice to their continued care. 
They could be withdrawn from the study for the following reasons: 
 At their own request – they might (i) withdrew from having treatment only 
but were happy to be followed up; or (ii) withdrew consent for further trial 
treatment and follow-up, but were willing to have any available follow-up 
information collected from healthcare records; or (iii) withdrew from further 
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trial treatment, and follow-up information to be collected. 
 At the request of their legally authorised representative.  
 If, in the opinion of the investigator or the Data Monitoring and Ethics 
Committee (DMEC), continuation in the study was detrimental to the 
patient’s  well-being.  
 
They must be discontinued from study medication based on the following 
circumstances:  
 Pregnancy or constant failure to use a medically acceptable form of birth 
control in the 4 months of the study period (every attempt must be made 
to follow up patients who became pregnant to determine the outcome of 
the pregnancy). 
 Grade 3 or 4 systemic toxicity (424) or SAEs thought to be related to study 
treatment and not alleviated by symptomatic treatment after cessation the 
patient’s medication of up to 4 weeks. 
 Serious infection requiring parenteral (intravenous, intramuscular) 
antimicrobial agent or hypotension suggestive of impending sepsis 
syndrome. 
 Acute or re-activation of tuberculosis or hepatitis infection. 
 Confirmed blood dyscrasia or a demyelinating disorder (such as multiple 
sclerosis or optic neuritis). 
 Progression to SLE in patients with DLE only. 
 Worsening in BILAG-2004 in organ systems other than mucocutaneous 
compared to baseline in SLE patients with DLE. 
 The patients’ compliance. If they were to miss the treatment by 4 or more 
consecutive injections, then they would be withdrawn from further therapy.  
7.2.10. Primary endpoint 
Since the patients had DLE lesions that were refractory to the standard 
therapy with anti-malarial agents, there was no other proven effective second 
line agent for this condition. Therefore, a relatively low hurdle was set. Hence, 
treatment with intra-dermal injection of etanercept was deemed successful if 
there was a decrease of 20% from baseline at Week 12 in the ML-SADDLE 
score. This was also in line with response criteria for other ARDs such as RA 
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and psoriatic arthritis where a reduction of 20% from baseline in the ACR 
disease activity index was used as primary endpoints in clinical trials (425, 
426).  
Therefore, the primary endpoint for this study was at least 6 patients achieving 
the ML-SADDLE 20 response (defined as reduction ≥20% in total activity from 
baseline) at Week 12 for a phase 3 trial to be recommended. 
7.2.11. Secondary endpoints 
i. Proportion of patients with ML-SADDLE-50 and 70 response. 
ii. Change in physician’s VAS and daily oral prednisolone requirement at 
Week 12. 
iii. Change in patient-reported outcomes; DLQI and patient’s VAS at Week 
12. 
iv. Change in the total score of OCT parameters at Week 12. 
v. Change in the difference in temperature between active DLE and non-
active areas using thermography at Week 12. 
vi. Change in the difference in perfusion between active DLE and non-
active areas using LDI at Week 12. 
vii. Change in the overall grade of histology score of skin biopsy at Week 
12. 
viii. Incidence of AEs, ARs, SAEs, SARs and SUSARs. 
ix. New development or worsening of positive auto-antibodies titres: ANA, 
anti-dsDNA, anti-ENAs and ACA  at Week 7 and 15. 
x. Change in complement (C3 and C4) levels to below the normal limit (if 
normal at baseline) at Week 7 and 15. 
xi. For SLE patients with DLE, change in disease activity as assessed 
using the BILAG-2004 score and SLEDAI-2K indices at Week 7 and 
15.  





7.2.12. Statistical analyses 
Sample size calculation and STOP/GO criteria 
Based on the current evidence (272) and from clinical experience, after 
treatment failure to an anti-malarial agent, there is no second line agent which 
is effective. Most patients would have exhausted various csDMARDs such as 
acitretin, thalidomide, retinoids, dapsone, methotrexate and mycophenolate 
mofetil; all with limited benefit. 
Therefore, we considered that if intra-dermal injection of etanercept could 
reduce the ML-SADDLE score by 20% or more from baseline score in 30% or 
more patients who were refractory to other treatments, then this would be 
worthwhile to assess further in a phase III trial. However, if the response rate 
was lower than 10%, then intra-dermal injection of etanercept in DLE should 
be rejected from further consideration.  
Using a maximum significance level of 5% and power of 80% in a minimax 
design required 15 patients to be recruited in the first cohort. If 2 or more 
patients were considered responders from the interim analysis, then a second 
cohort of 10 patients would be recruited. While the outcomes data for each of 
the first 15 patients were collected, recruitment of second cohort of patients 
would continue. This accrual would stop if a total of 25 patients had been 
recruited prior to a complete evaluation of the results from the first cohort. 
Should this occur, then study would be treated as per a single-stage design 
with no interim analyses required. Otherwise, a formal interim analysis would 
take place.   
During the interim analysis, if there were less than two responders, then the 
accrual of second cohort would be suspended. The interim analysis would 
take into account data from the second cohort of patients that had been 
collected. In this circumstance, the stopping rule for permanently terminating 
accrual could be calculated using the formula:  
c*≈ r1 (1- (n*/n2)) + r2 (n*/n2);  
where c* was the maximum number of responders required for trial 
termination, r1 was the maximum number of responders for terminating the 
trial in the first stage based on the original minimax design, n* was the number 
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of patients (with complete data) that had been accrued in the second cohort, 
r2 was the total maximum number of responders in the first and second stages 
that would result in a phase III trial not going ahead based on the original 
minimax design, and n2 was the number of patients in the second cohort.  
For example, if there were less than 2 responders when the first 15 patients 
were analysed while 5 further patients had completed follow-up in the second 
cohort, then the criteria for permanently stopping recruitment in the interim 
analysis, C* would be  = 1(1-(5/10))+5(5/10) = 3. Hence, if 3 or fewer of the 
20 patients responded to treatment in the first cohort, then further recruitment 
would be permanently terminated.  
Once the second cohort had been recruited and the study was completed, if 
6 or more of the combined 25 patients were considered responders, a phase 
III RCT could be recommended. 
Missing data 
For the primary and secondary efficacy analyses, complete data might be 
missing if the patients met the early discontinuation of study criteria as per 
section 7.2.8. The effect that any missing data might have on results would be 
assessed using sensitivity analysis of augmented data sets. Dropouts 
(essentially, those who withdrew consent for continued follow-up) or missing 
data for laboratory components in BILAG-2004, SLEDAI and safety analysis 
were included in the analysis by multiple imputation method for missing data 
if appropriate.  
Analyses 
All data including patients who withdrew from the therapy were included in the 
final analysis (full analysis set). Descriptive summary statistics including 
number of patients, mean, standard deviation, median, 25% and 75% 
quartiles were reported for all continuous variables. Frequency distributions 
were provided for categorical data. The number of cases that met the primary 
and secondary endpoints were summarised using proportion and 95% CIs. 
Continuous variables were compared either using Student’s T-tests or Mann-
Whitney U tests whilst Fisher’s exact test was used for categorical variables. 
Correlation between two continuous variables was assessed using Pearson’s 
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correlation. To evaluate responsiveness to therapy, predictive values of each 
of the three ML-SADDLE response criteria were evaluated against LDI and 
were reported in terms of sensitivity, specificity, PPV, NPV and their 
respective 95% CIs. 
Line listings of all AEs, SARs, SAEs and SUSARs were provided. Statistical 
analyses were performed using IBM SPSS Statistics v21.0 (IBM Corp, 
Armonk, New York, USA) and Stata v.13.1 (StataCorp College Station, Texas, 
USA) for Windows. 
7.3. Results 
7.3.1. Study summary 
All 25 patients were recruited within the 18-month period set for this study. Of 
this, 17 patients completed the primary efficacy assessment [Did not attend 
Week 12 visit=1, early withdrawals=7 (personal choice=2, AE=2, worsening 
of DLE=1, non-compliance to protocol=1 and pregnant=1)]. The flowchart of 





Figure 7-3 CONSORT flow diagram of TARGET-DLE trial 
All 25 patients were recruited into the study over a period of 18 months. 
Of this, 24/25 received the intervention. 7 patients discontinued 
treatment early. At the end of the study, complete data were available for 
17 patients for per protocol set analysis. However, for primary endpoint 





7.3.2. Patient characteristics 
Baseline characteristics are summarised in Table 7-3. Notably, this cohort 
comprised resistant DLE patients with median (range) number of previous 
systemic therapies (csDMARDs and bDMARDs) of 5 (1-16).  
Table 7-3 Baseline characteristics of the 25 patients recruited in TARGET-
DLE trial 
Characteristic Values 
Mean Age (SD), Years 47 (12) 
Female : Male 18 : 7 
Race, n (%) 
    Caucasian 
    South Asian 
    Afro-Caribbean  
 
18 (72) 
  6 (24) 
  1 (4) 
Median DLE duration (Range), Years 10 (0.5 – 26.5) 
Previous positive skin biopsy for DLE, n (%) 19 (76) 
Concurrent SLE, n (%) 6 (24) 
ANA positive, n (%) 
     anti-dsDNA  
     anti-Ro  
     anti-La  
     anti-Sm  
     anti-Chromatin  
     anti-RNP  
     anti-Ribosomal P  
     anti-Sm/RNP 











Low C3 or C4 complement levels, n (%) 1 (4) 
Concomitant csDMARDs excluding anti-malarials, n (%) 
    Methotrexate 
    Thalidomide 
    Azathioprine 






Concomitant anti-malarial agents, n (%) 14 (56) 




Median no. previous cs and bDMARDs (Range) 5 (1 – 16) 
Family history of ARDs, n (%) 6 (24) 
Ever smoked, n (%) 
    Current 
    Previous 
20 (80) 
15 (60) 
  5 (20) 
 
ARD: autoimmune rheumatic disease; bDMARDs: biological disease modifying anti-
rheumatic drugs; cs: conventional synthetic; DLE: discoid lupus erythematosus; 
dsDNA: double-stranded deoxyribonucleic acid; RNP: ribonucleic peptide 
 
7.3.3. Treatment characteristics 
In terms of feasibility of therapy administration, 10/25 (40%) adhered to all 
11 injections planned. The median percentage treatment compliance was 




Table 7-4 Treatment characteristics and compliance to therapy 
Treatment characteristic Values 
Anatomical site for injection i.e. lesion with the highest pre-
treatment SADDLE score; n 
       Scalp 
       Cheek 
       Upper back 
       Forehead 
       Nose 
       Ear 




  4 
  2 
  2 
  1 
  1 
  1 
Patients who completed all 11 intra-dermal injections 
included the test dose, n (%) 
  10 (40) 
Median percentage treatment compliance i.e. number of 
injections received/expected number of injections received, 
(range) 
80 (18 – 100) 
Reason for treatment interruption, n 
      Concurrent infection 
      Early withdrawals 
      Logistics issues 
      Other Personal reasons 
 
12 
  7 
  4 
  4 
Dose modification that violated the trial protocol, n    0 
 
* One patient withdrew prior to receiving first treatment, hence total number was 24 




7.3.4. Primary endpoint 
Since all 25 patients were recruited prior to complete evaluation of the results 
from the first cohort i.e. the first 15 patients, no formal interim analysis was 
undertaken. Therefore, this study was treated as per a single-stage design.   
In the full analysis set, the primary endpoint was met with 13/25 (52%, 95% 
CI 31-73) meeting the ML-SADDLE 20 response rate at week 12. The mean 
ML-SADDLE had reduced from 5.2 (SD 1.6) pre-treatment to 2.5 (1.8) post-
treatment; mean difference 2.7 (95% CI 1.7 to 3.7); p<0.001. At week 15, the 
ML-SADDLE 20 response rate was sustained at 52% (95% CI 31-73). 
7.3.5. Secondary endpoint: Efficacy 
For higher hurdle endpoints, the ML-SADDLE 50 response rates at week 12 
and week 15 week were both 12/25 (48%, 95% CI 27-69) whilst the ML-
SADDLE 70 response rates for week 12 and week 15 were 5/25 (20%, 3-37) 
and 6/25 (24%, 6-42) respectively.  
Of 7 patients who were on daily oral prednisolone at baseline, none of them 
had their dose reduced or increased at week 12. At week 15, 2/7 had their 
dose doubled by the medical team since they were hospitalised due to 
infections. Of 18 patients who were not on daily oral prednisolone at baseline, 
none of them required treatment with steroid throughout the trial. 
There were significant improvements at week 12 from baseline for most of the 
key secondary efficacy endpoints including physician’s VAS, patient-reported 
outcomes (DLQI and patient’s VAS) and objective outcome measures (LDI 
and thermography).  
Although there was a trend to improvement in the total OCT score, mean 
difference between pre-treatment and post-treatment was not significant. 
These results are shown in Table 7-5 whilst photographs and LDI images of 
those who had improved with therapy are depicted in Figures 7-4 to 7-6.  
Thirteen patients underwent skin biopsy procedures at baseline. Of these, 
6/13 had paired pre- and post-biopsy samples. Of those with paired biopsy 
samples, 2/6 had histology score improved, 2/6 remained the same and 2/6 
had worsening score at week 12.  
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There was a trend to correlation between total histology score and ML-




Table 7-5 Results of secondary efficacy endpoints 
Endpoint Baseline Week 12 Mean difference (95% CI), p-value  
Physician VAS, mean (SD) mm 53.1 (16) 23.2 (20) 29.9 (19.4 to 40.4), p<0.001 
Patient VAS, mean (SD) mm 56.9 (28) 29.7 (28) 27.2 (12.2 to 40.1), p<0.001 
DLQI, mean (SD) 11.4 (7) 6.5 (6) 4.9 (2.6 to 7.1), p<0.001 
LDI, mean (SD) perfusion unit (PU) 495.1 (224) 376.2 (223) 118.9 (23.7 to 214.0), p=0.018 
Thermography, mean (SD), ºC 1.92 (1.17) 1.08 (1.05) 0.84 (0.30 to 1.39), p=0.005 
OCT score, mean (SD) 4.4 3.7 0.7 (-0.3 to 1.7), p=0.144 
 


















Figure 7-4 Photographs of Patent 05 who responded to intra-dermal injection of etanercept 
















Figure 7-5 Photographs of Patient 07 who responded to intra-dermal injection of etanercept 
This patient met the ML-SADDLE 70 response at Week 12. This was an exceptional case where her scarring alopecia did improve with therapy. The red 















Figure 7-6 Images from laser doppler imaging of Patient 25 who had a partial reduction in ML-SADDLE score post-treatment 
This patient had a partial reduction in  ML-SADDLE score from 5 at baseline to 2 at week 12. This partial improvement as rated by clinical assessment was 
supported  by LDI.  The blue circles drawn outside the numbers 1-5 represent regions of interest (ROI) in the analyses. The ROI with the highest score was 




7.3.6. Secondary endpoints: Safety 
Incidence of AEs, ARs, SAEs, SARs and SUSARs 
There were 53 AEs recorded in this study as described in Table 7-6. Of these, 
29/53 were treatment-emergent recorded in 14 patients. Most of the AEs were 
due to lower respiratory tract infection (LRTI); n=6. Injection-site reaction or 
infection cases were recorded in 4 patients. Grade 3 or higher systemic 
toxicity AEs were recorded in 4 patients (LRTI = 1, Presumed infection, source 
unidentified = 1,  Heart failure = 1, Worsening of chilblains = 1). One patient 
became pregnant after receiving one dose of intra-dermal injection of 
etanercept and she had to be withdrawn from the study. The outcomes for 
both mother and baby were uneventful. Withdrawals due to AEs were 
recorded in 2 patients.  
Table 7-6 Adverse events recorded in TARGET-DLE trial 
Characteristic Values 
All Adverse Events (AEs), n 51 
Treatment-emergent AEs, n 
Infection 
    Lower respiratory tract infection 
    Presumed infection 
    Urinary tract infection 
    Injection related-skin infection 
    Pharyngitis 
    Otitis externa 
Skin 
    Pruritus 
    Injection related swelling/oedema 
    Worsening of subacute cutaneous lupus 
Nervous system 
    Headache 
    Dizziness 
Respiratory 
    Upper respiratory tract infection 
    Cough 
    Pleuritic chest pain 
29 
 
  6 
  1 
  2 
  1 
  1 
  1 
 
  1 
  3 
  1 
  
  4 
  1 
 
  1 
  1 





    Heart failure 
Gastrointestinal 
    Vomiting 
    Faecal incontinence 
General 
    Fatigue 
 
  1 
   
  1 
  1 
  
  1 
Grade 3 or higher AE, n   4 
AE of special interest: Pregnancy, n   1 
All Serious Adverse Events (SAEs), n 
    Presumed Infection – source/organism unidentified, n 
    Lower respiratory tract infection, n 
    Heart failure, n 
    Worsening of chilblains lupus, n  
  4 
  1 
  1 
  1 
  1 
AE leading to discontinuation of study, n   2 
AR, SAR and SUSAR, n   0 
Deaths, n   0 
 
AE: adverse event; AR: adverse reaction; SAE: serious adverse event; SAR; serious adverse 





No patient had new development of ANA or clinically significant worsening of 
autoantibodies titres (anti-dsDNA, anti-ENAs and ACA) from Baseline to 
Week 15. 
One patient (4%) had Anti-B2 glycoprotein antibody positivity detected at 
Week 7; 21.00 U/mL from 14.70 U/mL at Baseline (normal <19.99 U/mL). 
There was no history of venous or arterial thrombosis observed. Her ANA 
remained negative. At Week 15, the Anti-B2 glycoprotein antibody reverted 
back to normal.  
The one patient with low baseline complement levels had their levels 
normalised at Early Withdrawal visit (week 7). Two patients (8%) had changes 
in complement levels to <LLN at Week 7 but only one (4%) had persistently 
low levels at Week 15. 
SLE disease activity 
Of 6 patients with concurrent SLE, only 4 completed the study. Those who 
withdrew early did not have deterioration in either BILAG-2004 or SLEDAI-2K 
scores.  
Of 4 patients who completed the study, only 1 patient had increased in 
SLEDAI-2K score from 8 to 10 points due to worsening of complement levels 
at week 7 and week 15. However, her BILAG-2004 activities improved at week 
15. Details are as below: 
 Her Baseline BILAG Activities were: (i) Grade B Mucocutaneous (Mild 
skin eruption – worse;  mild and severe alopecia – worse), and (ii) 
Grade B Musculoskeletal (Mild and moderate arthritis – same). Her 
SLEDAI-2K score was 8 points (rash, alopecia and arthritis). 
 At week 7, she had (i) Grade B Mucocutaneous (mild rash – same; mild 
and severe alopecia – same), and (ii) Grade B Musculoskeletal (mild 
and moderate arthritis – same). Her SLEDAI-2K score had increased 
at Week 7 to 10 points (rash, alopecia, arthritis and new low 
complement)  
 At week 15, her BILAG activities improved; (i) Grade C Mucocutaneous 
(Mild skin eruption – improving, mild and severe alopecia – improving) 
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and (ii) Grade B Musculoskeletal (Mild and Moderate arthritis – same). 
Her SLEDAI-2K score remained at 10 points (arthritis, rash, alopecia, 
low complement). 
Serum etanercept level 
Trough serum etanercept levels were detected in 6/23 (26%) of the patients. 
Exploratory analysis 
Predictive values of the three ML-SADDLE response criteria were compared 
against responsiveness to therapy as measured by LDI. There were 12 
responders as defined by ≥20% reduction in the relative difference in mean 
perfusion between active and non-active CLE lesions using LDI whilst 5 were 
non-responders. Of the three ML-SADDLE criteria, ML-SADDLE 20 was most 
strongly associated with improvement in LDI. Of those who were LDI 
responders, 11/13 (85%) had met ML-SADDLE 20 response versus 1/4 (25%) 
who had not; p=0.053. Moreover, ML-SADDLE 20 had higher sensitivity and 
similar specificity to ML-SADDLE 50 criteria in predicting responders as 
defined by LDI. The predictive values of the three ML-SADDLE response 
criteria are summarised in Table 7-7. 
Table 7-7 Predictive values of ML-SADDLE criteria in terms of association 







PPV %       
(95% CI) 
NPV %      
(95% CI) 
ML-SADDLE 20 91.7 (61.5 -
99.8) 
60.0 (14.7 – 
94.7) 
84.6 (65.0 – 
94.2) 
75.0 (28.7 – 
95.7) 
ML-SADDLE 50 83.3 (51.6 – 
97.9) 
60.0 (14.7 – 
94.7) 
83.3 (62.4 – 
93.8) 
60.0 (26.0 – 
86.5) 
ML-SADDLE 70 33.3 (9.9 – 
65.1) 
80.0 (28.4 – 
99.5) 
80.0 (36.8 – 
96.5) 
33.3 (21.6 – 
47.5) 
 






This report presented the results from a phase II open label trial, which was 
the first to evaluate the efficacy and safety of an existing drug, etanercept, 
licensed for other indications but using a novel route of administration using 
intra-dermal injection for remission induction in DLE. The primary endpoint as 
assessed using ML-SADDLE 20 response rate was achieved and the therapy 
was well tolerated.  
In this study, just over half of the patients responded to intra-dermal injection 
of etanercept. This response rate was particularly notable because of the 
inclusion of cohort, which comprised patients who were refractory to various 
systemic therapies as well as median disease duration of about a decade. A 
Cochrane review in 2017 only identified a small number of formal studies that 
had been undertaken in this field including topical therapies (n=4) and one 
study compared hydroxychloroquine and acitretin (198). The response rates 
reported by the authors based on variable outcome measures with these 
therapies ranged from 10% to 68% (427-431). However, none of these trials 
were of high quality when they were assessed using the Grading of 
Recommendation, Assessment, Development and Evaluation (GRADE) 
(432). In contrast, TARGET-DLE was a well-designed trial and this treatment 
exhibited efficacy across multiple endpoints including patient-reported 
outcomes and objective outcome measures.  
This study offers insights into the pathogenesis of DLE and help direct future 
therapies. Deposition of immune complexes containing IgM, IgG and 
complement C3 at the dermo-epidermal junction is pathognomonic in DLE. 
However, this direct immunofluorescence test can also be detected in non-
lesional biopsies (70). This observation suggests that although autoantibodies 
are involved in the formation of skin lesions, additional mediators are needed 
for DLE lesions to develop. This may also explain the failure of treatment with 
B-cell depleting agent in this particular subtype of CLE (17). TNF is a major 
pro-inflammatory cytokine that is overexpressed in the kidney and skin lesions 
from patients with SLE (433). Research in animals studies showed that 
intradermal injection of lupus serum into the skin of TNF-deficient mice failed 
to induce an inflammatory response (434), suggesting the importance of this 
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cytokine in the development of skin lesions. Thus translating findings from 
bench to bedside, this study shows that TNF-blockade is effective in inducing 
remission of active DLE. Analysis of skin biopsy samples for TNF and 
expression of other cytokines are in progress and can help stratify those who 
will respond to this therapy. 
There were no major safety signals from administration of TNF-blockade 
therapy using an intra-dermal injection in this study. Although the number of 
AEs reported were high, only 29 were treatment-emergent. This could be 
attributed to frequency of visits and over 3/4 of the patients were either current 
or previous smokers. None of the patients had progression or worsening of 
lupus from immunological and disease activity perspectives. In addition, the 
frequency of injection-site reaction was very low. Compliance to treatment was 
also satisfactory with patients receiving the treatment on average 80% of the 
time. However, just over a quarter of the patients withdrew early in this study 
with 4/25 (16%) of them discontinued due to reasons other than adverse 
events or pregnancy. Thus, a more refined drug delivery of TNF-blockade 
either using topical or microneedles (435) would help resolve these issues. 
With regards to cost, treatment with intra-dermal injection is cost-saving. A 12-
week course of treatment up to 10mg of etanercept weekly costs 5 times 
cheaper than systemic etanercept administration as well as without inducing 
systemic autoantibody production. 
This study has some limitations. First, this was an open label trial. Hence, our 
results could be influenced by reporting bias from both the participants and 
investigators. However, evidences of efficacy were also supported by 
objective measures including LDI and thermography. Second, the lack of a 
control group made the results difficult to interpret. This was overcome by 
applying the Simon’s 2-stage minimax design, which estimated the number of 
patients needed to treat based on an observed response rate over other 
experimental therapies i.e. after failure of an anti-malarial. Next, 19/25 (76%) 
were on concomitant csDMARDs or anti-malarials, thus efficacy could not be 
contributed to etanercept alone. Lastly, this study was designed for remission 
induction using a short course regimen. Although the ML-SADDLE response 




To conclude, a low dose intradermal injection of etanercept up to 10mg 
substantially reduced clinical activity, met its primary and most secondary 
endpoints including patient-reported outcomes and objective measures. This 
therapy was tolerable in DLE patients who were refractory to anti-malarials 
and other systemic therapies. The results support further development of 
therapy in multi-centre trials. Analyses of other imaging and histological 
biomarkers are ongoing and can help stratifying patients for response. 
7.6. Key messages 
i. Administration of etanercept (potentially harmful in SLE) using a novel 
route, intra-dermal injection is effective for remission induction in 
refractory DLE. 
ii. No major safety signals were observed including induction of systemic 
autoantibody production. 
iii. The results from this trial will be used to power a phase III trial. 
iv. This trial also confirms the role of TNF in the pathogenesis of DLE. 
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Chapter 8. Discussion 
8.1. General discussion of results 
The data presented in this thesis highlighted challenges in the management 
and the need to tailor therapies to the individual patient with SLE. Given the 
heterogeneity in clinical phenotype and response to therapy, it is likely that 
there is no one-size-fits-all therapy for the treatment of SLE. This programme 
of research was designed to formulate a number of ways where personalised 
therapy based on immunopathogenesis could be offered in order to improve 
the outcomes of At-Risk and established SLE patients. These were focussed 
on two key clinical areas: (i) the pre-clinical stage and (ii) refining the use of 
rituximab in patients with moderate to severe SLE. By identifying predictors of 
progression to clinical autoimmunity, response and non-response to B-cell 
depletion therapy and utilising new therapies to overcome deficiency of 
rituximab, the unifying hypothesis of this thesis had been addressed.    
Disease prevention should be a focus of research and management of ARDs. 
However, this cannot not be undertaken if immunopathogenesis of the 
disease is poorly understood and prognostic biomarkers are not identified. 
IFN-Is are important mediators of autoimmunity but their role in AI-CTD 
initiation is unclear. This could be contributed to variability in the methods for 
quantifying IFN activities. A previous study retrospectively analysed IFN 
activity in sera from 55 At-Risk individuals for at least 5 years prior to SLE 
classification. They reported that enhancement of the IFN-II pathway led to 
accumulation of autoantibodies and subsequent elevations in IFN-I activity 
preceding the classification of SLE (340). However, these data need to be 
interpreted with caution since measurement of IFNs activity in serum are 
unreliable as proteins are unstable in serum. Although they showed that both 
types of IFNs were important in the pathogenesis of SLE, their use as 
prognostic biomarkers were lacking. In order to overcome the deficiency in 
quantifying IFN activity, our group, has published on two continuous ISG 
expression scores (IFN-Score-A and IFN-Score-B), that in combination better 
identified clinically meaningful differences in IFN status between, and within 
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ARDs (320). By undertaking the largest prospective study of At-Risk 
individuals to date with longitudinal follow-up until progression to AI-CTD 
(meeting classification criteria), I showed that IFN-Score-B and a family history 
of ARDs were independently predictive (in a multivariable analysis) of 
progression to AI-CTD at 12 months. These results confirmed the importance 
of IFNs in disease initiation; a cut-off level of IFN-Score-B with a moderate 
diagnostic accuracy was also defined (336). This important finding will 
contribute to the design of future prevention studies. Once these biomarkers 
are validated, the predictive value of IFN scores may allow us to identify 
patients with imminent AI-CTD for earlier intervention, which is aimed at 
preventing disease and avoiding irreversible organ damage.   
My programme of research then looked into ways to improve or modify the 
use of rituximab in SLE by undertaking a prospective study of the largest 
cohort study reported to date. A high degree of response to the first cycle of 
rituximab (MCR + PCR = 82%; MCR = 50%) at 6 months was observed in our 
cohort (246). This response rate was similar to another large study from 
London (MCR + PCR = 67%) (341). However, the response rate in this cohort 
was higher compared to the BILAG-BR registry (MCR + PCR = 49%) (232). 
The discrepancy between this cohort and the BILAG registry could be 
attributed to inclusion of more non-Caucasian patients (with more severe end-
organ involvement and poorer prognosis); 40% in the latter versus 32% in the 
former and more ANA negative patients; 13% in the latter versus 0% in the 
former. Additionally, the efficacy could be under-reported in the latter since 
only 71% of the patients (compared to 94% in the former) had complete BILAG 
response data at 6 months. There was also limited data on predictors of 
response to rituximab. I showed in a multivariable analysis that B-cell 
depletion post-rituximab (as measured using HSFC) was the only consistent 
predictor of any BILAG response and MCR to rituximab (246). This biomarker 
was validated in a second cohort in this thesis. Therefore, treatment with anti-
CD20 mAb should aim of achieving complete B-cell depletion and this finding 
also provided a rationale for B-cell monitoring before and after therapy with 
rituximab. With regards to factors predicting B-cell depletion with rituximab, 
lower plasmablasts and normal complement levels were independently 
predictive. Therefore, for those with higher plasmablasts pre-rituximab, 
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treatment modification could be employed to improve depletion either by 
increasing the dose or adding an extra infusion, as our group previously 
showed in RA (236). For those with low complement levels pre-rituximab, 
experience in CLL showed that combining rituximab with complement 
correction therapy i.e. fresh frozen plasma could enhance depletion and 
response (436, 437). However, only one case report had reported on efficacy 
of similar strategy in SLE (438). Thus, more evidence are needed before we 
extrapolate findings between SLE and B-cell malignancies. 
Most SLE patients experienced a relapse following the first cycle of rituximab. 
I had validated in a second cohort in this thesis that repopulation of 
plasmablasts of >0.0008×109/L (measured at 6 months post-rituximab) 
increased the risk of clinical relapse within the next 6 months (246). Therefore, 
these patients could be considered for early retreatment in order to reduce the 
higher burden of B-cell numbers and enhanced depletion in the subsequent 
cycle. Importantly, for those with plasmablasts of ≤0.0008×109/L at 6 months, 
monitoring for clinical relapse would appear an acceptable strategy. 
What about the efficacy of repeat cycles with rituximab? Repeat cycles with 
rituximab was effective with 85% of the patients continued to respond. 
However, we observed 12% cases of 2NDNR. This phenomenon was 
associated with anti-rituximab antibodies and could be predicted by higher 
pre-rituximab plasmablasts and non-use of concomitant therapy with 
DMARDs (excluding anti-malarials only). This 2NDNR was overcome by 
switching therapy from rituximab to humanised anti-CD20 agents which 
improved depletion and response subsequently.  
Since the importance of achieving complete B-cell depletion and keeping 
lower B-cell numbers during rituximab therapy had been established in this 
thesis, a concern was that this strategy could lead to increased risk of an 
infection. By undertaking a large retrospective real-world cohort of SLE and 
other ARD patients who were treated with rituximab, I showed that serious 
infections within the 12 months of first cycle rituximab could be predicted by a 
previous history of cancer, chronic lung disease, previous severe infection and 
low IgG. The association of low IgG with serious infection was similar to the 
one reported by the French registry (262). However, the strengths of my study 
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compared to this registry were longer duration of follow-up, methods of dealing 
with missing data were better defined and majority of data for immunoglobulin 
levels were available (95% versus 49% in registry). Thus, patients with these 
characteristics should be counselled regarding the risk of serious infection 
prior to commencing rituximab. With regards to repeat cycles with rituximab, 
this was the first study to identify predictors of serious infections for up to the 
first five cycles using a complex mixed effect logistic regression analysis. Risk 
factors that might inform cessation of therapy or modify using half-dose 
regimen from safety perspective were baseline comorbidities including 
previous cancer, chronic lung disease and previous history of severe infection 
as well as pre-rituximab variables in any cycle such as higher corticosteroid 
dose, longer time-to-rituximab retreatment and larger percentage of change 
in IgM. Thus, my results provided a rationale for immunoglobulin monitoring 
before first cycle rituximab, at least 4-6 monthly post-treatment and before any 
retreatment particularly in those who demonstrated low baseline Ig levels. 
Importantly, achieving B-cell depletion and maintaining low B-cell subsets 
numbers during rituximab treatment appeared to be relatively safe from the 
perspective of infection.  
It is important to note that not all SLE manifestations respond to rituximab. 
DLE appeared to be B-cell independent from our experience in treating this 
condition with B-cell depleting agent (17). Thus, targeting other molecules 
should be more appropriate than using rituximab. TNF is implicated in the 
pathogenesis of DLE (400-402). Although some case series had shown that 
the use of short-term systemic TNF-blockade therapies in SLE were effective 
and without major safety signals (281, 285, 439), two large RCTs that 
evaluated the efficacy and safety of infliximab and etanercept in SLE were 
terminated prematurely (281) due to poor recruitment because of a potential 
concern in the induction of pathogenic autoantibodies that might render SLE 
worse. Hence, a stronger level of evidence is needed for use of TNF-blockers 
in lupus. In the TARGET-DLE trial, I showed that a low dose intradermal 
injection of etanercept (up to 10mg) substantially reduced clinical activity, met 
its primary (ML-SADDLE 20 response rate of 52%) and most secondary 
endpoints including the patient-reported outcomes. Neither major safety 
signals nor evidence of induction of systemic autoimmunity were observed 
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with this therapy. Thus, these results supported further development of this 
therapy in multi-centre trials. Although this study was an open label trial, 
reporting bias was overcome by evidence for efficacy using objective outcome 
measures including LDI and thermography.  
8.2. Impact of research 
This programme of research is of importance both nationally and globally in 
improving the treatment of SLE. By optimising the way the current therapy 
with rituximab is used and providing the proof-of-concept for a novel therapy, 
unnecessary toxicity, cost and patient inconvenience could be avoided.  
To undertake this research, I successfully secured two prestigious personal 
funding awards worth £0.5 million from the National Institute for Health 
Research (NIHR) and £15,000 worth of drugs supply from an industry partner, 
Pfizer.   
Since the publication of my results, monitoring for B-cell biomarkers have 
been adopted routinely in Leeds to make treatment decisions regarding 
rituximab treatment that are cost-effective and safe. I am currently leading a 
project to establish a treatment algorithm on the use of rituximab based on the 
biomarkers and results presented in this thesis, to be used in the West 
Yorkshire region. Moreover, the outcomes of my long-term data particularly 
those with 2NDNR have provided a strategy for the most resistant patients 
and led to a proposal to NHS England on behalf of the UK lupus community. 
Furthermore, we have a formal collaboration with Roche to use B-cell 
biomarkers as one of the trial endpoints of a global phase II RCT in lupus 
nephritis, which is currently recruiting patients. Roche is also about to grant 
us the use of obinutuzumab in a small number of patients with 2NDNR to 
rituximab as a compassionate use.  
As the outcome the clinical trial of intra-dermal injection of etanercept for 
remission induction in DLE is positive, these results will be used to power a 
large multicentre phase III trial which I plan to lead during my next stage of 
career as a post-doctoral researcher. If effective, this would be the only 
targeted therapy shown to work for DLE.  
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With regards to collaboration arising from my PhD training, I have worked with 
Prof Ian Bruce at the Lupus Unit, Manchester during my visiting placement. I 
am currently analysing the dataset pertaining to variability in mucocutaneous 
response to rituximab and belimumab using the BILAG-BR registry. This may 
confirm our previous finding that response to B-cell therapy depends on skin 
subtypes and will help in stratification of biological therapies. I am also 
appointed as the BILAG Renal Sub-Committee Working Group member for 
which I am leading a project to revise the glossary and scoring for the renal 
domain. 
In terms of dissemination, I am the first author in three original research 
articles which have been published in a 3-star specialty-leading journal; 
Annals of the Rheumatic Diseases (Impact factor:12.8), which makes me  
Research Exercise Framework (REF)-returnable to the university for the 2021 
assessment. I have delivered 7 oral and 6 poster presentations at international 
conferences, an oral presentation as an invited speaker at the British Society 
of Rheumatology Conference in 2017, awarded the Runner-up Prize in the 
University of Leeds Post-Graduate Researcher of the Year 2017 and won two 
poster prizes. My findings have also been disseminated widely using various 
medium of communications including twitter and research commentary 
published in press and newsletters. Lastly, I have organised a Lupus 
Awareness Event in 2016 where the coverage of our research was broadcast 
by BBC Look North.  
8.3. Future perspectives 
The available data clearly demonstrate that rituximab-based B-cell depletion 
therapy improves outcomes for the majority of patients with SLE. Moreover, 
the licensing of rituximab biosimilars also has increased its cost-effectiveness 
profile. However, some patients respond poorly, likely due to various 
rituximab-resistance mechanisms or heterogeneity in disease subtypes. 
Although several humanised anti-CD20 mAbs have now entered clinical trials 
for use in RA and SLE, it is still too early to predict whether they will be more 
effective as currently there is no data comparing these mAbs in head-to-head 
trials with rituximab. Additionally, whether these agents will also be effective 
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in patients with incomplete B-cell depletion with rituximab is also unknown. 
Presumably, this may depend upon the reason for resistance in the first place. 
If development of anti-rituximab antibody is responsible, then alternative 
humanised mAbs should be effective as demonstrated in this thesis. 
Alternatively, if a patient-intrinsic mechanistic defect is responsible, then 
unless this is overcome by the new therapies, then no improvement in 
response would be expected. Therefore, my next research agenda is to 
assess this mechanistic defect by undertaking laboratory works to assess the 
effect of FCGR polymorphism, expression of fc gamma receptor IIIa on natural 
killer (NK) cells, degranulation activity of NK cells in the presence of rituximab-
coated patient’s B-cells, complement function and BAFF/APRIL on the level 
of B-cell depletion to allow for treatment stratification as well as appropriate 
modification to therapy to be employed to improve depletion.  
A significant minority of patients with SLE responded less well to B-cell 
depletion therapy despite complete B-cell depletion. This might be attributed 
to higher BAFF levels (248) and/or IFN-Is (440), which might promote B-cell 
differentiation and/or plasma cell activity. Therefore, sequential anti-BAFF or 
anti-IFN agents after B-cell depletion therapy may target these potential 
alternative resistance mechanisms. Alternatively, some patients with SLE who 
had persistently high anti-dsDNA antibodies despite B-cell depletion therapy 
might respond poorly owing to high plasma cell activity (441). Thus, targeting 
plasma cells using proteasome inhibitors may benefit this subgroup of patients 
although vigilance is needed in terms of safety from prolonged B-cell depletion 
(442). 
Thus, optimising B-cell depletion therapy with agents that potentially 
overcome disease-related immune defects and mechanism of resistance that 
operate beyond B-cell depletion would be important to explore in clinical trials, 
if we are to improve overall clinical response to B-cell targeted therapies in 
SLE. 
With regards to optimising the treatment for B-cell independent manifestation 
such as DLE, although compliance to intra-dermal injection of etanercept was 
satisfactory in the TARGET-DLE trial, a more refined drug delivery of TNF-
blockade would help in improving patient’s compliance and convenience. My 
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next research agenda is to evaluate whether a TNF-blocker can be effectively 
administered through microneedles (435) or use an alternative molecule 
containing a TNF receptor fragment that is currently under investigation for 
ocular indication. Should the outcome of this be positive, then I will embark on 
a large multi-centre RCT of intra-lesional TNF-blocker for remission induction 
in DLE. 
Lastly, in terms of disease prevention, validation study of the prognostic ability 
of the IFN scores that we discovered is currently in progress. Once this is 
validated, a prevention study will be undertaken where patients with imminent 
AI-CTD are assigned earlier intervention using therapies that block IFNs or 
conventional immunosuppressants to avoid irreversible organ damage and 
glucocorticoid exposure. 
8.4. Conclusions 
IFN status that preceded clinically overt disease in AI-CTD was described 
through a comprehensive evaluation using clinical data, skin biopsy, blood 
interferons and imaging in a unique cohort of At-Risk (ANA-positive with 
limited symptoms) individuals. Using a novel two-score system for interferon 
status that we recently reported, higher IFN-Score-B and a family history of 
ARD were predictive of progression to AI-CTD (mostly SLE) within the 
following 12 months.  
B-cell depletion (as measured using HSFC post-rituximab) was associated 
with better clinical response in SLE. Additionally, another B-cell biomarker i.e. 
repopulation of plasmablasts at 6 months post-rituximab was associated with 
imminent relapse over the next 6 months. Thus, from a treatment stratification 
perspective, B-cells should be monitored in clinical practice.   
Despite a high degree of efficacy of rituximab demonstrated in the initial and 
subsequent repeat cycles, some patients lost response in subsequent cycles 
due to anti-rituximab antibodies. This was overcome by switching therapy to 
humanised anti-CD20 agents.  
Finally, a novel therapy using intra-dermal injection of etanercept met its 
primary endpoint and most secondary endpoints for remission induction of a 
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B-cell independent manifestation, DLE, when investigated in a phase II open 
label trial. There was no major safety signal or induction of systemic 
autoimmunity observed during the study.  
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